>>I WANT TO WELCOME YOU ALL
TO THE OPEN NATIONAL ADVISORY
COUNCIL DRUG ABUSE, IT IS A
PLEASURE TO HAVE YOU ALL AND I
APPRECIATE THE OPPORTUNITY TO
HAVE ALL OF OUR ACTIVITIES.
BEFORE WE START I NEED TO READ
THE FOLLOWING, THE GOVERNMENT IN
THE SUN SHINE ACT AND FEDERAL
ADVISORY COMMITTEE ACT REQUIRES
THAT AS MANY ADVISORY COMMITTEE
MEETINGS AS POSSIBLE BE OPEN TO
THE PUBLIC.
THIS INCLUDES MEETINGS OF THE
NATIONAL ADVISORY COUNCIL ON
DRUG ABUSE.
TODAY'S MEETING IS OPEN TO THE
PUBLIC AND IS BEING VIDEOCAST
AND RECORDED.
MINUTES WILL BE AVAILABLE ON
THENOID DA HOME PAGE.
RECORDINGS OF THE OPEN COUNCIL
MEETING ARE POSTED ON THE NIH
VIDEOCAST SIGHT.
MEMBERS OF THE PUBLIC WHO MAY
WISH TO EXPRESS VIEWS REGARDING
ANY ITEMS DISCUSSED DURING THIS
MEETING MAY DO SO BY WRITING TO
DR. SUSAN WISE, EXECUTIVE
SECRETARY WITHIN TEN DAYS OF THE
MEETING.
ANY WRITTEN STATEMENT BY MEMBERS
OF THE PUBLIC WILL RECEIVE
CAREFUL CONSIDERATION.
NOW I WANT TO WELCOME THE NEW
COUNCIL MEMBERS THE FIRST ONE IS
DR. CHARLES CHAVKIN, PAIN
RESEARCH DEPARTMENT OF
DEPARTMENT OF PHARMACOLOGY,
UNIVERSITY OF WASHINGTON.
IT IS ALSO DIRECTOR OF THE
UNIVERSITY OF WASHINGTON CENTER
OF EXCELLENCE IN NEUROSCIENCE OF
ADDICTION, PAIN AND EMOTION.
DR. CHAVKIN'S RESEARCH IS ON THE
MOLECULAR PHARMACOLOGY OF THE
ENDOGENOUS OPIOID PEPTIDES AND
OPIOID RECEPTORS WHICH HAS LED
TO IMPORTANT INCITES ABOUT
FUNCTIONAL SELECTIVITY OF OPIOID
LIGANDS AND THE ROLE OF THE THE
KAPPA OPIOID IN MEDIATING THE
STRESS COMPONENTS OF ADDICTION
RISK.
EXPANDING SUCCESS OF
UNDER-REPRESENTED AND FIRST
GENERATION INDIVIDUALS TO
SCIENTIFIC RESEARCH CAREERS.
BY PROVIDING OUTREACH TO K 12
STUDENTS UNDERGRADUATE AND
GRADUATE STUDENTS.
A SUMMER TRAIN PROGRAM DESIGNED
TO PROVIDE INTENSIVE RESEARCH
TRAINING AND PROFESSIONAL
DEVELOPMENT FOR UNDERSERVED
STUDENTS. HE RECEIVED HIS
Ph.D. IN PHARMACOLOGY FROM
STANFORD UNIVERSITY.
WELCOME DR. CHAVKIN.
OUR SECOND NEW MEMBER IS DR.
ANNA CHILDRESS, ALSO WELL KNOWN
TO THE FIELD.
SHE IS RESEARCH PROFESSOR IN
PSYCHIATRY AND DIRECTOR OF BRAIN
BEHAVIORAL VULNERABILITY
LABORATORY IN THE CENTER FOR
STUDIES ON ADDICTION AT THE
UNIVERSITY OF PENNSYLVANIA FAIR
MONT SCHOOL OF MEDICINE.
HER RESEARCH FOCUS ON BRAIN
SUBSTRATES OF PLEASURE AND
COMPETITIVE MOTIVATION AND THE
ROLE IN ADDICTION RELAPSE.
WITH A FOCUS ON TRIGGER DRUG
MOTIVATION AND BIOBEHAVIORAL OR
PHARMACOLOGICAL INTERVENTIONS.
DR. CHILDRESS RECEIVED HER
Ph.D. IN PSYCHOLOGY FROM
(INAUDIBLE) COLLEGE, WELCOME TO
NIDA COUNCIL.
I'M GOING TO ASK RIGHT NOW FOR
ANY COUNCIL MEMBERS IF YOU HAVE
ANY COMMENTS OR HAVE CORRECTIONS
TO THE MINUTES FROM THE
SEPTEMBER 2021 COUNCIL MEETING.
A COPY OF THE MEETING MADE
AVAILABLE TO YOU IN THE
ELECTRONIC COUNCIL BOOK UNDER
THE NIDA CURRENT COUNCIL PACK.
SO IF YOU DON'T HAVE QUESTIONS
OR COMMENTS I'LL ASK FOR MOTION
FOR APPROVAL.
ALL THOSE APPROVED.
ANYONE OPPOSED?
ABSTAIN?
I AM GOING TO ADD SO MOTION IS
CARRIED.
I WOULD LIKE TO ALSO ASK FOR A
VOTE ON THE COUNCIL OPERATING
PROCEDURES.
SO WE DO THIS AS WELL ONCE A
YEAR THERE IN THE ELECTRONIC
COUNCIL BOOK, ESSENTIALLY THEY
ARE THE SAME AS THEY WERE THE
LAST FEW YEARS, THE ONLY CHANGE
MADE WAS TO EXCLUDE THE NEED FOR
COUNCIL APPROVAL FOR
ADMINISTRATIVE SUPPLEMENT TO
PROMOTE REENTRY AND
REINTEGRATION IN RESEARCH
CAREERS.
SO CAN I GET A MOTION TO APPROVE
THE OPERATING PROCEDURES?
SECOND.
APPROVE.
ANY DENIALS?
THANK YOU.
>> NOW I WANT TO ANNOUNCE THE
FUTURE COUNCIL DATES, THE NEXT
MEETING WILL BE ON TWO DAYS WHEN
WE DO JOINTLY WITH THE ALCOHOL
INSTITUTE.
AND IT IS MAY 10 FOR THE NIDA
ONE AND ON MAY 11 FOR THE CRAN,
ALCOHOL AND CANCER INSTITUTE.
AND THE OTHER MEETING ON THIS
YEAR IS GOING TO BE ON SEPTEMBER
13.
WITH THAT I AM READY TO PRESENT
THE DIRECTORS REPORT.
SUSAN, DO I START OR NOT?
>>
PLEASE START.
YOU ARE SHARING YOUR SCREEN.
>> I WILL BE SHARING MY SCREEN.
I WILL NEED TO NODE (INAUDIBLE)
OTHERWISE I WILL BE SPEAKING TO
NO ONE.
>> IT IS NOT YET IN THE SLIDE
SHOW MODE.
>> THERE IT IS.
>> PERFECT.
>> I LIKE TO START WITH OUR
BUDGET BECAUSE THAT GIVES A
PERSPECTIVE WHERE WE ARE RIGHT
NOW AND WHERE WE WILL BE GOING
TO THE NEXT YEAR.
UNFORTUNATELY DIFFICULT WE ARE
IN A CONTINUING RESOLUTION THE
2032 BUDGET HAS NOT
MATERIALIZED.
AND AS YOU READ IN THE
NEWSPAPERS, AS SHORT CONTINUED
RESOLUTION WAS NOW PLACE FROM ON
MARCH, I THINK MARCH 11.
SO WHAT YOU CAN SEE FROM THE
FINAL BUDGETS FOR 2021 VERSUS
WHAT WE SHOULD BE GETTING ON
2022, THERE WERE SIGNIFICANT
INCREASES IN OUR BUDGET AND AS I
EXPRESS AND EXPLAINING THE TASK,
I PRESENT SEPARATELY OUR BASE
BUDGET FROM THAT OF THE FIELD
WHICH IS ALSO BASE BUDGET
BECAUSE MANAGEMENT OF THE HEEL
PROJECTS AND THE FUNDING THAT
COMES THROUGH HEEL IS MUCH MORE
COMPLEX AND IS ACTUALLY OVERSEEN
BY THE OFFICE OF THE DIRECTOR.
SO WE HAVE SEEN INCREASES
DIRECTLY IN TO THE BASE FUNDING
FOR NIDA THAT GOES DIRECTLY
WITHOUT HAVING TO HAVE OVERSIGHT
AT MANAGEMENT FOR THE DIRECTORS
OFFICE AND WE HAVE SEEN
INCREASES INTO THE BUDGETS FOR
HEEL THAT IS OVERSEEN B BY THE
DIRECTOR.
THIS CONSTITUTES THE LARGEST
INCREASE IF IT DOES MATERIALIZE
IN 2022 THAT THE INSTITUTE HAS
FOR HIGHLIGHTS THE OPPORTUNITIES
THAT EXCEEDS FOR ALSO SCIENCE
AND REFLECTS URGENCY TO ADDRESS
THE OVERDOSE CRISIS THAT OUR
COUNTRY IS LEADING.
AND THE RECOGNITION THAT SCIENCE
IS IMPORTANT IN ADDRESSING
OVERALL PROBLEM OF ADDICTION.
THE BUDGET DISTRIBUTION THE WAY
THAT WE PRIORITIZE BASICALLY
WHICH FUNDS ARE GOING TO WHICH
DIVISION, IS DIFFERENT FOR THE
NON-HEEL RESEARCH VERSUS THE
HEEL RESEARCH.
THE DIFFERENCE IS BASICALLY BY
THE FACT THAT WITH RESEARCH
THERE IS A GREAT DEAL OF URGENCY
TO FUND PROJECTS THAT LEAD TO
RELATIVELY FAST AND IMPORTANT
CONTROL OF THE OVERDOSE CRISIS,
THINGS THAT CAN BE IMPLEMENTED
RIGHT NOW.
AS A RESULT OF THAT FUNDING IN
THE FUNDED THROUGH HEEL FOCUS
MUCH MORE ON IMPLEMENTATION AND
SERVICES RESEARCH THAT THE
AMOUNT OF MONEY THAT IS EVEN
THROUGH OUR DIRECT INVESTMENT
EVEN THOUGH WE HAVE THE FUNDING
FOR EPIDEMIOLOGY SERVICES AND
PREVENTION RESEARCH WHICH
OVERSEES THIS TYPE OF WORK HAS
BEEN VERY ROBUST.
THROUGH THIS FUNDING WE HAVE
MORE RESOURCES TO FUND BASIC
KNOWLEDGE THAT THEN OF COURSE
INFORMS THE DEVELOPMENT OF
MEDICATION AND THERAPEUTIC.
WHICH ARE ALSO FUNDED BY AS WELL
AS THROUGH THE HEEL BUDGET.
AS IT RELATES TO CHANGES IN THE
STAFF AT NIDA DR. JAK STAT A
NIDA CHIEF OF STAFF DECIDED TO
RETIRE ON DECEMBER 31, THIS IS A
BIG LOSS BECAUSE JACK HAS BEEN
AN INCREDIBLE PARTNER IN MANY,
MANY ACTIVITIES, VERY VERY
TALENTED.
BASICALLY VERY MUCH INTERESTED
AND HE SAID I OOH E NOT GOING TO
DISENGAGE FROM MY INVOLVEMENT
BUT THAT WAS OPEN NOW FOR CHIEF
OF STAFF AND HE WAS ALSO THE
DIRECTOR FOR THE OFFICE OF
SCIENCE POLICY AND
COMMUNICATION, AND VERY GLAD TO
ANNOUNCE WE NOW HAVE FORMAL
DIRECTOR JENNIFER WHO HAS TAKEN
POSITION OF DIRECTOR AND ALSO
IMMEDIATELY STARTED WITH A VERY,
VERY ACTIVE ROLE AND GET TO --
INTERACT WITH MORE IN THIS NEW
ROLE.
MAJOR CHANGES HAVE HAPPENED AS
YOU CAN SEE, NOT JUST THE
CURRENT PANDEMIC BUT FRANCIS
COLLINS, DIRECTOR OF THE NIH
DECIDED TO RETIRE, REALLY NOT
RETIRING, STAYING AS AN
INVESTIGATOR BUT HE IS RETIRING
FROM HIS ROLE AS NIH DIRECTOR
AND LARRY TABAK WHO HAS BEEN THE
MAIN DEPUTY DIRECTOR ASSUMING
THE ROLE OF ACTING DIRECTOR AND
LARRY HAS BEEN INVOLVED ALL
ALONG IN MANY PROJECTS, THAT ARE
RELEVANT TO NIDA INCLUDING THE
HEEL INITIATIVE.
AS A RESULT OF THAT NOW THE NEW
PERSON THAT HAS THE OVERSIGHT
FOR THE HEEL INITIATIVE ITSELF
IS DR. LARRY TABAK.
THE OTHER CRUCIAL ASPECT THAT
HAS ACTUALLY AFFECTED ALL OF OUR
LIVES AT MULTIPLE LEVELS FROM
OBVIOUSLY SCIENTIFIC PERSPECTIVE
HAS BEEN ACTUALLY A BIG
CHALLENGE BUT ALSO AN
OPPORTUNITY TO ADVANCE NEW
DEVELOPMENTS AND KNOWLEDGE ABOUT
WHAT COVID DOES IN OUR BODIES
AND AS ADVANCE OUR UNDERSTANDING
OF IMMUNE FUNCTION AND THAT
TECHNOLOGIES IN ORDER TO BE ABLE
TO DETECT IT.
IT CASTS VERY ACCELERATED
KNOWLEDGE AND INNOVATION INTO
THIS SPACE.
THE -- THIS IS AGAIN OVERSEEN
THROUGH THE DIRECTORS OFFICE AND
IT GAUGES BOTH RESEARCH THAT IS
-- THAT AIMS AT UNDERSTANDING
KNOWLEDGE BASIC KNOWLEDGE BUT
IMPORTANTLY HIGHLIGHTING
TRANSLATION IN NEW TREATMENTS
AND VACCINES AND NEW TOOLS FOR
ACTUALLY DETECTION OF THE VIRUS.
IT HAS BEEN ABLE TO ACCELERATE
THIS IN WAYS THAT HAVE NOT BEEN
POSSIBLE IN THE PAST.
IMPORTANTLY ALSO COVID
INITIATIVES FUNDED THROUGH THE
OFFICE OF DIRECTOR ARE VERY MUCH
NOW RECOGNIZING IMPORTANCE OF
POST ACUTE COVID SYNDROME IN
THAT IS ACTUALLY PUTS A NEW
CHALLENGE THAT RELATES NOT JUST
TO THE INFECTION ITSELF BUT
CONSEQUENCES OF THOSE INFECTIONS
MAY HAVE LONG TERM AND WHAT IT
WILL MEAN FOR THE POPULATION AND
IMPORTANTLY OF COURSE HOW WE DO
SCIENCE TO ADDRESS, FOR US AND
NIDA, ONE OF THE QUESTIONS HAS
BEEN JUMPING IS HOW COVID AFFECT
THOSE INDIVIDUALS SUFFERING FROM
SUBSTANCE USE DISORDERS, WHAT
ARE THE RISK FACTORS, RISK FOR
OUTCOMES AND HOW IT AFFECTS THE
MOST VULNERABLE AND NOW WITH THE
LONG LASTING COVID HOW DO DRUGS,
FOR EXAMPLE, AFFECT THE
DEVELOPMENT OF THESE CHRONIC
SYNDROMES ASSOCIATED WITH COVID.
THIS OF COURSE IS NOT KNOWN BUT
WE HAVE BEEN VERY PROACTIVE IN
SUPPLEMENTING RESEARCHERS TO BE
ABLE TO START TO ADDRESS THESE
QUESTIONS.
WITH RESPECT TO THE BRAIN
INITIATIVE, YOU ACTUALLY WANT TO
HIGHLIGHT THAT IT IS NOW BRAIN
2.0, LED BY DR. (INDISCERNIBLE)
PART OF THE NINDS IN THE NEXT
ROUND OF THE BRAIN INITIATIVE,
THEY ARE GOING TO BE THREE MAIN
PROJECTS ONE TO CREATE THE BRAIN
CELL ATLAS OF THE HUMAN BRAIN,
WHICH IS QUITE EXTRAORDINARY,
THE OTHER IS TO CREATE A WHOLE
MICROCONNECTIVITY OF MAMMALIAN
BRAIN AND THIRDED IS TO DEVELOP
TOOLS THAT HAVE BEEN ABLE
PRECISION ACCESS TO SPECIFIC
CELL TYPES.
AGAIN THIS IS AS TRANSFORMATIVE
AS IT GETS BECAUSE IN THE PAST
WE COULD NOT IN ANYWAY
SPECIFICALLY TARGET ONE CELL
TYPE OR EVEN WITH COVID.
NOW IT IS POSSIBLE FOR US TO
RECORD THOSE CELL TASKS AND IN
ADVANCES IN GENETIC TECHNOLOGY
LIKE CRISPER ENABLE US TO MODIFY
IN WAYS THAT ALLOW US TO
UNDERSTAND HOW THEY AFFECT
MICROCIRCUITRY HOW THEY AFFECT
BEHAVIOR.
VERY IMPORTANTLY FOR DRUG USE
BECAUSE IT CAN ENABLE US TO
INVESTIGATE WHICH CELLS ARE MORE
SENSITIVE, WHICH ARE RESPONSIBLE
FOR LONG LASTING EFFECTS MANY
THE PROCESS OF ADDICTION.
I WANT TO ADVERTISE THAT THE
ANIMAL MEETING FROM THE BRAIN
INITIATIVE MEETING IS GOING TO
TAKE PLACE JUNE 21ST AND 22ND AA
ARE OPENING UP BASICALLY IT IS
OPEN UP FOR SUBMISSION OF -- AND
THE DEADLINES ARE FEBRUARY 25 IF
YOU WANT TO SUBMIT THE SYMPOSIA.
MY GENERAL ASPECT.
WITH THAT I WANT TO JUMP INTO
WHERE ARE WE WITH DRUG USE IN
OUR COUNTRY.
AMID THE COVID PANDEMIC AND
OPIOID CRISIS.
LAST YEAR THE MONITORING THE
FUTURE WHICH RELEASES THIS DATA
IN DECEMBER, WHICH REFLECTS THE
DATA FOR THE 2021 PROVIDED US
EVIDENCE OF THE MOST DRAMATIC
REDUCTION IN THE USE OF DRUGS
AMONG TEENAGERS AND AS YOU KNOW
THE MONITORS IN THE FUTURE IS 8,
10 AND 12TH GRADERS.
THERE'S SIGNIFICANT REDUCTION IN
FOR THESE INDICATORS WHICH IS
PAST YEAR USE, OF ILLICIT
SUBSTANCES AND BASICALLY ALL OF
THE DRUGS.
ALMOST ALL THE DRUGS.
SIGNIFICANTLY DECREASE FROM ONE
YEAR TO THE OTHER, MOST NOTABLE
WHERE DECREASES IN H ALCOHOL
MARIJUANA AND NICOTINE.
IT IS ALSO REMARKABLE THAT THEY
ARE SEEING IT IN ALL THE GRADES
AND YOU SEE THIS SHARP DECLINE,
AMONG 10TH GRADERS THE QUESTIONS
THAT EMERGE IS WHAT DOES THIS
MEAN AND I'M JUST GOING TO SHOW
YOU THE DATA FOR THE DRUGS WHERE
WE SAW LARGEST CHANGES SO LET ME
GUIDE, THIS IS -- I'M SHOWING
YOU DATA FROM 2021 FOR 8 AND
12TH GRADERS.
SO FOR ALCOHOL MARIJUANA AND
NICOTINE, HERE WE HAVE 8, 10,
HERE WE HAVE 12TH GRADERS.
THE FIRST COLUMN IS 2020 AND THE
SECOND COLUMN IS 2021.
YOU CAN SEE THE SIGNIFICANT
REDUCTION IN ALCOHOL, LOOK AT
REDUCTION IN ALCOHOL FOR 10
GRADERS WHICH IS HUGE.
THESE ARE THE LARGEST CHANGES
THAT WE HAVE SEEN IN ONE SINGLE
YEAR IN DECREASE IN DRUG
CONSUMPTION.
WE HAVE SEEN THIS LARGE CHANGES
FROM INCREASES WITH VAPING BUT
NEVER WITH THIS LEVEL OF
DECREASE, ALSO SEEING IT WITH IN
THE 12TH GRADERS.
THE SAME STORY FOR MARIJUANA,
LOOK AT DRAMATIC REDUCTION IN
MARIJUANA USE AMONG 10 GRADERS
ALSO AMONG 12TH GRADERS FOR
MARIJUANA.
AND SIMILARLY WE ARE SEEING
REDUCTIONS FOR VAPING NICOTINE.
SO WHAT DOES THIS MEAN?
I THIS IS IT IS IMPORTANT FOR US
TO ASK THE QUESTION AND TRY TO
ACTUALLY UNDERSTAND IT BECAUSE
IF -- IT POINTS TO FACTORS THAT
ARE DRIVING THE DRUG TAKING IN
MY BRAIN WHAT I LIKE TO
SPECULATE IS THAT WE KNOW PEER
PRESSURE IS VERY IMPORTANT IN
DRUG TAKING AND DRUG TAKING
AMONG TEENAGERS IS A GROUP PEER
ACTIVITY.
SO TO THE EXTENT THAT
ADOLESCENTS HAVE LESS
OPPORTUNITY OF GETTING TOGETHER
AT SPORTING EVENTS OR EVEN AT
SCHOOL OR PARTIES THAT DECREASE
THEIR ABILITY TO CONSUME THESE
DRUGS.
ALSO TO THE EXTENT THERE WERE
MANY OF THEM LEARNING FROM HOME
WHETHER SOME OF THEM WITH THEIR
PARENTS OVERSEEING THEM THAT MAY
ALSO HAVE MADE IT HARDER FOR
THEM TO ACTUALLY ACCESS THE
DRUGS.
WITH THESE IMPORTANT QUESTION
BASED ON THIS ONE WILL HAPPEN
ONCE THE LIFE OF THIS TEENAGERS
IN SCHOOL BACK TO WHAT IT WAS IN
THE PAST IN TERMS OF SOCIAL
INTERACTION.
QUESTIONS YOU CAN ASK IS DOES
THIS REFLECT THE PATTERNS IN ALL
THE AGE GROUPS?
THE ANSWER IS ABSOLUTELY NOT.
AND WHAT WE SEE, THIS IS VERY
UNIQUE TO ADOLESCENTS.
WHAT WE SEE FOR EXAMPLE, THIS IS
DATA FROM MONITORING THE FUTURE
OR FOR INDIVIDUALS THAT ARE
MONITORING TO THEIR COLLEGE
YEARS, I WANT YOU TO FOCUS ON
MARIJUANA USE FROM 2015 TO 2020.
I'M PRESENTING HERE DATA THAT
RELATES -- THAT COMPARES THOSE
THAT HAVE COLLEGE VERSUS THOSE
THAT ARE NOT ON COLLEGE.
I'M PRESENTING BASICALLY PAST
YEAR FOR 2015.
DAILY USE OF MARIJUANA FOR 2015,
INDIVIDUALS THAT ARE ACTUALLY ON
COLLEGE AND THESE NON-COLLEGE.
YOU SEE ON DAILY VIEW THERE'S
MANY MORE NON-COLLEGE
INDIVIDUALS THAT ARE SMOKING
WARE MARIJUANA.
FAST FORWARD TO 2020, WHERE YOU
CAN SEE SIGNIFICANT RISE IN THE
DAILY USE OF MARIJUANA FOR BOTH
GROUPS IN TERMS OF PERCENTAGES
IS THE LARGEST FOR THOSE IN
COLLEGE.
WE ARE ALSO SEEK 10% INCREASES
OVERALL IN CONSUMPTION OF
MARIJUANA, THERE'S REALLY NO
DIFFERENCE BETWEEN COLLEGE AND
NON-COLLEGE.
SO OVERALL THERE ARE SOME DRUGS
AMONG THESE YOUNG GROUP OF
INDIVIDUALS THAT CHANGE AND
OTHERSES THAT DID NOT CHANGE ON
THE COVID PANDEMIC, EVIDENCED BY
THE COMPARISON BETWEEN 2019 AND
2020.
IN 2019 WHICH IS PRE-PANDEMIC
BASICALLY THIS FOR MARIJUANA
VAPING, THIS IS FOR NICOTINE
VAPING.
THERE APPEARS TO BE SOME SLIGHT
CHANGES WITH NOTING THAT IT IS
VERY SIGNIFICANT, WHAT WE ARE
SEEING MAJOR CHANGES IN
SIGNIFICANCE IS I WOULD SAY WITH
ALCOHOL DRINKING, AND ALCOHOL
DRINKING FOR COLLEGE KIDS GOT
SIGNIFICANTLY DECREASED DURING
THE PANDEMIC AND AGAIN THIS WILL
REFLECT THE FACT THAT ALCOHOL
DRINKING AMONG YOUNG ADULTS
BASICALLY COLLEGE KIDS IS VERY
MUCH LINKED ALSO WITH SOCIAL
ACTIVITIES AND THE SOCIAL
DISTANCES IS ACTUALLY MADE THIS
HARDER.
AGAIN WE WILL SEE HOW THIS
EMERGES ONCE RESTRICTIONS ARE
REMOVED.
THERE IS ALSO VERY INTERESTING
CHANGE THAT CAPTURE MY EYE WHICH
WAS IN TERMS OF VIEWS AMONG
THESE INDIVIDUALS.
IT CAPTURE MY EYES BECAUSE WE
HAVE NEVER SEEN THAT LEVEL OF
PREVALENCE OF USE OF
HALLUCINOGENIC DRUGS EVER.
THIS IS MOST NOTABLE ACTUALLY I
WOULD SAY YOU SEE FROM THE 2019
TO 2020 BUT THE DELTA IS MOST
NOTABLE AMONG THOSE THAT ARE
GOING TO COLLEGE AND 5.3% TO
8.6%.
IT IS CLOSE TO 10% AMONG THOSE
THAT ARE NOT GOING TO COLLEGE.
AND OBVIOUSLY ONE OF THE FACT
THATHATFACTORSTHAT DRIVE INCREASED ATTENTI ON
TO HALLUCINOGENIC DRUGS
INCLUDING THE DIALOGUE REGARDING
ITS POTENTIAL THERAPEUTIC
BENEFITS FOR MENTAL HEALTH, AS
WELL AS I GUESS ISOLATION AND
ROUTINE LIFESTYLE THAT THE COVID
PANDEMIC HAS IMPOSED UPON ALL OF
US THAT MAY MAKE CERTAIN DRUGS
THAT CHANGE MENTAL STATES MORE
APPEALING UNDER THESE CONDITIONS
BUT AGAIN THIS IS A TIME
SPECULATIVE FOLLOWING THESE
TRENDS WILL ENABLE US TO GET A
BETTER UNDERSTANDING ABOUT WHAT
IS DRIVING THEM.
AS RELATES OF COURSE TO HOW DO
WE UNDERSTAND DRUG TAKING IN
ADOLESCENCE AND WHAT ARE THE
FACTORS OF MAKING THEM
VULNERABLE PERHAPS ONE OF THE
MOST EXCITING STORIES HAS BEEN
THE A B C D STORY DONE IN
PARTNERSHIP WITH ALCOHOL
INSTITUTE AS WELL AS OTHER
INSTITUTES AT NIH INCLUDING
NIMH.
HIS STUDY BASICALLY STARTED
ASSESSMENTS IN 2016, 2017, IS
ACTUALLY READY TO GET INTO THE
7TH YEAR OF INCEPTION, IT
FOLLOWS CLOSE TO 12,000 KITS
FROM AREAS ALL OVER THE UNITED
STATES.
AND IT IS QUITE EXTRAORDINARY
LED BY DR. DICES DIS IN WHAT I
BASICALLY REFER TO AS PROBABLY A
STRIKINGLY WELL MANAGED PROGRAM,
THIS IS EVIDENCED BY LEVEL OF
RETENTION.
12,000, CLOSE TO 12,000 PERCENT
RETAIN CLOSE TO 98% DESPITE THE
COVID PANDEMIC.
SO THAT GETS YOU AN IDEA HOW
WELL THIS IS BEING MANAGED.
IN THE MEANTIME THE DATA IS
DEPOSITED REGULARLY SO IT CAN BE
OPEN ACCESS AND AVAILABLE TO ALL
INVESTIGATORS.
THESE GUYS LED RAPIDLY TO
PUBLICATION, NOT JUST FROM THOSE
INDIVIDUALS THAT ARE A B C D
INVESTIGATORS BUT IMPORTANTLY
FOR EVERYONE THAT IS INTERESTED
ON QUERYING THE DATA TO ANSWER
QUESTIONS THAT RELATE TO HOW THE
BRAIN DEVELOPS AND HOW BEHAVIORS
FROM CHILDREN CHANGE AND IT --
THERE HAS NOT BEEN ANOTHER
DATABASE THAT HAS THE ABILITY TO
SAMPLE SIZE TO ADDRESS THIS SO
IT IS BEING VERY TRANSFORMATIVE
IN ADVANCING OUR UNDERSTANDING.
YOU CAN SEE THE RATE OF
INCREASES IN PUBLICATION IS JUST
GOING UP, LEAST AS OF NOW 298
PUBLICATIONS OUT OF THE A B C D.
RAPIDLY WE REALIZE THE
OPPORTUNITY THAT THE A B C D
HAVE FOR RELATING LETTING US
INVESTIGATE AND UNDERSTAND
CHANGES IN LIFE OF TEENAGERS
WITH COVID PANDEMIC.
RAPIDLY WE PROVIDED SUPPLEMENTS
TO THE A B C D INVESTIGATORS SO
THAT THEY COULD DO SURVEYS THAT
WILL MONITOR THE ACTIVITY AND
CONSEQUENCES OF THAT COVID
CHANGES TO THESE TEENAGERS.
OUT OF THAT I CAME MULTIPLE
PUBLICATIONS AND THESE ARE
ACTUALLY ADDRESS HERE, THAT
IDENTIFY INDEED AS WE WOULD HAVE
EXPECTED, THE COVID PANDEMIC HAS
HAD A MAJOR TOLL IN ADOLESCENTS,
THEY ARE VERY SIGNIFICANT
DIFFERENCES BETWEEN THEM, SOME
ARE MORE VULNERABLE THAN OTHERS
BUT OVERALL TEENAGERS ARE
REPORTING HIGHER LEVELS ON --
ALSO REPORTING HIGHER LEVELS OF
BOREDOM.
THOSE TEENAGERS ARE -- START
WITH MORE THE MORE VULNERABLE
ARE ONES THAT ARE DISRUPTED THE
MOST.
BY THE PANDEMIC WITH HIGH
IRDIESES STRESS AND ALSO WHAT IT
IS CLEAR TOO IS THERE'S CERTAIN
LIFESTYLES AND FAMILY BEHAVIORS
THAT CAN PROVIDE RESILIENCE AND
PROTECTION AND THERE'S A RECENT
PAPER THAT ACTUALLY SHOWS THAT
THOSE TEENAGERS THAT COME FROM
FAMILIES WHERE THERE IS A VERY
WELL STRUCTURED DAY THEY HAVE
TIMES THEY GO TO BED AND WAKE UP
AND PHYSICAL ACTIVITY AND THEY
EAT TOGETHER.
THAT HELPS AMELIORATE THE
CHALLENGES FROM THE COVID
PANDEMIC.
THIS IS JUST WHAT THEY ARE,
MONITORING MULTIPLE FACETS OF
THE COVID PANDEMIC IN A LOT OF
TEENAGERS.
FROM THE PERSPECTIVE COVID-19
FROM POST ACUTE SYNDROME OF
COVID IT OFFERS EXTRAORDINARY
OPPORTUNITY TO KNOW WHAT DOES IT
DO, WHAT DOES THIS INFECTION DO
TO THE BRAIN AND DOES IT HAVE
LONG LASTING EFFECT OR IF IT HAS
LONG LASTING EFFECT IS IT ONLY
SEEN IN THOSE THAT HAVE PAST.
WHAT ARE THOSE CHANGES?
THIS ALSO IMPORTANT TO REALIZE
THAT BECAUSE CHANGES HAVE BEEN
NOT JUST FROM THE VIRUS ITSELF
BUT FROM SOCIAL STRUCTURE WAY
THEY ARE LEARNING, HOW DOES THAT
IMPACT BRAIN DEVELOPMENT AND
BEHAVIOR.
WE PARTNER, WITH THE RECOVER
INITIATIVE AT THE NIH, WHICH
FOLLOWS INDIVIDUALS TO SEE WHAT
ARE THE MECHANISMS THAT ARE
UNDERLYING THE POST AQUME
SYNDROME NEUROINFLAMMATORY
VASCULAR OR VIRUS ITSELF, THERE
ARE SEVEN YOU HAVE SEEN
CERTAINLY FROM DATA THAT STARTED
TO BE PUBLISHED IN ADULTS THAT
IMMUNE MECHANISMS ARE VERY
IMPORTANT IN THE BRAIN CHANGES.
THERE IS ALSO SOME EVIDENCE THAT
INDICATES VIRAL PRESENCE IN THE
BRAIN ACTUALLY IN SEVERAL BRAIN
REGIONS AND AS BASED ON POST
MORTEM BRAINS.
WE WILL THROUGH THE A B C D
PARTNERS SO WE CAN NOW FOCUS
MUCH GREATER LINE ON TEENAGERS
WITH THIS FUNDING WE WILL BE
OBTAINING COVID ANTIBODY TESTING
OF THE CAREGIVER AND SURVEY
SYSTEMATICALLY FOR PAST
SYMPTOMS.
DIFFERENTIATES INFECTION FROM
GENERAL PANDEMIC RELATED EFFECTS
AND I WILL HIGHLIGHT ANOTHER
IMPORTANT AREA OF RESEARCH THAT
PERTAINS TO ADOLESCENTS IS THEY
DO GET INFECTED ARE THERE
NEGATIVE EFFECTS OF DRUGS.
SO HOW WILL DRUGS BE AFFECTING
THEIR LIKELIHOOD OF DEVELOPING
PATHS HAY DEVELOP PAST AND
CONSUME DRUG DOES THIS
EXACERBATE IT.
THOSE ARE QUESTIONS WE DON'T
HAVE ANSWERS ABOUT.
WE KNOW THAT IS NOT GOOD FOR YOU
TO TAKE DRUGS IF YOU HAVE HIV
BECAUSE IT ACCELERATES
INFLAMMATORY RESPONSE, SOME OF
THESE DRUGS.
THE OTHER MAJOR PROGRAM THAT WE
ARE LAUNCHING THAT IS SEPTEMBER
OF 2021 THAT IS ALSO VERY
RELEVANT TO UNDERSTANDING DRUG
EXPOSURE IN THE BRAIN AND HOW
ADVERSE SOCIAL ENVIRONMENTS
INFLUENCES RACE OF CHILDREN TO
TAKE DRUGS LATER OEN AND OTHER
MENTAL HEALTH CONDITIONS,
FOLLOWING VERY MUCH THE TEMPLATE
FROM THE A B C D INITIATED IN
INFANCY IS THE HBCD STUDY THAT
GRANTS WERE FUNDED ON SEPTEMBER
OF LAST YEAR PI 25 SITES MET
OCTOBER OF LAST YEAR.
THESE ARE THE SITES.
WE HAD FUNDED THROUGH A PILOT
PROJECT SOME OF THESE SITES.
THERE IS ALREADY DATA SHOWING
EFFECTS OF COVID, PRELIMINARY
DATA SHOWING EFFECTS ON BRAIN
DEVELOPMENT OF THE MOTHER
GETTING COVID DURING PREGNANCY
HOW THAT AFFECTS THE DEVELOPMENT
OF THE NEWBORN.
SO THAT ALSO HIGHLIGHTS HOW
IMPORTANT IT IS GOING TO BE TO
FOLLOW THESE CHILDREN THAT ARE
BORN DURING THE COVID PANDEMIC
AND AGAIN, THE SITES SELECTED
WERE SELECTED TO BE ABLE TO
RECRUIT.
FROM PARTICULARLY VULNERABLE
HOUSEHOLDS WHERE IT IS HIGH RATE
OF DRUG USE.
AND OBVIOUSLY WE ARE INTERESTED
IN UNDERSTANDING HOW OPIOID USE
DURING PREGNANCY WITH AND
WITHOUT OTHER DRUGS INFLUENCES
BRAIN DEVELOPMENT BUT THIS IS
HAPPENING ALSO AT THE SAME TIME
WE ARE UNDERGOING SOCIETAL
CHANGES FROM COVID AND
EVERYTHING THAT COMES WITH IT.
INCLUDING INFECTION, INCLUDING
INFECTIONS OF THESE SOME OF
THESE CHILDREN.
SO HOW IMPORTANT IS THIS?
I THINK JUST HIGHLIGHTING THIS
IS BASICALLY NOTHING TO DO PER
SE WITH HAVING BEEN INFECTED
WITH BUT A STUDY DONE BY ONE OF
THE INVESTIGATORS FROM THE HBCD
MONITORING CHILDREN IN EARLY
CHILDHOOD WHEN THEY ARE THREE
MONTHS OLD UP TO THREE YEARS OF
AGE MONITORING THEM FOR THEIR
COVID CAPABILITIES AND
(INAUDIBLE) PERIODICALLY, SO HE
WAS ABLE TO OBTAIN 112 CHILDREN
BORN DURING THE COVID PERIOD AND
EVALUATED IN THE SAME WAY.
THIS IS APPROPRIATE IT HAS NOT
BEEN PUBLISHED FORMALLY YET.
I WANT TO LOOK AT IT, THE
FINDINGS ARE QUITE LARGE.
ACTUALLY SHOWING THAT THESE
CHILDREN THAT ARE WITHIN ONE
YEAR OF AGE HAVE TWO STANDARD
DEVIATIONS FROM THAT PERFORMANCE
WHERE IT IS VEERABLE OR
NON-VEERABLE FUNCTIONING
INVESTIGATORS HAVE BEEN
RECORDING OVER THE PAST NINE
YEARS.
THIS AGAIN IS NOT THE COVID
INFECTION ITSELF, VIRUS, IT
APPEARS TO BE RELATED TO THE
MAJOR CHANGES IN WHICH THIS NEW
VERY YOUNG CHILDREN ONE YEAR OF
AGE MAYBE DEPRIVE OF SOCIAL
INTERACTIONS OTHERWISE THEY WILL
HAVE BEEN EXPOSED TO HAD THERE
BEEN NOT SOCIAL ISOLATION AND
HAD THEIR PARENTS NOT BASICALLY
BEEN ABLE TO PERHAPS GO
INTERACTING IN WAYS THAT THEY
WERE BRAIN DEVELOPMENT, AGAIN,
WE ARE, IT IS VERY DIFFICULT TO
REALLY UNDERSTAND WHAT IS
DRIVING THIS -- WHAT APPEARS
DEVELOPMENTAL DELAYS BUT IT IS
LIKELY TO BE LOT OF SOCIAL
STIMULATION WHICH IS
EXTRAORDINARILY IMPORTANT FOR
BRAIN DEVELOPMENT DUE TO THE
CONSEQUENCES OF WHAT WE ARE
BEING FORCED TO LIVE FROM THE
COVID PANDEMIC.
THEN FROM THE COVID PANDEMIC TO
THE OVERDOSE CRISIS, I HAVE BEEN
PRESENTING EVERY TIME I SPEAK AT
COUNCIL WHERE ARE WE WITH THE
COVID PANDEMIC AND YOU HAVE SEEN
WITH THE COVID PANDEMIC THE
NUMBER OF OVERDOSE DEATHS
SKYROCKETED.
SINCE I LAST PRESENTED IN
SEPTEMBER OF LAST YEAR, TO
COUNCIL WE HAVE REACHED MORE
THAN 100,000 PEOPLE HAVE DIED
OVER ONE YEAR PERIOD.
THAT WAS IN 6/20/21 COMPARED TO
6, 2020 AT THE 84,000, HA THAT
IS AN OVERALL 20% INCREASE, I
HIGHLIGHT TO YOU WHAT I GOT
DRUGS THAT ARE ACTUALLY
ACCOUNTING FOR THESE DRAMATIC
NON--- OVERDOSE DEATH AND
HIGHLIGHT HOW WE CHANGED.
HEROIN OVERDOSES ARE GOING DOWN
AND OVERDOSES FROM PRESCRIPTION
OPIOIDS ARE NOT GROWING,
ACTUALLY QUITE STABLE.
THE INCREASES ARE DUE TO TWO
TYPES OF DRUGS, BASICALLY
FENTANYL AND THE OTHER IS
METHAMPHETAMINE.
I WANT TO HIGHLIGHT AS WE HAVE
BEEN VERY ORAWAY HOW FENTANYL
HAS CREATED IN THE OVERDOSE
DEATH.
WHAT I WANT TO PAY ATTENTION TO
THIS NUMBER HERE, 43% OF
INCREASE IN OVERDOSE, BECAUSE IT
IS CLEARLY METHAMPHETAMINE IS
HAVING AN INCREASE IMPACT ON
MORTALITY, I HAVE SEEN WITH
OVERDOSES BUT IT IS ALSO LIKELY
NEGATIVELY AFFECTING MANY OTHER
OUTCOMES, MEDICAL AND BASICALLY
BEHAVIORAL.
MT. AMPHETAMINE IS MOST ADDICT
GIVE DRUGS THAT WE KNOW AND ALSO
HIGHLY TOXIC AND THOUGH IT HAS
HIGH PRODUCING OVERDOSE DEATH AS
IS THE CASE WITH OPIOIDS BECAUSE
THEY STOP YOU FROM BREATHING,
ACTUALLY IT DOES CAUSE MAJOR
DAMAGE AND CARDIOVASCULAR
PATHOLOGY.
THESE DEATHS FROM
METHAMPHETAMINE, 75% ARE
AEVERYBODYIATED WITH FENTANYL.
SO THE METHAMPHETAMINE DRUGS ARE
WIDESPREAD, NOT JUST LIMBED TO
THE WEST COAST BUT ALSO TO THE
EAST COAST.
ARE HAVE A HIGH PROBABILITY OF
BEING LACED WITH FENTANYL WHICH
INCREASES THE RISK OF MORTALITY
FOR THOSE THAT TAKE THEM.
THIS IS A SPACE THAT IS VERY
CHALLENGING.
AND I THINK IT IS ALSO
CHALLENGING IN TERMS OF
RECOGNIZING THAT METHAMPHETAMINE
IS BECOMING A MAJOR, MAJOR DRUG
OF ABUSE, A PROMINENT DRUG AFTER
ABUSE.
THERE IS ALSO CURRENTLY WE
PRESENT ON THIS BUT I'M SHOWING
IT IN INDICATOR TABLE THAT I
THINK TELLS US THE WHOLE STORY
ABOUT HOW THE GRAPHICS GOT
CHANGED IN THE OPIOID CRISIS OR
OVERDOSE CRISIS IS BETTER LABEL
OVERDOSE CRISIS, BECAUSE YES, IT
IS STARTED BY DAY 8 -- BASICALLY
PREDOMINANTLY INFLUENCING THE
THE TEST FROM WHITE AMERICANS
AND AS YOU SEE HERE IN RED.
BECAUSE OF PRESCRIPTION OF
OPIOIDS.
ANY PARALLEL YOU SAW RATE OF
OVERDOSE DEATH WAS EQUIVALENT
FOR AMERICAN INDIANS.
OVERALL FOR BLACK AMERICANS HAVE
HAD STABLE LEVELS OF OVERDOSE
AND THOSE LEVELS WERE STABLE
UNTIL AROUND 12, 13 WHEN THEY
START TO GO UP THAT'S WHEN WE
SEE INCREASE REPRESENTATION OF
-- BUT IMPORTANTLY NOW HAVE
FENTANYL WHICH IS CONTAMINATED
ALL OF THE DRUGS.
AND THEN FENTANYL
METHAMPHETAMINE BUT FENTANYL
CONTAMINATING COCAINE.
THAT COMBINATION IS LIKELY ALSO
TO ACCOUNT FOR WHY WE ARE SEEING
INCREASE IN DEATH FROM COCAINE.
WHAT I WANTED TO SEE HOW
DRAMATIC SHOWED UP.
WE TRANSLATE THESE GRAPHS IN TO
THE NUMBER OF INDIVIDUALS PER
HUNDRED, THOUSANDS OF POPULATION
THAT DIED, YOU CAN SEE FOR
WHITES IT IS 33 PER 100,000.
FOR BLACKS 35.4 AND FOR AMERICAN
INDIANS IT GOES TO 42 PER
100,000.
SO THIS IS A GROUP THAT AGAIN IS
ALSO DEVASTATED BY THE OVERDOSE
DEATH, AMERICAN INDIANS WE KNOW
THAT HAVE ALWAYS BEEN HAVING A
HIGHER NUMBER OF OVERDOSES PRO
METHAMPHETAMINE THAN OTHER
GROUPS.
SO THESE VERY STEEP RISE IN
OVERDOSE MORTALITY AND AMERICAN
INDIANS ALASKA NATIVES LIKELY TO
IN PART REFLECT CONTAMINATION AS
MENTIONED BEFORE WITH
METHAMPHETAMINE WITH FENTANYL.
IT DOES HIGHLIGHT HORRIFIC
DISPARITIES WE ARE FACENING THE
OVERDOSE CRISIS NOW THAT ARE
BECOMING ACCENTED, THE NEED TO
ACTUALLY DO INTERVENTIONS THAT
CAN -- THAT CONTAIN.
WHAT IS IT THAT WE CAN DO?
WITH SCIENCE AND OBVIOUSLY WE
HAVE BEEN WORKING VERY, VERY
AGGRESSIVELY TO TRY TO IDENTIFY
INTERVENTION SCIENCE THAT CAN
HELP ADDRESS THIS CRISIS.
ONE OF THEM WE KNOW THAT THE
MOST POWERFUL TOOLS THAT WE HAVE
FOR ACTUALLY CONTROLLING AND
PREVENTING OVERDOSE DEATH RELATE
TO TWO THINGS VERY SIMPLE
THINGS.
ONE OF THEM IS PROVIDED
MEDICATION FOR OPIOID USE
DISORDERS AND AT LARGE GROUP OF
PEOPLE AS WE CAN BUT DISTRIBUTE
NALOXONE, IT'S BEEN
INVESTIGATORS DOING MODELING
HAVE SHOWN THAT THESE ARE THE
TWO MOST -- THE TOOLS WE HAVE
THAT IMPLEMENT HAVE THE MOST
DRAMATIC EFFECT IN PREVENTING
OVERDOSE.
SO AT THE SAME TIME WE REALIZE
THE MEDICATIONS THAT WE
CURRENTLY HAVE WHILE B BEING
EFFECTIVE IN PROTECTING
INDIVIDUALS THAT THERE IS A
PROBLEM IN TERMS OF RETENTION
AND THE RISK OF RELAPSE IS
PRETTY HIGH EVEN IF YOU ARE ON
THIS MEDICATION SO WE NEED TO
ENHANCE MEDICATION THAT MAY OR
COMBINE MEDICATION THAT MAY
IMPROVE RETENTION.
AS IT RELATES TO NALOXONE WHICH
IS REALLY AN EXTRAORDINARY DRUG
FOR REVERTING OVERDOSES AND
REVERTS OVERDOSE FENTANYL, AS
POTENT OPIOID AS IT IS PROVIDED
THAT YOU ACTUALLY GIVE IT IN IF
TIME AT THE SUFFICIENT DOSE.
BUT IT IS ALSO CLEAR THAT THE --
THESE DRUGS HAVE LONGER FENTANYL
AND OTHER ANALOGS, OTHER EFFECTS
THAN NALOXONE AND NEED TO HAVING
ALTERNATIVES TO NALOXONE
INCLUDING THE ADDRESSING THE
CHALLENGES OF HOW DO YOU ENSURE
THAT YOU ARE GOING TO BE ABLE TO
DELIVER NALOXONE SUFFICIENTLY
RAPIDLY BECAUSE FENTANYL GETS
INTO THE BRAIN AS MUCH FASTER
THAN HEROIN AND AS A RESULT OF
THAT HIT GREATER DEPRESSION WHEN
PUT THESE TWO TOGETHER.
EXTRAORDINARY FOR MICROKINETICS
INTO THE BRAIN AND HIGH POTENCY
AND THAT IS WHY YOU ARE FACING
THESE VERY HIGH RATES OF
OVERDOSE MORTALITY.
SO BEING ABLE TO DESIGN
INJECTORS OR METHODS THAT ENABLE
INDIVIDUAL TO UNDERSTAND AND
IDENTIFY WHEN SOMEONE MAYBE
GOING THROUGH OVERDOSE SO IT CAN
BE ADMINISTRATION OF THE
NALOXONE THROUGH MOUTH INJECTOR
OR ACTUALLY AN EMERGENCY SERVICE
IDENTIFICATION.
THERE IS ALSO WORK ONGOING TO
DEVELOP ALTERNATIVES SUCH AS
STIMULATING OF RESPIRATION,
MONOCLONAL ANTIBODIES FOR
FENTANYL, MONOCLONAL ANTIBODIES
THAT ADDRESS, PERHAPS EVEN HELP
WITH TREATMENT, DRUGS THAT CAN
SEQUESTER THESE COMPOUNDS SO
THEY CAN MINIMIZE THE TOXIC
EFFECT OF THESE DRUGS.
AND IN TERMS OF THERAPEUTICS
THEY ARE THERAPEUTIC THAT FOLLOW
NEW FORMULATIONS THAT IN MANY
WAYS ARE THE LOW HANGING FRUIT
BECAUSE IT WILL IMPROVE
RETENTION TO TREATMENT AND A LOT
OF WORK HAS GONE WITH
BUPRENORPHINE AND NALTREXONE BUT
NO WORK GOING ON WITH METHADONE.
AND AS A RESULT OF THAT ONE OF
THE PROJECTS THAT WE ARE FUNDING
IS THIS EXTENDED RATES OF
FORMULATION WITH THE ORAL
METHADONE THROUGH THAT COVID
WILL CHANGE THE WAY THAT
PATIENTS THAT ARE METHADONE ARE
ACTUALLY TREAT BADS IT WILL
ALLOW METHADONE IN A SAFE WAY
AND THE PATIENTS DON'T HAVE THE
BURDEN TO HAVE TO TAKE IT FROM A
DAILY BASIS.
ADVANCES IN OUR UNDERSTANDING OF
THE NEUROCIRCUITRY THAT INVOLVED
IN VARIOUS STAGES OF ADDICTION
CYCLE, AS WELL AS THE
DEVELOPMENT OF TOOLS WITH MORE
PRECISE STIMULATION OR
INNOVATION OF THESE CIRCUITS
PROVIDES MECHANISMS THAT
ACTUALLY ALLOW US TO FREE
BASICALLY POTENTIAL TO TREAT
ADDICTED BEHAVIORS BY THEMSELVES
OR COMBINATION WITH MEDICATIONS
WHETHER TRANSCRANIAL MAGNETIC
SIMULATION, BRAIN CURRENT
STIMULATION, EVEN DEEP BRAIN
STIMULATION AND THERE'S BEEN
SOME FASCINATING ADVANCES IN THE
BRAIN STIMULATION THAT ENABLE
YOU TO DELIVER STIMULATION ON
THE BASIS OF THE PATTERN OF
NEURONAL ACTIVITY THAT
INDIVIDUAL HAS THAT IS
ASSOCIATED WITH BEHAVIOR YOU ARE
TARGETING.
THIS OF COURSE HAS BEEN APPLY
FOR PARKINSON DISEASE, APPLIED
ONE CASE APPLIED FOR DEPRESSION.
WITH WHY SIGNIFICANT RESULT.
THIS NEEDS TO BE EXPLORED.
SIMILARLY FOR PERIPHERAL NERVE
STIMULATION ALLOWS US A MEANS TO
MODIFY CIRCUIT ACTIVITY.
AS IT RELATES TO NEW
OPPORTUNITIES FOR MEDICATION
DEVELOPMENT WHETHER IT IS FOR
OPIOID USE DISORDER MT.
AMPHETAMINE USE DISORDERS, NEW
TARGETS ARE COMING OUT FROM
SCIENCE, WE HAVE ALL THESE BASIC
SCIENCE AND DISCOVERIES AND THE
IDEA IS HOW TO MOVE THEM INTO
THE ULTIMATELY THERAPEUTIC
WORLD.
THAT'S WHERE THE VALUE OF THAT
EXISTS SO DR. (INAUDIBLE) AND
HER TEAM CAME UP WITH A PROCESS
THAT SAYS MAYBE IT IS JUST TOO
AMBITIOUS TO TRY TO DO THIS
THROWN THE VALLEY OF DEATH BUT
WHY ESTABLISH THAT ENABLES US TO
GO ONE STEP AT A TIME.
SO THEY A-- CLIMB UP OUT OF THE
VALLEY OF DEATH THROUGH THE
SUCCESSFUL PROGRAM THAT IS FA I
WILFACILITATING BRINGING OF
COMPOUNDS CLOSER TO PHASE 1 OR
PHASE 2 CLINICAL TRIALS.
AS EXCITING OBVIOUSLY IS VERY
EXCITING ALL THIS RESEARCH IN
TERMS OF THERAPEUTICS.
ANOTHER EXTREMELY IMPORTANT AREA
OF RESEARCH, AGAIN GREAT URGENCY
IS WE HAVE TREATMENT THAT WORK
AND WE HAVE NALOXONE THAT
REVERTS OVERDOSES AND WE KNOW
WHAT TO DO TO HELP ACTUALLY IF
WE DID, WE WILL BASICALLY ON ALL
THIS MODELING RESOURCE WE WILL
BE ABLE TO RETAIN AND REVERT THE
EPIDEMIC.
WE ARE NOT DOING IT, WE ARE
BASICALLY THERE ARE MAJOR
CHALLENGES IN THE DELIVERY OF
THIS INTERVENTIONS AND THAT
RELATES TO PLEA MENNATION
SCIENCE, WHAT MODELS OF CARE,
WHAT SYSTEMS SHOULD WE BE USING
TO DEPLOY THESE THERAPEUTICS.
FOR US IN THE FIELD OF SUBSTANCE
USE DISORDERS, THERE IS THAT
EXTRAORDINARY OPPORTUNITY OF
ENGAGING HEALTHCARE SYSTEMS
BECAUSE THEY ARE BASICALLY
ACCESSIBLE IN PRINCIPLE TO
EVERYONE.
BUT THEY HAVE NOT ENGAGED
TYPICALLY ON SCREENING OR
TREATING PEOPLE WITH SUBSTANCE
USE DISORDER FOR OPIOID USE
DISORDER.
SO AN OPPORTUNITY TO BRING THE
HELPER SYSTEM.
SO WE LAUNCHED SEVERAL PROJECTS
LIEU THE CLINICAL TRIAL NETWORKS
TO MAXIMIZE THAT DEPLOYMENT.
WHAT WE ALSO A ACTUALLY FOR THE
TREATMENT OF SUBSTANCE USE
DISORDER THE STEP BECOMES VERY
IMPORTANT FOR US BECAUSE THERE
IS SIGNIFICANTLY LARGE NUMBER OF
PEOPLE THAT SUFFER FROM
SUBSTANCE USE DISORDER OR OPIOID
USE DISORDER AND IN JUSTICE
SETTINGS.
AND RESEARCH HAS SHOWN IF YOU
ARE ABLE TO ACCURATELY PROVIDE
TREATMENT, WHILE IN JAIL OR
UNDER PAROLE, YOU SIGNIFICANTLY
IMPROVE THEIR OUTCOMES.
>> YOU JUST MUTED YOURSELF.
>> I WAS COMMENTING THAT WHILE
THE PROGRAMS HAVE SHOWN IN THAT
IMPLEMENTING TREATMENT IN JAILS
ACTUALLY PREVENTS MORTALITY,
ALSO IMPROVES RETENTION IN
TREATMENT, THERE IS A NEW PAPER
THAT WAS RELEASED FROM
MASSACHUSETTS THAT SHOWS
INTERVENTION THAT GIVE
BUPRENORPHINE IN THE JAIL
ACTUALLY PREVENTED
REINCARCERATION.
SO THIS IS DIFFERENT FROM WHAT
OTHER FINDINGS HAVE SHOWN THAT
HAVE BEEN UNABLE TO ACTUALLY
DOCUMENT A POSITIVITY RATE ON
INCARCERATION IN THIS STUDY IT
IS NOTABLE THEY DO SHOW IT,
ACTUALLY.
BUT MAY REFLECT THE FACT THIS
PARTICULAR JAILS WERE IN RURAL
COMMUNITIES BUT IT DOES
HIGHLIGHT HOW CRUCIAL IT IS FOR
US TO UNDERSTAND AND BRING
FORWARD THESE TREATMENTS IN TO
THE JUSTICE SETTING SO THAT
PATIENTS CAN BE PROVIDED THE
HELP THEY NEED.
THIS IS DONE THROUGH THE FUNDING
WE GET THROUGH THE HEEL
INITIATIVE.
THAT ALLOW US TO BASICALLY FUND
JUSTICE COMMUNITY INNOVATION
NETWORK THAT IS ABLY LED BY
TRISHA WHEEL AND HER TEAM IN DR.
BLANKO'S DIVISION.
THEN WE HAVE THE COMMUNITY SO IT
IS HEALTHCARE, JUSTICE,
COMMUNITIES, PARTNERING ACROSS
DIFFERENT MEMBERS OF THE
COMMUNITIES WHETHER IT IS POLICE
DEPARTMENT, WHETHER IT IS THE
STATE AGENT, OR HOSPITALS, THE
JAIL SYSTEMS.
INTEGRATING THE ACTIVITIES THAT
RESEARCH HAS SHOWN WHICH THERE
IS EVIDENCE OF BENEFIT ACROSS
ALL THESE PLAYERS IN THE
COMMUNITY IS WHAT THE COMMUNITY
STUDY IS DOING AND LEARNING HOW
THE CREATE NETWORKS OF
COLLABORATION AND HOW TO
MAXIMIZE OBTAINING OF DATA AND
US SEMINATION.
DISSEMINATION.
I ALSO WANT TO MAKE YOU AWARE OF
A NEW PROGRAM LAUNCHED LAST YEAR
AT THE END OF LAST YEAR WHICH IS
THAT HEEL INTEGRITY MANAGEMENT
USE OF PAIN AND USE DISORDER AND
RECOVERY LED BY DR. SHELLEY SHOE
WHICH ADDRESSES ONE OF THE MOST
CHALLENGING ISSUES THAT WE HAVE
IN THE TREATMENT OF INDIVIDUALS
WITH AN OPIOID USE DISORDER.
AND THAT IS INDIVIDUALS THAT
HAVE CHRONIC PAIN AND HAVE
OPIOID USE DISORDER.
AND THE PREVALENCE OF THIS
CO-MORBIDITIES IS QUITE HIGH.
IT IS BASICALLY BETWEEN 25 TO
30% INDIVIDUALS WITH OPIOID USE
DISORDER HAVE CHRONIC PAIN
SYNDROMES.
WHAT IS NOTABLE IS CHRONIC PAIN
REMAINS EVEN AFTER REMISSION AND
TREATMENT OF THE OPIOID USE
DISORDER.
IT IS CHALLENGING BECAUSE HOW DO
YOU TREAT FROM?
SO THIS NETWORK WILL ENABLE
ADVANCING THESE AREA OF RESEARCH
RESEARCH, TO HELP UNDERSTAND
WHAT ARE THE MODES TESTIFY
TREATMENT OPTIMAL FOR IMPROVE
FUNCTIONING OF INDIVIDUALS
SUFFERING FROM THIS CO-MORBID
CONDITIONS.
TO ADDRESS THE QUESTION WE NEED
TO UNDERSTAND,S DO CHRONIC
EXPOSURE TO OPIOIDS A FACTOR
THAT CONTRIBUTES TO THE CHRONIC
PAIN CONDITIONING CELL AS COULD
BE PERHAPS SUGGESTED BY THE FACT
THAT INDIVIDUALS WITH OPIOID USE
DISORDER THAT ARE IN REMISSION
CONTINUE TO PERCEIVE -- HAVE
CHRONIC PAIN.
AS WE GO FORWARD AND MOVE TO ALL
THESE INITIATIVES, IT IS CLEAR
THAT WHEN WE SPEAK ABOUT
PREVENTION, ANOTHER
EXTRAORDINARY IMPORTANT
COMPONENT THAT NEEDS TO BE
ADDRESSED, ON THE OVERDOSE
CRISIS, IT SHOULD BE NOT JUST
INDIVIDUALS WITH PAIN THAT
DEVELOPS OPIOID USE DISORDER,
THAT'S OF COURSE EXTRAORDINARILY
IMPORTANT THAT IS WHY HALF THE
HEEL INITIATIVE GOES IMPROVING
MANAGEMENT OF PAIN ON PATIENTS
THAT NEED IDEATION OF SUFFERING
OTHERWISE THEY WILL SAVE DRUGS
AND HIGH RISK OF CONSUMING THEM
AND OVERDOSING WHAT WE ALSO NEED
TO LOOK AT FROM THE PERSPECTIVE
OF ABOUT WHAT IS IT DRIVING
THESE HIGH RATES OF DRUG TAKING
IN HOUR COUNTRY.
WHAT IS IT THAT MAKES PEOPLE
VULNERABLE?
WE KNOW OF COURSE THAT THERE ARE
SOCIAL FACTORS THAT INCREASE
VULNERABILITY AND BIOLOGICAL AND
GENETIC.
BUT EXPRESSION OF BIOLOGICAL
GENETIC FACTORS IS BASICALLY
ACCELERATED OR PREVENTED
DEPENDING ON THE ENVIRONMENT SO
UNDERSTANDING THOSE
ENVIRONMENTAL EXPOSURES AND
PREVENTING THEIR ESCALATION
REVERSING THEM MEANS ONE OF THE
MAIN AIMS OF THE PREVENTION
RESEARCH PROJECT THAT NIDA
FUNDS.
AMONG THEM THERE IS ONE THAT I'M
ACTUALLY WANT TO HIGHLIGHT.
BECAUSE AS WE DEVELOP SCIENCE
AND KNOWLEDGE IT BECOMES
INCREASINGLY IMPERATIVE WE TAKE
AN OPPORTUNITY TO TRANSLATE
THOSE FINDINGS.
INTO ACTIONS THAT CAN HELP THOSE
SUFFERING FROM SUBSTANCE USE
DISORDER.
IN OUR CASE FOR EXAMPLE WE HAVE
INVESTED SIGNIFICANT RESOURCES
TO TRY TO BASICALLY EXPAND
INVOLVEMENT OF THE HEALTHCARE IN
THE TREATMENT OF SUBSTANCE USE
DISORDERS AND IMPORTANTLY ON THE
MODERATE TO SEVERE SUBSTANCE USE
DISORDER.
WHAT WE HAVE DONE RELATIVELY
VERY LETHAL AS IT RELATES TO HOW
DO WE INTERVENE FOR INSHIPPENS
OF DRUG EXPERIMENTATION.
THIS IS WHERE WIFE VERY MUCH
CREATED QUESTION ANSWER SERVICE
TO ENABLE WILL ENABLE HEALTHCARE
PROVIDERS TO SCREEN INDIVIDUALS
SO HOPEFULLY WE CAN DETECT EARLY
CONSUMPTION AND INTERVENTIONS
ULTIMATELY PREVENT FROM
ESCALATING.
IN FACT THE AMERICAN PEDIATRIC
ASSOCIATION RECOMMENDS THAT THAT
SCREENING BE APPLIED TO
CHILDREN.
PREVENTING SERVICES TASK FORCE
ARE NOT PER SE RECOMMENDED
BECAUSE THERE IS INSUFFICIENT
EVIDENCE.
BEING ABLE TO IDENTIFY
OPPORTUNITIES THAT FOR US IN
RESEARCH TO TRANSLATE AND
RECOVER THE GAP OF KNOWLEDGE
THAT WILL BRING THESE SERVICES
SUCH THAT THEY CAN BE REIMBURSED
WHO HAVE MAJOR IMPACT.
AS WE MOVE FORWARD IN TERMS OF
PREVENTION, WHETHER THROUGH HEAL
DOLLARS OR OTHER DOLLARS FROM
NIDA, TRYING TO ADVANCE AREAS
WHERE THERE IS EVIDENCE GAPS SO
WE CAN GET CLOSER TO ENSURE
SCREENING INTERVENTIONS THAT AS
WELL AS TREATMENT INTERVENTION
EARLY ON WILL BE REIMBURSED.
WE CAN TAKE -- ACTUALLY EMULATE
WHAT OTHERS HAVE DONE IN THE
DIABETES FIELD FOR EXAMPLE,
SCREENING AND TREATMENT FOR
PRE-DIABETES IS REIMBURSED.
THIS HAPPEN BECAUSE AGAIN THERE
WAS EVIDENCE HA SHOWED THERE WAS
BENEFIT.
EXPANDING THAT EVIDENCE IN THE
FIELD OF SUBSTANCE USE DISORDER
WILL BE VALUABLE.
I WANT YOU TO -- TO UPDATE YOU
ALSO WHERE WE ARE WITH OUR
RACIAL AND EQUITY INITIATIVE AS
MENTIONED WE HAVE WORKPLACE
WORKING GROUP WORK FORCE WORKING
GROUP AND RESEARCH GAPS AND
OPPORTUNITIES WORKING GROUP AND
VIRUS FOR THE WORKPLACE WE
COMPLETED A CLIMATE SURVEY THAT
WAS DONE BY CONTRACTOR, WE
WANTED IT TO BE INDEPENDENT OF
NIDA, AND RESULTS ARE GOING TO
BE USED TO IDENTIFY ACTIONABLE
PROBLEMS THAT CAN BE TARGETED.
AS RELATES TO THE WORK FORCE WE
EXPANDED THE MULTIPLE SOURCES
THAT ARE GIVEN TO MINORITY
INVESTIGATORS UNDER-REPRESENTED
GROUPS AS WELL AS AIM TO EXPAND
OUR INVESTMENT IN MINORITY
SERVICING INSTITUTIONS THROUGH
DIFFERENT MECHANISMS.
IN TERMS OF RESEARCH GAPS AND
OPPORTUNITIES IT BASICALLY AGAIN
BECOME CLEAR WE NEED TO ADDRESS
AND IDENTIFY OPPORTUNITIES AND
AGAIN HIGHLIGHTING RIGHT NOW
ACTIONABLE WHERE WE CAN HAVE
ACTUAL INTERVENTIONS THAT CAN
HELP REMOVE THE TREMENDOUS
HEALTH DISPARITIES THAT WE ARE
OBSERVING IN THE WHOLE SUBSTANCE
USE FIELD.
FINALLY I WANT TO MAKE YOU AWARE
OF REALLY REMARKABLE JOB NIDA
COMMUNICATIONS HAVE BEEN DOING
IN ORDER TO BRING FORTH THE
KNOWLEDGE THAT WE HAVE AND
OVERDOSE CRISIS AND OPIOID
CRISIS, YET THE COVID PANDEMIC
IS FAIRLY DEVASTATING AND BUT WE
CANNOT FORGET IN ANY WAY THE
OVERDOSE CRISIS.
IN FACT MORE YOUNG PEOPLE HAVE
BEEN DIE -- HAVE DIED IN 2021
FROM THE OVERDOSES THAT FROM
COVID.
SO THESE ARE TWO THINGS THAT
SHOULDN'T BE FOR ONE AGAINST THE
OTHER BUT TACKLE SO IN ONE YEAR
IN 2021 THE NIDA COMMUNICATIONS
OFFICE DOUBLED THE MEDIA OUTLET
26 PRESS RELEASES.
THERE WERE MORE THAN 550 MILLION
INTERACTIONS, 300 INTERVIEWS
WITH NIDA EXPERTS, THIS LEVEL OF
ACTIVITY IS COMPARABLE TO THAT
OF MUCH LARGER INSTITUTES SUCH
AS THE CANCER INSTITUTES OR THE
NEUROLOGY INSTITUTES.
THERE'S BEEN ON EDS HIGHLIGHTED
ON TOPICS THAT ARE RELEVANT TO
WHAT IS GOING ON AND THAT
REQUIRE AGAIN INTERVENTION.
OF THIS WHAT HAS RECENT MOST
INTEREST ACTUALLY, THE
RECOGNITION OF THE RISING
OVERDOSE DEATH AND HOW RISING
OVERDOSE DEATH BASICALLY NOW
AFFECTING UNDER-REPRESENTED
GROUPS, MUCH MORE.
THAT INFLUENCE SUBSTANCE USE ON
COVID BASICALLY EXACERBATES ALL
THE OUTCOMES AND THE IMPACT OF
COVID INFECTIOUS AND
NON-INFECTION ON ADOLESCENTS AND
CHILDREN.
AND WELCOME BASICALLY ALLOW YOU
TO GO IN TO IT AND -- FIT THAT,
ULTIMATELY WE DON'T DISSEMINATE
KNOWLEDGE AND THAT IMPLICATIONS
OF THAT KNOWLEDGE AND THE DATA
THAT WE ARE OBTAINING, PEOPLE
WILL IGNORE IT SO WE HAVE AN
OPPORTUNITY RIGHT NOW TO MOVE
THE FIELD IN WAYS THAT WE HAD
NOT HAD IN THE PAST.
AND WITH THAT I WANT TO END MY
PRESENTATIONS AND I'M GOING TO
STOP SHARING AND I'M OPEN TO
QUESTIONS IF YOU HAVE ANY.
>> HI NORA, ANDREA HERE, THANKS
FOR SHARING THAT.
THAT'S HELPFUL INFORMATION.
THE SLIDE YOU SHARED ABOUT THE
SOME OF THE EVIDENCE AROUND
PREVENTION I THINK IS REALLY
INTERESTING MADE ME THINK OF A
FEW INTERACTIONS THAT I HAVE HAD
WITH STATE LEADERS.
IN PARTICULAR NOT AROUND
PREVENTION BUT AROUND TREATMENT.
AND AROUND VIRTUAL MODALITIES OF
TREATMENT FOR SUBSTANCE USE
DISORDERS.
AND I THINK THAT THERE IS A VERY
BIG ROLE FOR SOMEONE IN
GOVERNMENT PERHAPS NIDA, TO HELP
DISSEMINATE EMERGING AND
ESTABLISHED EVIDENCE BASED
PRACTICES, AROUND VIRTUAL
TREATMENT OF OPIOID USE
DISORDER.
I KNOW THAT SCIENCE IS SOMEWHAT
EMERGING, AND I THINK THAT IT IS
A VERY BIG GAP FOR POLICY MAKERS
AND HAS A LOT TO DO WITH ACCESS
TO TREATMENT IN AN EQUITABLE
WAY.
A LOT OF REALLY BELL INTENTIONED
REGULATORS ARE GRASPING FOR
EVIDENCE TO SHAPE SOME OF THEIR
POLICY AND I THINK THE
EQUIVALENT OF WHAT YOU DESCRIBE
IN THAT PREVENTION PIECE WILL BE
REALLY POWERFUL IF THERE'S
ALREADY EVIDENCE AND I THINK
THERE'S SOME EMERGING EVIDENCE
THAT THERE COULD BE A FILLING OF
THAT EVIDENCE GAP IT COULD GO A
LONG WAY IN ADDRESSING SOME OF
THESE PRIORITIES AROUND EQUITY
ACCESS AND TREATMENT.
IN WHATEVER DIRECTION EVIDENCE
SHOWS.
MAYBE IT SHOWS GREAT VIRTUAL IS
A GREAT MODALITY OR MAYBE IT
SHOWS MAYBE DEPENDS ON SEVERITY
ILLNESS OR OTHER CONTEXT OR
VARIABLES.
I WANT TO CONVEY THAT IS HAPPEN
NOTHING NOT JUST STATES WHERE
THERE'S REGRESSION OF EVIDENCE,
PARTICULARLY LED BY SCIENCE,
THEY START STRUGGLING THERE.
SO FOOD FOR THOUGHT AND
CERTAINLY WELCOME OTHER FOLKS
PERSPECTIVES IF THEY CAN THINK
OF SOMETHING OTHER THAN WHAT I
DESCRIBE.
THANKS, NORA.
>> NO, NO, THANK YOU FOR
BRINGING THIS QUESTION.
ABSOLUTELY WE ARE VERY
INTERESTED AND I THINK IT IS
CRUEL BECAUSE YOU ARE RIGHT,
ACCESS TO DIGITAL THERAPEUTICS
ACTUALLY GOOD QUALITY COULD MAKE
A BIG DIFFERENCE FOR THOSE THAT
OTHERWISE COULDN'T HAVE ACCESS
TO THAT.
SO WE ARE FUNDING SEVERAL
RESEARCHERS, THE QUESTION IS, IS
THERE SUFFICIENT EVIDENCE, THAT
IS WHY WE HAVE THE RESEARCHERS
LOOKING AT IT.
THERE'S CLEAR EVIDENCE THAT VERY
CONSTRAINED ENVIRONMENT AND SOME
THERAPEUTICS BENEFITS AND SOME
OF THESE DIGITAL THERAPEUTIC
INTERVENTIONS HAVE BEEN SHOWN TO
BE AS EFFECTIVE AS FACE TO FACE
CONTACT IN SOME PLACES EVEN
BETTER.
BUT AGAIN, THEY ARE CONSTRAINED
BY THE CONTEXT IN WHICH THEY
WERE DONE.
SO THROUGH HEEL FUNDING AS WELL
AS NON-HEEL FUNDING WE ARE
FUNDING THIS IS AN AREA THAT WE
HAVE SEVERAL RESEARCHERS
WORKING.
>> GREAT, ONE OTHER QUICK
COMMENT FOR EVERYONE'S AWARENESS
HEALTH SERVICES RESEARCHERS IN
ADDICTION SPACE THERE IS A NEW
CPT CODE MODIFIER FOR AUDIO ONLY
TELEHEALTH THAT I'M NOT SURE
FOLKS REALIZE IS JUST CODIFIED
AND I THINK THAT OPENS A VERY
INTERESTING DOOR FOR EVALUATING
SAFETY EFFICACY OF AUDIO ONLY.
SUBSTANCE USE DISORDER TREATMENT
COUNSELING ETZ.
SO THROWING IT OUT THERE.
THANK YOU.
>> THANKS FOR ACTUALLY BRINGING
IT UP.
I WAS NOT AWARE.
SO IT IS RARE, ABSOLUTELY.
I SEE THAT DR. GREENFIELD HAS
HER HAND UP.
>> YOU ARE MUTED.
YOU ARE STILL MUTED.
>> HERE WE GO.
TWO YEARS OF ZOOM AND STILL HARD
TO UNMUTE.
IN ANY EVENT, THANK YOU SO MUCH
FOR THAT INCREDIBLE PRESENTATION
AND HOW INFORMATIVE IT WAS IN SO
MANY WAYS.
I WANTED TO BUILD OFF SOMETHING
THAT ANDRE JUST SAID, THE AREA
THAT YOU ARE TALKING ABOUT,
ABOUT CERTAIN HOW DO WE DO THAT
EARLY PREVENTION EARLY
SCREENING, EVERY TYPE OF
SCREENING IN ALMOST EVERY TYPE
OF HEALTHCARE CONTEXT FOR AS
LONG AS I HAVE BEEN IN THE FIELD
HAS GENERALLY BEEN PLAGUED BY
FOUR DIFFERENT AREAS THAT
CLINICIANS SAY, I DON'T HAVE THE
TRAINING TO DO IT, I DON'T HAVE
THE TIME TO DO IT, I DON'T HAVE
THE REIMBURSEMENT TO DO IT.
AND IF A PERSON SCREENS POSITIVE
WHAT SHOULD I DO ABOUT IT.
THAT IS THE FOUR -- THAT IS THE
NEXUS OF FOUR THINGS THAT SEEMS
TO PLAGUE ALL THE WAY THROUGH.
AND I DO AGREE WITH ANDRE THE
TECHNOLOGY AND VIRTUAL SPACE IS
ACTUALLY REALLY FANTASTIC
ADVANCE IN THE FIELD WHERE WE
CAN BEGIN TO PAIR CERTAIN TYPES
OF TECHNOLOGY INTERVENTIONS TO
ASSIST CLINICIANS ACROSS
MULTIPLE CONTEXTS.
HERE IS ACTUALLY SOMETHING THAT
YOU CAN USE, HERE IS SOMETHING
WE CAN TRAIN YOU ON, HERE IS
SOMETHING YOU CAN PROVIDE TO
PATIENTS, IF THEY DO SCREEN
POSITIVE AS A FIRST STEP.
IT IS A COMPLICATED THING AND
DOES DEPEND ON CONTEXT AND
ENVIRONMENT.
I WANT TO SAY THERE IS A BIG
OPEN PATHWAY.
FOR INVESTIGATION IN THIS AREA.
AND IT PROBABLY DOES FALL UNDER
THE REALM OF IMPLEMENTATION
SCIENCE SO I WILL STOP THERE.
>> WHAT YOU ARE PUTTING IN MY
BRAIN OBVIOUSLY IS -- BECAUSE WE
ARE, CERTAINLY WE CAN SAY
SCREENING WE NEED TO BE ABLE TO
PROVIDE TREATMENT AND NEED TO
SHOW EVIDENCE HA THAT TREATMENT
MAKES A DIFFERENCE IN THE EARLY
STAGES OF THE CASCADE OF
SUBSTANCE USE DISORDER.
SO WE ARE HAVING ACCESS TO THAT
DIGITAL SUPPORT TO MAKE A BIG
DIFFERENCE AND MAKE IT MORE
PRACTICAL.
WE -- OUR PERSPECTIVE ON THIS IS
LET'S WORK WITH MODELS THAT WORK
TO MAKE THIS HAPPEN.
WE ARE VERY AWARE WE NEED TO
BUILD KNOWLEDGE BASE TO SHOW TO
ENSURE YOU HAVE TO TRAIN ALSO,
WE NEED TO TRAIN PROVIDERS HOW
TO DO IT AND THERE AGAIN LIEU
THE CPN, BASICALLY WE ALSO -- WE
ARE DEVELOPING MODELS THAT CAN
HELP IDENTIFY OPTIMAL WAY FOR
CLINICIANS TO WORK IN THE
SUBSTANCE ABUSE SPACE OR
INTEGRATE BEHAVIORAL CURVE
SOMEONE WITH EXPERTISE.
THEN WITH VARIOUS CLINICIANS
THAT CAN ALSO MAKE IT POSSIBLE.
SO IT IS UNDERSTANDING THAT
THERE ARE NOT JUST ONE MODEL
THAT CAN WORK.
AND TAKING ADVANTAGE OF THESE
DIGITAL TECHNOLOGIES AUDIO ONLY
TECHNOLOGIES IS SOMETHING ON THE
TABLE AND WE SHOULD BE
EVALUATING IT.
ANY OTHER QUESTIONS?
>> NORA, I -- IF YOUR TEAM WOULD
LIKE ANY SUGGESTIONS AROUND
RESEARCH PRIORITIES THAT WILL
HELP FULFILL RESEARCH AND POLICY
GAPS PLEASE LET ME KNOW.
THERE IS VERY SPECIFIC AREAS
WHERE FOR EXAMPLE A STATE
CREDENTIALING AUTHORITY WILL SAY
NO WE CAN'T CREDENTIAL A VIRTUAL
PROVIDER UNLESS YOU DO WITHDRAW
MANAGEMENT BUT IT IS KIND OF
LIKE A BETWEEN A ROCK AND HARD
PLACE BECAUSE SHOULD VIRTUAL
PROVIDERS BE DOING WITHDRAW
MANAGEMENT.
I HAVE SEEN IT DONE SAFELY BUT
I'M ALSO TERRIFIED OF SEEING
THAT DONE SO WHAT IS THE
RESEARCH SAY?
DOES IT SAY IT IS SAFE DO
VIRTUAL -- CAN YOU DO LEVEL
HIGHER THAN 2.1 VIRTUALLY?
I'M A LITTLE ANXIOUS ABOUT THAT
BUT THERE'S -- WE HAVE LIKE THE
SCIENCE TO PROVE SAFE OR NOT
SAFE.
I THINK THOSE AREAS OF NUANCE
CAN BE SUPER INTERESTING TO HAVE
A LITTLE BIT MORE ROBUST
EVIDENCE.
>> I COMPLETELY AGREE.
THIS IS PART OF THE JOB OF
COUNCIL TO BRING FORWARD
OPPORTUNITIES OF RESEARCH, ONE
OF THE SPACES THAT WE CAN INPUT
WE ALSO BRING TOGETHER POLICY
EXPERTS AND AGENCIES TO IDENTIFY
WHAT ARE THE MAIN CHALLENGES AND
QUESTIONS TO BRING FORWARD.
SO AGAIN THESE EXACTLY WHAT WE
ARE HOPING TO GET FROM COUNCIL,
ULTIMATELY LOOKING HOW THINGS
ARE GOING WITH THE OVERDOSE
CRISIS, IT IS CLEAR THAT
POLICIES, BRINGING UP A POLICY
IS PROBABLY ONE OF THE MOST
CONSEQUENTIAL THINGS WE CAN DO
FOR BRINGING IN TRANSLATION
KNOWLEDGE INTO A PRACTICE.
OTHERWISE THE MOMENT THAT THERE
IS A POLICY THAT FACILITATES
BEING DONE IT WILL HAPPEN SO
YES.
I WELCOME VERY MUCH INPUT THAT
MAY HAVE VERY SPECIFIC THINGS
FROM EXPERIENCE ACTUALLY HAVE
BEEN A ROADBLOCK.
MY UNDERSTANDING WAS THAT SHARON
HAD A QUESTION BUT ANNA ROSE --
>> MINE IS A VERY MUNDANE
QUESTION AND NOT REALLY A HUGE
POLICY LEVEL, IT IS MORE LEVEL
DAY-TO-DAY OPERATIONS AND THINGS
THAT MAKE LIFE MORE EASIER OR
MORE DIFFICULT.
WE TALKED A LITTLE BIT ABOUT THE
LAST COUNCIL MEETING ABOUT THE
ABILITY TO HAVE A CLEAR WAY TO
TEST FOR FENTANYL THAT YOU CAN
USE AT RESEARCH CLINICAL SITE
BUT ETZ SPECIALLY CLINICAL
RESEARCH SITE SO YOU KNOW WHAT'S
GOING ON RATHER THAN COST AND
DELAY WITH PCR THINGS THAT TAKE
LONGER.
SO I WONDERED IF IN ALL THE
WONDERFUL INNOVATIONS WE HAD
GOING ON, THE SMALL BUSINESS
OPPORTUNITIES THAT WERE
DISCUSSED, IF THERE'S BEEN
CONSIDERATION IS THAT A PATH TO
TRY TO TAKE FORWARD AND
ENCOURAGE FDA TO LOOK TOWARD
SOMETHING CLEAR WAVED?
I KNOW THIS IS A MUNDANE THING
COMPARED TO THE META ISSUES BUT
IT IS SOMETHING THAT WOULD MAKE
LIFE MORE MANAGEABLE AT THE
CLINICAL RESEARCH AND CLINICAL
LEVEL IF WE HAD A CLEANER WAY
THAT DOESN'T REQUIRE
LABORATORIES.
WOULD BE THE CASE IN THE
HOSPITAL.
>> ANNA ROSE, RAIDING ONE OF THE
ISSUES WE HAVE BEEN FRUSTRATED
LIKE HELL, HOW LONG IT TAKES TO
GET DATA OVERDOSE DEATH.
I'M PRESENTING DATA THAT IT'S
SEVEN MONTHS OLD.
IN THE MEANTIME WE DON'T KNOW
WHAT IS HAPPENING RIGHT NOW.
SO ONE OF THE IMPEDIMENTS,
SEVERAL IMPEDIMENTS BUT ONE
IMPORTANT IMPEDIMENT THAT WE
HAVE BASICALLY HEARING ON IS
THAT CORONERS TAKE TIME DOING
ANALYSIS OF WHAT IS RESPONSIBLE
FOR THE DEATH.
SO ONE OF THE INITIATIVES THAT
WAS BROUGHT UP THROUGH DR.
ELAINE CHRIS TO HAVE WAS TO
ACTUALLY ACCELERATE THE TOOLS
AND TECHNOLOGIES TO BE ABLE TO
HAVE HIGHER SENSITIVITY FOR
DETECTION OF WAYS OF IDENTIFYING
DRUGS IN DIFFERENT ENVIRONMENTS,
AND ONE OF THEM IS THE CORONERS.
THE OTHER ONE TOO WAS EMERGENCY
DEPARTMENTS, SO BEING ABLE TO
HAVE ACCESS TO WHAT TESTING THAT
WILL ALLOW YOU TO GET
INFORMATION WHAT THE PERSON HAS
ON BOARD WILL BE VERY VALUABLE.
THESE TOOLS HAVE TO BE
ACCESSIBLE, BECAUSE IT IS VERY
SOPHISTICATED AND EXPENSIVE NOT
GOING TO BE HAPPENING, ALSO
THROUGH THE HEEL INITIATIVE, WE
HAVE VERY SPECIFIC INTEREST ON
ACCELERATING THE DEVELOPMENT OF
FENTANYL TEST RISK TARGETING THE
TOOLS THAT HELP A PERSON THAT IS
TAKING DRUGS EVALUATE THAT
CONTENT OF THE DRUGS THEY ARE
AIMING TO CONSUME.
>> SO THAT -- THOSE STRIPS THAT
WE TRIED TO GET, YOU CAN GET
THEM AND IF YOU ARE A PURELY
PUBLIC HEALTH SITE YOU CAN USE
THEM.
BUT IRONICALLY IF YOU ARE A
CLINICAL RESEARCH SITE IN
ACADEMIC SETTING, APPARENTLY
FROM NURSE PRACTICERS IS A
LIABILITY INVOLVED BECAUSE IT IS
NOT CLEAR WAVED, NOT APPROVED SO
BASICALLY YOU ARE GIVING IT TO
SOMEONE OVERDOSE THEY SAY THEY
DIDN'T GET THE RIGHT THING, TO
TEST THEIR DRUGS.
IS HARM REDUCTION IDEA.
SO WE BUMPED INTO THAT AS A
BARRIER SO EVEN THOUGH I ORDERED
STRIPS FROM CANADA, NO ONE IS
COMFORTABLE USING THEM AT OUR
SITE SO IT IS A -- AND WE DO
HAVE THE OPPORTUNITY TO SEND
THEM OUT FENTANYL PANEL AT THE
HOSPITAL AND GET IT BACK NEXT
DAY OR DAY AFTER, BUT IT DOESN'T
HELP YOU AT THAT MOMENT AND
DOESN'T HELP YOU GIVING
SOMETHING TO THE PATIENT TO TEST
THEIR DRUGS SHOULD THEY CHOOSE
TO.
BY THE WAY IN PHILADELPHIA,
FENTANYL IS EVERYWHERE NOW SO IT
IS PRETTY MUCH HE PLACED HEROIN,
WE HAVE MOSTLY PEOPLE COMING IN
FENTANYL POSITIVE BUT HEROIN
NEGATIVE.
THAT IS THE PROFILE.
ALSO ADDING IN STIMULANTS FOR
SURE.
BUT ANYWAY, IT IS KIND OF A --
IT IS SOMETHING THAT WOULD BE
VERY HELPFUL BUT I JUST DON'T
EVEN KNOW WHERE THE PROGRESS IS
ON THIS WITH REGARD TO FDA AND
HOW HARD IT IS TO GET FROM
SOMETHING THAT IS NOT CLEAR
WAVED TO SOMETHING THAT IS CLEAR
WAVED.
>> THE HEEL INITIATIVE IS VERY
MUCH BORN OUT OF DR. JANET
WOODCOCK WHO BROUGHT THAT UP AND
ACTUALLY DO STUDIES TO
CHARACTERIZE AND DEVELOP
STANDARDS FOR FENTANYL TEST
STRIPS, SO VERY INTERESTED IN
THE FDA IS ENGAGED AND WILL
BASICALLY WORK WITH THE FDA,
ABSOLUTELY.
AND BUT WHAT YOU ARE SAYING IS
NOT JUST -- THIS IS EXACTLY
THROUGHOUT THE SAME THING, NOT
JUST FOCUSING ON THE FENTANYL
TEST STRIPS THAT HELP
INDIVIDUALS THAT ARE TAKING
DRUGS BUT IMPORTANTLY ALSO THE
OTHER THE REST OF INDIVIDUALS
THAT BENEFIT FROM GETTING
INFORMATION ABOUT CONTENT OF
DRUGS.
YOU ARE ABSOLUTELY -- SO YES, WE
WANT TO ENGAGE WITH FDA.
SO THESE THINGS ARE STANDARDIZED
AND APPROVED AND USED IN
HOSPITAL SETTINGS.
>> THANKS.
I SEE DR. ROSS'S HAND RAISED.
>> THANKS, NORA.
I AM REFLECTING ON AGAIN LIKE
LAST TIME, THESE UNEQUAL OUTCOME
SLIDES YOU SHOW US AND I WORK
WITH AMERICAN COMMUNITIES ON
OPIOID RESPONSE ISSUES, AND IT
IS DOWN RIGHT TERRIFYING.
ALSO HAVING A TEENAGE SON I
THINK MANY OF US -- IT'S
TERRIFYING THAT PEOPLE WILL
EXPERIMENT AND SO THIS
CONVERSATION IN SO MANY WAYS
FEELS LIKE EVERY SINGLE THING
THAT ALL OF YOU ARE BRINGING UP
IS HITTING OUR TRIBES AND JUST
THREEFOLD FOUR FOLD DIFFERENT
WAYS.
SO ANDRE YOU BRING UP CLINICAL
CARE AS TREATMENT FOR EXAMPLE
AND WE HAVE PROVIDERS AS YOU
BRING UP SHELLEY MAINLY ALL
THOSE THINGS BUT HAVING NO TIME
TO RETRAIN, NEED TORR APPROVAL
INNOVATION SO IT IS NOT M.D. ETZ
OR EVEN NURSES DOING THIS KIND
OF CARE, HOW CAN WE TRAIN
PARAPROFESSIONALS TO HELP.
SO HA IS THE TREATMENT SIDE BUT
WHAT ABOUT PREVENTION?
FENTANYL TEST STRIPS HARM
REDUCTION MODEL HOW DO WE GET
IMMUNITY MEMBERS ENGAGED IN
WORKING WITH TRIBAL COUNCIL TO
REDUCE STIGMA, ALL THESE ISSUES
COME CRASHING TOGETHER BUT
BACKING UP EVEN FURTHER I JUST
KEEP THINKING ABOUT THE SUPPLY
CHAIN FOR FENTANYL.
YOU LOOK LEFT RIGHT UP AND DOWN,
PEOPLE ARE BLAMING CHINA AND
INDIA AND MEXICO, IT DOESN'T
REALLY -- IT IS COMING FROM
QUAINT -- I'M CURIOUS IS THERE A
ROLE FOR RESEARCH FOR NIDA, IN
THIS POLICY ADVOCACY IN THIS
WORK THAT I KNOW IS REALLY
USUALLY RELEGATED OVER TO THE
FEDS TO DEAL WITH THIS.
HOW CAN WE STOP THIS.
THIS CRISIS IS KILLING IT.
TWO PEOPLE LAST WEEK IN MY TINY
TRIBAL COMMUNITY.
HOW DO WE ENTER MULTI-LEVEL
ATTACK THIS ISSUE, IT IS
EXHAUSTING AND I DONE HAVE ANY
SOLUTIONS BUT I DO WANT TO SAY
YES HARM REDUCTION HOW WE
INTERRUPT THE SUPPLY CHAIN AND
NORA, YOU ARE SHOWING DATA FOR
YOUNG PEOPLE WHERE WHICH ARE
SIMULTANEOUSLY SEEING REDUCTION
IN PANDEMIC AND MOST DRUG AND
ALCOHOL USE BUT INCREASES IN
OVERDOSE IS THAT JUST A POTENCY
ISSUE OR SOMETHING UNIQUE ABOUT
I DON'T KNOW SOCIAL MEDIA KITS
OR WHAT IS GOING ON THERE THAT
IT'S DIFFERENT?
CURIOUS ABOUT THAT.
ANY COMPLAINING BEING
QUESTIONED.
>> NO.
I THINK YOU ARE LIVING THIS IN
RIGHT EXPERIENCE SO ACTUALLY
THAT VOICE IS CRUCIAL FOR US TO
HEAR.
WE CANNOT BECOME COMPLACENT.
THE INCREASE IN OVERDOSE ARE
BASICALLY HITTING WORST 18 TO 34
YEARS OLD.
SO OVERDOSES DO APPEAR IN
ADOLESCENTS AND CHILDREN THOUGH
USUALLY CHILDREN ACCIDENTS AND
THEY STARTED TO ACTUALLY, I'M
INTRIGUE BECAUSE OVERALL VERY
LOW IN ADOLESCENTS BUT THERE ARE
THINGS THAT ARE STARTING TO
WORRY ME.
ONE OF THEM IN LAST YEAR I THINK
IT MAY HAVE BEEN NOVEMBER, NEW
JERSEY THERE WAS THE DETECTION
OF FENTANYL IN MARIJUANA.
AND THIS IS OF CONCERN BECAUSE
THIS IS A DRUG THAT TEENAGERS
ARE USING.
SO SUPPLY OF MARIJUANA BECOMES
NOW INCREASINGLY MORE TAKEN WITH
FENTANYL, THAT WILL POSE A MAJOR
RISK FOR THESE TEENAGERS.
ALSO AT RISK IF THEY PURCHASE
ELICIT PRESCRIPTION MEDICATION
AND THEY DO THAT FOR EXAMPLE
WITH STIMULANTS.
AND THERE'S ALSO EVIDENCE
STIMULANTS CAN HAVE CONTAIN
FEBRUARY NIL.
AND THAT -- FENTANYL.
TO THE EXTENT THAT FENTANYL IS
VERY EASY TO MANUFACTURE AND
VERY CHEAP, YOU CAN SEE HOW IT
POSES AND WHY IS ONE OF THE
REASONS WHY ACTUALLY EXPANDING
EVERYWHERE, YOU HAVE A
TREMENDOUS INCENTIVE FROM THE
PERSPECTIVE OF WHAT DEALERS ARE
BASICALLY MAKING BY SELLING
THESE DRUGS.
IT IS AN ISSUE OF CONCERN.
WE NEED TO PAY ATTENTION TO IT.
AS OF NOW IN ADOLESCENTS IS NOT
THE GROUP HIGH RISK OF OVERDOSE
AND AGAIN I'M SPEAKING IN TERMS
OF POPULATION, WE NEED TO DWELL,
THIS DATA I SHOW YOU CLEARLY
SAYS SO, WHEN WE FEEL CONFIDENT
OTHERS NOT MORE CHANGE WE NEED
TO DWELL IN SOME GROUPS.
IF WE DON'T DO WE MAY SEE THAT
IN SOME GROUPS THERE IS INCREASE
IN OVERDOSES IN TEENAGERS THAT
WERE NOT DETECTED OTHERWISE.
SO I DON'T KNOW, IT IS REALLY
DEVASTATING WHAT IS GOING ON IN
AMERICAN INDIAN AND ALASKA
NATIVE COMMUNITIES.
I'M WORKING WITH THE TRIBES AND
IT IS AGAIN, IT IS AN ISSUE THAT
WILL REQUIRE WE CREATE
PARTNERSHIPS WITH THEM.
AS WE ADDRESS ALL THE CHALLENGE
IT IS WAY THAT IT IS GOING TO
HAPPEN IS BY ALL FROM THE
SCIENCE TO THOSE PROVIDERS OF
TREATMENT, AND PREVENTION
WORKING TOGETHER.
BECAUSE SCIENCE BY ITSELF IS
INSUFFICIENT.
WE NEED TO BRING IT TO THE NEXT
LEVEL.
I SEE GAIL HAS HER HANDS UP.
>> I WANT TO ASK ABOUT
DIVERSITY, I WANT TALK ABOUT
ACTIVE SURVEILLANCE, 20 EDs
ACROSS THE COUNTRY.
WE ARE SEEING 75, 76% OF
PATIENTS POSITIVE FOR FEINT
MILL.
THERE HAVE BEEN AND WE ARE USING
A NON-CLEAR WAVE FROM FENTANYL
STRIPS, WE HAVE AT LEAST
SOMEWHERE AROUND THREE OR FIVE
CASES WHEN WE ARE CONVINCED THAT
THEY REALLY DID.
AND THE R STRIPS WEREN'T
SENSITIVE ENOUGH TO PICK UP BUT
IN GENERAL PRETTY GOOD.
WE ARE ALSO SEEING 30% OF
INDIVIDUALS, THIS IS OUTS OF
SAMPLE OF 800 OR SO OF THE URINE
THAT WE ARE SEEING 30% ARE THE
ONLY OPIOID IS FENTANYL.
SO REGARDLESS WHAT THE PERSON
THINKS, IT IS ONLY FENTANYL, NOT
LIKE THERE IS SOME OTHER
SYNTHETIC -- THERE'S HEROIN, IT
IS ONLY FENTANYL.
SO WE ARE SEEING QUITE A BIT OF
IT.
BUT WHAT I WANTED TO ASK YOU
ABOUT NORA WAS THE DIVERSITY
GRANTS.
I KNOW PEOPLE -- THERE'S BEEN
SOME DISCUSSION THAT THERE'S NOT
A LOT OF PEOPLE WHO ARE APPLYING
BUT THE DIVERSITY GRANTS ARE
VERY SMALL IN FINANCE AND
BUDGET.
SO I'M PUTTING A PULLY OUT
THERE, THAT IN THE DIVERSITY
SUPPLEMENTS EVEN IF PIGGY
BACKING OFF ANOTHER GRANTS SAY A
LARGE ONE LIKE EDM MENTION I DO
NEED MONEY FOR EVALUATION
STATISTICAL SUPPORT, REVIEWING
TRANSCRIPTS, IF THERE'S SOME
QUALITATIVE PARTS OF IT.
IT IS NOT A HUGE AMOUNT OF MONEY
BUT EARN CERTAINLY MORE THAN
$1,500 A YEAR.
SO IT'S CERTAINLY MORE THAN
$1,500 A YEAR.
GIVEN ALSO TO INVESTIGATOR IS
VERY SMALL.
SO I'M JUST MAKING A PLEA THAT
WE TRY TO THINK ABOUT ALLOCATING
A LITTLE BIT MORE MONEY FROM FOR
THE DIVERSITY SUPPLEMENTS.
>> WE ARE LOOKING INTO IT, I
NEED TO UNDERSTAND EXACTLY WHERE
IF IT IS -- INCREASE IT AND HOW
THAT WAS ESTABLISHED AND HOW TO
DO IT BUT WE WILL LOOK INTO IT.
>> THANK YOU.
>> SUSAN, I THINK THERE ARE NO
MORE QUESTIONS.
SO IF THERE ARE NO MORE
QUESTIONS WE CAN GO INTO THE
NEXT ITEM IN THE AGENDA AND I
TURN THE MICROPHONE TO YOU.
>> THANK YOU, THE NEXT ITEM IS
GOING TO BE WILSON COMPTON, WHO
WILL GIVE THE 2022 TRY ANNUAL
ADVISORY COUNCIL REPORT ON
INCLUSION OF WOMEN AND
MINORITIES IN IN CLINICAL
RESEARCH.
ARE YOU SHARING YOUR SCREEN OR
DO WE -- ARE WE SHOWING THE
SLIDES?
>> I WILL BE SHARING MY SCREEN
IN A MOMENT.
THANK YOU.
>> THANKS FOR THIS OPPORTUNITY
TO SHARE WITH YOU A REQUIREMENT
FOR NIH.
YOU MIGHT ASK WHY IS WILSON
DOING THIS, WHY IS DEPUTY
DIRECTOR OF THE INSTITUTE?
THIS IS A TRADITION ACROSS NIH
BECAUSE IT IS SO IMPORTANT THE
ISSUES INVOLVED IN MAKING SURE
WE PROVIDE ADEQUATE
REPRESENTATION OF WOMEN AND
UNDER-- GENERALLY
UNDER-REPRESENTED MINORITIES IN
RESEARCH STUDIES.
SO WITH THAT LET ME BEGIN TO
SHARE, I WILL TELL YOU A LITTLE
BACKGROUND AND WHAT WE HAVE FOR
DATA REGARDING THIS TRIENNIAL
ADVISORY COUNCIL REPORT.
ARE YOU ABLE TO SEE IT?
>>
>> THAT WORKS.
PERFECT.
>> GOOD.
BASICALLY THIS IS A REPORT THAT
HAPPENS EVERY THREE YEARS, IT IS
AN OLD REQUIREMENT FOR NIH.
THE LAWINGS ESTABLISHING THE
REQUIREMENT TO INCLUDE WOMEN AND
MINORITIES GROUPS GOES BACK TO
1986 WHEN NIH ESTABLISHED THE
POLICY FOR WOMEN AND MINORITIES
INTO CLINICAL RESEARCH.
IT ADDED ADDITION OF MINORITIES
THROUGH NEXT YEAR, ADDITIONAL
WORK, STILL 25, 30 YEARS AGO IN
1993 AND '94.
WE HAVE BEEN WORKING SINCE THAT
TIME TO ASSURE THAT WOMEN AND
MINORITY GROUPS ARE INCLUDED IN
CLINICAL RESEARCH AT ALL THE NIH
INSTITUTES NIDA INCLUDED.
WE HAVE A DIVERSE PORTFOLIO
FALLING UNDER THIS POLICY
INCLUSION GUIDELINES.
WE HAVE A NUMBER OF STRATEGIES
FOR ENSURING COMPLIANCE.
THE IMPLEMENTATION OF GUIDELINES
INVOLVES REVIEW THAT INCLUDES
Y'ALL AS SECOND STAGE REVIEW.
PROGRAM STAFF, POLICY STAFF AND
GRANTS MANAGEMENT STAFF.
FUNDING ANNOUNCEMENTS CONTAIN
LANGUAGE ENCOURAGING AND
REQUIRING THAT WOMEN AND
MINORITIES BE INCLUDED IN
RESEARCH STUDY.
UNLESS INAPPROPRIATE FOR SOME
PARTICULAR SCIENTIFIC OR
CLINICAL REASON.
REVIEW AT INITIAL REVIEW GROUP
AND SECONDARY REVIEW AT COUNCIL
EVALUATE THESE APPLICATIONS AND
PROGRAM STAFF RESPONSIBLE FOR
REVIEWING INCLUSION INFORMATION
AND THE PLANT FOR SUCCESSFUL
RECRUITSMENT OF A DIVERSE
POPULATION OF CLINICAL SUBJECTS.
GRANTS MANAGEMENT STAFF ENSURE
TERMS AND CONDITIONS ARE
INCLUDED IN THE NOTICE OF AWARD.
AND INFORMATION ABOUT THE
INCLUSION IS DOCUMENTED IN THE
OFFICIAL GRANTS FILE.
IT IS NOT JUST EXTRAMURAL BUT
INTRAMURAL AS WELL REQUIRED TO
FOLLOW THESE GUIDELINES.
THE INTRAMURAL PROGRAM
INVESTIGATORS ARE REQUIRED TO
PROVIDE PLANTS FOR THE
APPROPRIATE INCLUSION OF WOMEN
AND MINORITIES. TRAINING IS
PROVIDED FOR STAFF AT ALL THESE
LEVELS BY NIH AND NIDA.
ON A REGULAR BASIS.
I'M GOING TO SHARE WITH YOU
BELIEFLY DATA SENT TO YOU AHEAD
OF TIME IN YOUR COUNCIL BOOK.
THE DATA FOR THE LAST FEW YEARS
WERE NOT DEVELOPED BY ME OR
DIRECTLY AT NIDA BUT THESE ARE
PROVIDED BY THE NIH OFFICE OF
EXTRAMURAL RESEARCH OER, AND ARE
BASED ON THE PRINCIPLE
INVESTIGATORS SELF-ROSTED DATA
FROM PARTICIPANTS SO MANY MAY
HAVE SUBMITTED DATA INCLUDED IN
THIS REPORT.
DATA IS STORED IN THE NIH HUMAN
SUBJECTS SYSTEM DATABASE.
I START OUT WITH SEX AND GENDER
DATA, OVERALL NUMBER OF RESEARCH
SUBJECTS ACROSS ALL OF NIDA
STUDIES IS TREMENDOUS.
1.6 MILLION IN FY 19, SOME
2.2 MILLION IN FY 20, QUITE A
BIT LOWER IN FY 21, THAT SPEAKS
TO THE COMPLEXITY OF DOING THE
LARGE SCALE PUPILLAGES STUDIES.
-- POPULATION STUDIES DURING THE
COVID PANDEMIC.
WHEN WE LOOK AT THE DIVERSITY IN
TERMS OF GENDER WE SEE THERE IS
A SLIGHT OVERREPRESENTATION OF
MEN IN OUR STUDIES ACROSS ALL
THREE YEARS.
MISSING DATA IS RARE THOSE MORE
COMMON IN MOST RECENT REPORTING
PERIOD.
I THOUGHT WE LOOK NOT ONLY
OVERALL BUT EXTRAMURAL
INTRAMURAL AND EMPHASIZE PHASE 3
STUDIES AS WELL FOR EACH
COMPONENT.
INTRAMURAL AND EXTRAMURAL ARE
SIMILAR IN TERMS OF RATES.
THE INTRAMURAL PROGRAM HAS
HIGHER RATE OF MALES THAN
FEMALES IN CLINICAL RESEARCH.
ALMOST NO CASES OF UNKNOWN SEX
OR GENDER.
WHEN IT COMES TO PHASE 3 TRIALS,
A SUB SETS OF CLINICAL RESEARCH
BUT IMPORTANT FOR REPRESENTATION
FOR CLINICAL DESIS MAKING, SEE
STRONG REPRESENTATION OF MEN AND
WOMEN AND SLIGHTLY HIGHER RATE
OF UNKNOWN PARTICULARLY 2019 BUT
LOW RATE OF UNKNOWN OR NOT
REPORTING INFORMATION IN 20 AND
21.
LET'S SWITCH TO RACE AND THEN
TALK ABOUT ETHNICITY.
RACIAL DATA IS MORE COMPLICATED.
T THE WAY THESE CHARTS ARE
ORGANIZATIONED IS IN ORDER --
ORGANIZED IS IN ORDER OF
PRESENTATION. SO IN 2019, 2%
CLINICAL SUBJECTS IN OUR STUDIES
WITH AMERICAN INDIAN, ALASKA
NATIVE, 2.3% ASIAN.
19% BLACK OR AFRICAN AMERICAN,
.3 NATIVE HAWAII OR PACIFIC
ISLANDER.
58% WHITE.
2% MORE THAN ONE RACE OR 6%
UNKNOWN OR NOT REPORTED.
PERCENTAGE OF MORE THAN ONE RACE
INCREASED IN 2021 AND WE SEE A
SHIFT OVER TIME BUT GENERALLY
THE SAME PATTERNS OVER THE THREE
YEARS.
COMPARING THE EXTRAMURAL PROGRAM
TO INTRAMURAL, WE SEE A LARGE
REPRESENTATION OF BLACK OR
AFRICAN AMERICAN PARTICIPANTS IN
OUR INTRAMURAL PROGRAM.
AND A LOWER PERCENTAGE OF WE
WILL COME BACK TO HISPANIC IN A
MINUTE.
LOWER PERCENTAGE OF WHITE
REFLECTING DEMOGRAPHICS IN
BALTIMORE WHERE INTRAMURAL
PROGRAM IS LOCATED.
IN PHASE 3 TRIALS WE SEE DIVERSE
POPULATION OF REPRESENTATIONS
THOUGH SURPRISED WE HAVE UNKNOWN
OR NOT REPORTED IN HIGHER
PERCENTAGE IN THIS CASE.
BUT WE HAVE STRONG
REPRESENTATION OF BLACK OR
AFRICAN AMERICAN IN OUR CLINICAL
PHASE 3 TRIALS.
WHEN WE LOOK AT ETHNICITY AS A
SEPARATE CATEGORY FROM RACE
COMPARING LATINO OR HISPANIC
IDENTIFIED INDIVIDUALS, WE SEE
THAT THE RATES ARE 9% IN 2019
AND 2020 AND A LITTLE HIGHER 7%
IN 2021 OVERALL.
EXTRAMURAL VERSUS INTRAMURAL,
INTRAMURAL HAS LOWER PERCENTAGE
OF HISPANIC OR LATINO
INDIVIDUALS REFLECTING THE
POPULATION IN BALTIMORE WHERE
RECRUITS ARE MOSTLY FROM.
WHEN WE LOOK AT PHASE 3 TRIALS
WE SEE A HIGHER REPRESENTATION
OF HISPANICS LIKE THE OVERALL
NUMBERS IN 2021.
SO THAT IS A RAPID FIRE REVIEW
OF A TRIENNIAL REPORT ABOUT
INCLUSION OF WOMEN AND MINORITY
PERSONS IN CLINICAL RESEARCH AT
NIDA AS PART OF OVERALL ACROSS
NIH.
I HOPE YOU WILL AGREE WITH ME WE
HAVE STRATEGIES IN PLACE TO
ENSURE COMPLIANCE WHICH DO
INVOLVE PARTICIPATION OF Y'ALL
AS PART OF A REVIEW BUT PROGRAM
POLICY AND GRANTS MANAGEMENT
AMONG THE REST OF OUR TEAM THAT
WORK ON THESE ISSUES.
MY REQUEST TO YOU IS FOR Y'ALL
TO CERTIFY OUR COMPLIANCE WITH
THE POLICY ON INCLUSION BIER FOR
THESE PAST THREE YEARS.
I WILL ANSWER QUESTIONS AS BEST
I CAN.
BEFORE I WRAP UP I WANT TO
ACKNOWLEDGE (INAUDIBLE) WHO
WORKS IN OUR CLINICAL TRIALS
NETWORK WHO DID JUST A WONDERFUL
JOB HELPING ME PREPARE THIS
PRESENTATION AN REALLY REMINDS
ME EACH THREE YEARS OF THIS
REQUIREMENT IF THEY ARE HAVING
BEEN PROBLEMS IN THE MEANTIME
ABOUT ONCE EVERY THREE YEARS WE
WILL BRING IT TO YOUR ATTENTION.
T WITH THAT LET ME STOP SHARING
AND OPEN UP SO I CAN SEE THERE'S
ANY QUESTIONS.
THEN WE WILL OPEN UP I HOPE FOR
CONCURRENCE WITH THIS REPORT.
FOR APPROVAL OF THIS INCLUSION
REPORT.
SHELLEY.
CAN'T TELL WHETHER YOU ARE
ASKING A QUESTION OR MAKING A
MOTION --
>> I'M GOING TO IF IT IS ALL
RIGHT JUST MAKE A QUICK COMMENT.
THANK YOU SO MUCH FOR THIS
REPORT WHICH I FIND REVIEWING
THE STATISTICS REALLY INCREDIBLY
IMPORTANT AND SALIENT FOR ALL OF
CLINICAL RESEARCH AND IT HAS
BEEN A LONG STRETCH OF TIME TO
INCREASE THE PROPORTION OF
INDIVIDUALS ENROLL IN CLINICAL
TRIALS, IN CLINICAL RESEARCH
ACROSS GENDER RACE ETHNICITY.
CLEARLY ALREADY MANY
IMPROVEMENTS IN SOME PLACES
WHERE WE STILL HAVE FAR TO GO.
ONE THING THAT IS ALWAYS A
CO-NUMBER DRUM IN CLINICAL RE--
CONUNDRUM IN CLINICAL RESEARCH
IS INTERSECTION WALLTY BETWEEN
GENDER RACE AN ETHNICITY AND WE
HAVE ISSUES TO FIND OUT
REPRESENTATION TO WE CAN
UNDERSTAND THINGS THAT ARE BOTH
GENDER AND CULTURALLY SPECIFIC
TO POPULATIONS.
SO I WANTED TO MENTION THAT
BECAUSE IT IS REALLY COMES UP
ALL THE TIME IN OUR SUBSTANCE
USE DISORDER AND SUBSTANCE USE
RESEARCH IN CLINICAL TRIALS AND
ACROSS ALL CLINICAL RESEARCH BUT
I THANK YOU FOR THE REPORT, IT
IS IMPORTANT WORK IN TERMS OF
TRACK ALL THIS AND PRESENTING TO
THE SCRIPS SO THANK YOU, VERY
MUCH.
>> I WOULD SAY THIS IS A THEME
YOU ARE GOING TO BE HEARING
REFLECTED IN THE -- IN SOME OF
THE REST OF THE PRESENTATION
COUNCIL IN TERMS OF RACIAL
ETHNIC EQUITY ISSUES.
AND YOUR COMMENTS ABOUT
INTERSEXUALITY IS TAKEN --
INTERSEXUALITY.
ADIFFERENT CROSSWALK BUT
CERTAINLY THAT IS POSSIBLE AND
WITH THESE LARGE NUMBERS THEY
ARE STABLE ESTIMATES.
FOR AT LEAST OVERALL FOR THE
CLINICAL RESEARCH PROGRAM.
INTERSEXUALITY.
COMMENTS
>> IF I CAN ASK FOR A MOTION TO
APPROVE THIS.
I'M SEEING A NUMBER OF HANDS
RAISED.
ANYONE DISAPPROVES WITH THE
APPROVAL?
I DON'T HEAR ANY SO THANK YOU
VERY MUCH AND I BELIEVE THAT
ENDS THIS PART OF MY
PRESENTATION TODAY.
>> WE ARE SCHEDULED FOR BREAK AT
2:30.
WE ARE A LITTLE AHEAD OF
SCHEDULE, ANY OTHER QUESTIONS
PEOPLE WANT TO BRING UP TO
WILSON OR NORA OR ANY ONE OF US
ON THE CALL, PLEASE YOU HAVE
ANOTHER CHANCE OTHERWISE WE GET
A NICE BREAK.
OKAY.
PLEASE GET BACK IN TIME OUR NEXT
SPEAKER IS AN OUTSIDE SPEAKER
WHICH DR. HILDRETH, IT WILL BE A
VERY INTERESTING DISCUSSION SO
HE STARTS AT 2:40.
PLEASE BE BACK BY THEN.
IT'S A PLEASURE FOR ME TO
INTRODUCE DR. JAMES HILDRETH WHO
IS A Ph.D. M.D. AND EXECUTIVE
OFFICER OF
MEHARRY MEDICAL
COLLEGE, THE NATION LARGEST
HISTORICALLY BLACK SCIENCE
CENTER.
HE OBTAINED BA IN CHEMISTRY FROM
HARVARD AND SELECTED THE FIRST
AFRICAN AMERICAN SCHOLAR FROM
ARKANSAS, OBTAIN Ph.D. IN
IMMUNOLOGY FROM OXFORD
UNIVERSITY WHERE HE STUDIED
BIOLOGY OF VIRUS SPECIFIC
CYTOTOXIC T-CELLS AND EXPERT IN
MONOCLONAL ANTIBODY TECHNOLOGY
AND CELL ADAPTATION.
OBTAIN M.D. FROM JOHNS HOPKINS
UNIVERSITY SCHOOL OF MEDICINE,
WORKING 1987 AS ASSISTANT
PROFESSOR AND WAS APPOINTED THE
FIRST ASSOCIATE DEAN FROM
GRADUATE STUDENTS, IN 202 HE
BECAME THE FIRST AFRICAN
AMERICAN IN THE 135 YEAR HISTORY
OF JOHNS HOPKINS TO EARN FULL
PROFESSORSHIP WITH TENURE IN
BASIC SCIENCES.
IN 205 HE BECAME DIRECTOR OF THE
NIH FUNDED CENTER FOR AIDS
HEALTH DISPARITIES RESEARCH AT
MEHARRY MEDICAL COLLEGE.
THEN IN 2011 HE BECAME TEN OF
THE COLLEGE BIOLOGICAL SCIENCES
UC DAVIS BEING THE FIRST AFRICAN
AMERICAN DEAN IN THE UNIVERSITY
THAT ALSO TENURE PROFESSORSHIPS
IN THE DEPARTMENT OF CELLULAR
AND MOLECULAR BIOLOGY, AND OF
SPECIAL MEDICINE.
HIS RESEARCH IN IMMUNOLOGY AND
VIROLOGY WITH A FOCUS ON HIV HAS
LED TO MORE THAN 135
PUBLICATIONS IN TOP JOURNALS AND
11 PATENTS.
HE HAS RECEIVED NUMEROUS NIH
GRANTS INCLUDING PRESTIGIOUS
PIONEER AWARD.
A TECHNOLOGY DEVELOPED BY DR.
HILDRETH WAS LICENSED BY
BIOGENENTECH AS THE BASIS FOR
FDA APPROVED DRUG RAPTIVA.
HE RECEIVED NUMEROUS AWARDS FOR
RESEARCH, COMMITMENT TO
DIVERSITY IN MEDICINE,
BIOMEDICAL RESEARCH AND SERVICE
TO THE COMMUNITIES.
THIS INCLUDES AMONG OTHERS HON
LAYER DEGREES IN INDUCTED TO
BLACK HALL OF FAME, JOHNS
HOPKINS UNIVERSITY SOCIETY OF
SCHOLAR, AND ELECTION TO
NATIONAL ACADEMY OF MEDICINE.
HE WAS RECENTLY NAMED ONE OF THE
50 MOST INFLUENTIAL CLINICAL
LEADERS BY MODERN HEALTHCARE.
HE SERVES IN TWO FDA ADVISORY
COMMITTEES, BUT SEEMS UNRELATED
BIOLOGICAL PROBLEMS AND ADVISORY
COMMITTEE AND THE ANTIMICROBIAL
DRUGS ADVISORY COMMITTEE OR THE
-- THAT COVID VACCINES AND DRUGS
FOR APPROVAL.
IN FEBRUARY OF 2021 HE WAS
APPOINTED BY PRESIDENT BIDEN TO
THE COVID HEALTH EQUITY TASK
FORCE.
HE HAS NUMEROUS ADVISORY BOARDS
INCLUDING HARVARD UNIVERSITY
BOARD OF OVERSEERS AN CURRENTLY
SERVES THE ADVISORY COUNCIL TO
THE NIH DIRECTOR, A SHARE OF THE
VETERANS ADMINISTRATION NATIONAL
ACADEMIC AFFILIATION COUNCIL AND
BOARD OF DIRECTORS OF THE
ASSOCIATION OF ACADEMIC HEALTH
CENTERS AND CHAIR OF THE
CHILDREN RESEARCH HOSPITAL
GRADUATE SCHOOL OF BIOMEDICAL
SCIENCES BOARD.
DR. HILDRETH, WELCOME, THANKS
FOR COMING AND SPEAKING WITH US.
>> THANK YOU, NORA.
I'M PLEASED TO BE WITH YOU TODAY
THANKS FOR GIVING ME A CHANCE
HEALTH DISPARITIES AND HOW WE
CAN CHANGE THAT.
SO I'M GOING TO SHARE MY KOREAN
IF THAT IS OKAY.
AND GET STARTED.
SO I WOULD LIKE TO MENTION I'M
LEADER OF MEHARRY MEDICAL
COLLEGE, BEEN AROUND SINCE 1876
FOUNDED AS A SCHOOL AFRICAN
AMERICANS WHO WERE RECENTLY
FREED FROM SLAVERY WITH LEARN
THE HEALING ARTS.
AT THE TIME IN THE SOUTH MEHARRY
WAS THE ONLY PLACE THAT IF YOU
WERE BLACK YOU COULD COME TO
LEARN TO BECOME A PHYSICIAN OR
HEELER.
-- HEALER.
SO TODAY I WANT TO TALK ABOUT
WHAT I CALL THE SIX DEGREES OF
SEPARATION, AND HOW WE MIGHT
CLOSE THE GAP IN HEALTH IN THE
UNITED STATES.
A CONTEXT FROM MY TALK IS
ANOTHER STORY WHICH IS THE SAME
SONG DIFFERENT MED DI TAIL OF
TWO PANDEMICS.
YESTERDAY WAS NATIONAL BLACK
AIDS WAY WARENESS DAY TO REMIND
US THERE WERE TWO PANDEMICS
UNDERWAY, NOT JUST ONE THAT'S
BEEN AROUND SINCE THE EARLY
'80s AND ANOTHER THAT STARTED
IN 2019.
SO LET'S TALK ABOUT THE OTHER
PANDEMIC VERY QUICKLY.
1981 IN THE SUMMER CDC REPORTED
SEVERAL YOUNG MEN WHO ARE ALL
HOMOSEXUALS, THE LEFT COAST AND
RIGHT COAST WHO CAME DOWN WITH
DISEASE THAT WERE PATHOGNOMONIC
OF IMMUNODEFICIENCY IN NEW
ENGLAND JOURNAL OF MEDICINE AND
DECEMBER BACK THE BACK REPORTS
REPORTING THE SAME PHENOMENON
AND AGAIN ALL THESE REPORTS HAVE
TO WITH HOMOSEXUALS IN
CALIFORNIA AND NEW YORK MOSTLY.
UNFORTUNATELY THIS DISEASE WAS
GIVEN A NAME GAY RELATED
IMMUNODEFICIENCY.
TELL YOU WHY SIGNIFICANT IN A
MOMENT.
IN 1983, COLORFUL SCIENTIST
IDENTIFIED THE BIAS RESPONSIBLE
FOR AIDS, WE KNOW HIV JUMPED
INTO HUMANS FROM CHIMPANZEES AT
LEAST 13 TIME, IN CAMEROON, THE
VIRUS MADE ITS WAY DOWN TORY
PUBLIC OF CONGO AND BECAME THE
EPICENTER OR SPREAD OF THE VIRUS
ALONG RIVER ROOTS AND RAILROADS
MADE IT WAY THROUGHOUT THE
CONTINENT OF AFRICA, MADE IT TO
POINT -- IN 1960 WE BELIEVE
THAT'S WHEN THE VIRUS SPREAD
AROUND THE WORLD.
IN THE PANDEMIC FASHION.
IN APRIL OF 1984 MARGARET
HECKLER THE THEN OF HHS
ANNOUNCED TO THE WORLD
SCIENTISTS DISCOVERED THE VIRUS
THAT CAUSES AIDS, SHE EXPRESSED
FERVENT HOPE ALMOST MADE A
PROMISE FOR A VACCINE IN TWO
YEARS.
ONE OF THE THINGS THAT WAS
STRIKING TO ME ABOUT THIS,
HAVING BEEN IN IT FROM THE
BEGINNING, FIRST CASES OF AIDS
WERE DISCOVERED IN 1981.
ARE THEN PRESIDENT REAGAN DIDN'T
MENTION THIS ILLNESS PUBLICLY
FOR SIX YEARS AND BY THAT TIME
60,000 CASES HAVE BEEN
IDENTIFIED MORE THAN 28,000
PEOPLE DIED.
PART OF REASON IS BECAUSE IT WAS
GIVEN THE NAME GAY RELATED
IMMUNODEFICIENCY.
AND THERE WAS THE BELIEF IT WAS
ONLY A PROBLEM THAT CONCERNED
GAY MEN AND AT THE TIME SOCIAL
CONSTRUCT WAS SUCH THAT NO ONE
THOUGHT A THAT TO BE A VERY
IMPORTANT PROBLEM IF IT WAS
RESTRICTED TO GAY MEN THIS SLIDE
SHOUGHS FROM THE BEGINNING IT
WAS NEVER A DISEASE OF GAY WHITE
MEN, IT IMPACTED THE WHOLE
POPULATION WHETHER BLACK WHITE
HISPANIC MALE OR FEMALE.
THE VIRUS INFECTED YOU AND
CAUSED DISEASE.
ONE OF THE THINGS THAT'S BEEN
TRUE THROUGHOUT THIS PANDEMIC IS
THAT HIV HAS BEEN PRIMARILY A
PROBLEM OF PEOPLE OF COLOR.
AND EVEN TODAY AS I SIT AND
SPEAK WITH YOU MORE THAN HALF OF
ALL THE CASES OF NEW INFECTIONS
OCCUR IN AFRICAN AMERICAN AND
HISPANIC MEN WHO HAVE SEX WITH
MEN.
WE HAVE MORE THAN 36 MILLION
PEOPLE LIVING WITH HIV AND 70%
WHO LIVE WITH IT ARE FOUND MANY
THE SOUTHERN AFRICAN CONTINENT
WHICH MEANS GLOBALLY AND HERE IN
THE UNITED STATES HIV AIDS IS
LARGELY A PROBLEM OF PEOPLE OF
COLOR.
VERY IMPORTANTLY AS I SAID
BEFORE 38 MILLION PEOPLE LIVING
WITH HIV MORE THAN A MILLION
PEOPLE BECOME NEWLY INFECTED
EACH YEAR AND MANY ARE STILL
DYING OF AIDS AROUND THE WORLD.
SO POINT IS THE HIV PANDEMIC IS
NOT OVER.
WE HAVE TWO PANDEMICS ON OUR
HANDS.
THE PANDEMIC DEYOUR IS COVID-19
CALLED BY VIRUS THAT BELONGS TO
THE HUMAN CORONA VIRUS FAMILY
SARS COV-2.
THESE THREE VIRUSES IN THIS
FAMILY ARE ONES THAT CAUSE
PANDEMICS, SARS IN 2003, MERS IN
2012 AND SARS COV-2 IN 2019.
DISEASE IS CHARACTERIZED BY
DESTRUCTION OF LOWER RESPIRATORY
TISSUE TWO THINGS HAPPEN THAT
ARE SIGNIFICANT, IT IS
DESTROYING TISSUES BUT
INFLAMMATORY RESPONSE TO THE
VIRUS IS EQUALLY DESTRUCTIVE AND
THAT IS MAKES THE DISEASE
SEVERE.
SO TODAY AS OF FEBRUARY 3, 386
MILLION PEOPLE REPORTED TO HAVE
A SARS COV-2 INFECTION AND MORE
THAN 5.7 MILLION PEOPLE DIED THE
REAL NUMBER IS CLOSER TO A
BILLION PEOPLE WHO HAD SARS
COV-2.
BECAUSE FOR EVERY CASE WE
DIAGNOSE THERE'S PROBABLY AT
LEAST THREE OTHERS THAT GO
UNDIAGNOSED.
HERE IN THE UNITED STATES
7.57 MILLION HAVE HAD COVID-19
OR INFECTION YESTERDAY I HEARD
NOW MORE THAN 900,000 PEOPLE
DIED.
AT THE RATE WE ARE GOING WE ARE
ALMOST CERTAINLY GOING TO
ECLIPSE THE 100 MILLION
DIAGNOSED CASES AND 1 MILLION
PEOPLE DEAD IN FROM 201 2019 AT PACE
WE ARE MOVING.
THIS IS A PROFOUND STATEMENT TO
THE POWER OF SCIENCE AND
RESEARCH, 10 BILLION SHOTS GIVEN
AROUND THE WORLD IN ALL VACCINES
INCLUDED, 22 ALL TOGETHER.
THAT ARE APPROVED FOR USE FOR
COVID-19.
AND THOSE ALL TOGETHER REPRESENT
10 BILLION SHOTS INTO ARMS.
HERE IN THE UNITED STATES, MORE
THAN 540 MILLION SHOTS HAVE BEEN
GIVEN AND THANKFULLY THAT MEANS
AS I SAID AND -- SIT AND SPEAK P
YOU, 64% OF THE POPULATION ARE
FULLY VACCINATED BY THAT WE MEAN
TWO SHOTS.
AND SMALL PERCENTAGE OF THOSE I
THINK 40% HAVE RECEIVED
BOOSTERS. SO THE FIRST CASES
WERE IDENTIFIED IN CHINA LATE
DECEMBER 2019.
THE VIRUS WAS IDENTIFIED JANUARY
7 PUBLISH FORD THE WORLD TO SEE.
THE FIRST CASE OUTSIDE OF CHINA
TOOK PLACE IN JANUARY 13TH,
2020.
AND THEY PROBABLY WAITED TOO
LONG TO DO SO BUT THE WHO
DECLARED THIS A PANDEMIC IN
MARCH 11, 2020.
SO IN AN EERIE PARALLEL TO HIV
AIDS, WE HAD A PRESIDENT WHO
AFTER ALMOST 5 MILLION CASES
HAVE BEEN IDENTIFIED TENS OF
THOUSANDS OF PEOPLE DEAD OR
PRESIDENT CHOSE TO IGNORE THIS
AS A TRUE PUBLIC HEALTH CRISIS
BY MAKING FALSE STATEMENTS ABOUT
IT AND ACTUALLY GETTING MANY THE
WAY OF PROGRESS IN TERMS OF
PUBLIC HEALTH RESPONSE AND
RESEARCH.
IT IS APARALLEL THAT WE RATHER
NOT SEE BUT STRIKING TO ME WE
HAD THOSE TWO SITUATIONS.
IN BOTH PANDEMICS.
IN CHINA EARLY ON IN THIS
PANDEMIC THEY MADE AN
OBSERVATION THAT WAS IMPORTANT I
THINK, THEY OBSERVED THAT 70% OF
THE PEOPLE WHO DIED OF COVID-19
HAD AT LEAST ONE CO-MORBID
CONDITION.
HIGH BLOOD PRESSURE
HYPERTENSION, DIABETES,s
SCHEMIC HEART DISEASE CHRONIC
LUNG DISEASE, STROKE.
OTHER MAJOR FACTOR WAS SMOKING.
THOSE WHO SMOKED HAD HIGHER RISK
OF DYING THAN THOSE WHO DIDN'T.
WHAT THAT MEANT WHEN YOU
TRANSPOSE PANDEMIC TO THE UNITED
STATES, IT WAS PREDICT AND
PREDICTABLE THAT AFRICAN
AMERICAN AND HISPANICS WOULD
HAVE THE MAJOR BURDEN OF THIS
DISEASE BECAUSE WE AS A
POPULATION HAVE MUCH HIGHER
RATES OF ALL THESE THINGS.
CARDIOVASCULAR DISEASE,
HYPERTENSION, DIABETES, OBESITY.
CANCER.
AND IT WAS PREDICTED THAT
MINORITY POPULATIONS WOULD BE
DISPROPORTIONATELY BURDENED BY
COVID-19.
THAT IS WHAT WE SAW.
THERE'S LOTS OF EXAMPLES TO SHOW
YOU BUT THESE ARE DATA FROM THE
SUMMER OF 2020 AND LOUISIANA
WHICH REPRESENTS THE MICHIGAN,
DETROIT, ILLINOIS, CHICAGO.
AS YOU CAN SEE ONE POINT IN THE
PANDEMIC THE INFECTION RATE OR
RATE OF DYING OF COVID-19 FOR
AFRICAN AMERICAN COMES COMPARED
TO WHITES WAS TEN TO ONE IN
DETROIT, MICHIGAN.
THE CDC NOW PUBLISHED SOME
CUMULATIVE DATA IN THIS REGARD,
AS YOU CAN SEE TALKING ABOUT
CASE, HOSPITALIZATIONS OR DEATH,
IF YOU ARE INDIGENOUS PERSON OR
HISPANIC OR BLACK YOUR CHANCE OF
HOSPITALIZED AND DYING, ARE MANY
FOLD HIGHER THAN IF GO ARE
WHITE.
SO THE TWO PANDEMICS POINT OUT
SOME REALLY INTERESTING THINGS.
FIRST OF ALL FAILED NATIONAL
LEADERSHIP, BECAUSE OF POLITICS
AND PREJUDICE, RESULTED IN A
DELAYED RESPONSE INEFFECTIVE
RESPONSE TO BOTH PANDEMICS EARLY
ON.
THE BOTH PANDEMICS REVEALED A
CHASM IN THE HEALTH STATUS OF
AFRICAN AMERICANS HISPANICS AND
INDIGENOUS PEOPLE, IN OUR
COUNTRY.
THESE LONG STANDING DISPARITIES
IN CHRONIC DISEASE ARE THE MAJOR
CONTRIBUTORS IN BOTH CASES
ACTUALLY, FOR WHY DISADVANTAGED
COMMUNITIES ARE SUFFERING SO
MUCH IN THESE TWO CASES.
AND THESE INEQUITIES IN BOTH
PANDEMICS ARE BEST UNDERSTOOD IN
THE CONTEXT OF THE SOCIAL
DETERMINANTS OF HEALTH WHICH I'M
SURE YOU HEARD QUITE A BIT
ABOUT.
THE WHO DEFINITION IS SOCIAL
DETERMINANTS OF HEALTH ARE
DEFINED THE CONDITIONS IN WHICH
WE ARE BORN GROW LIVE WORK AGE
AND I WOULD SAY DIE.
SHAPED BY THE DISTRIBUTION OF
MONEY POWER AN RESOURCES AT
LOCAL LEVEL COMMUNITY LEVELS AND
THROUGHOUT THE WORLD.
THE KEISER FAMILY FOUNDATION HAS
DONE A BEAUTIFUL ILLUSTRATION OF
FIVE PARAMETERS THAT WE LOOK AT
WHEN WE TALK ABOUT THE SOCIAL
DETERMINANTS OF HEALTH.
EDUCATION ACCESS, EQUALITY OF
THAT EDUCATION, HEALTHCARE
ACCESS AND EQUALITY OF THE
HEALTHCARE WE RECEIVE, THE BUILT
ENVIRONMENT, NEIGHBORHOODS WHICH
WE LIVE, SOCIAL COMMUNITY
CONTEXT, ECONOMIC STABILITY, AND
I REFER TO THESE AS THE FIVE
DEGREES OF SEPARATION.
BUT THEY ARE SIX DEGREES OF
SEPARATION THAT BECAME QUITE
APPARENT IN THE COVID-19
PANDEMIC THAT 6-DEGREE
SEPARATION IS TECHNOLOGY.
TECHNOLOGY HAS PLAYED AN
IMPORTANT ROLE IN RESPONDING TO
PANDEMIC BUT ALSO SHOWN A HUGE
GAP IN TERMS OF POPULATIONS IN
OUR COUNTRY THEY ARE ABLE TO
TAKE ADVANTAGE OF TECHNOLOGY.
SOME OF THE THINGS WE CAN POINT
TO IN THESE SIX DEGREES OF
SEPARATION THERE IS ALSO --
THERE IS POOR ACCESS TO
EDUCATION ALSO POOR ACCESS TO
HEALTH INFORMATION WHICH IS
IMPACTFUL.
IN THE CASE OF HIV AND ALSO TO
SOME EXTENT COVID-19, MINORITY
COMMUNITIES RELATE TO GET
MEDICAL CARE IN CASE OF HIV IF
YOU CAME LATE INTO CARE THE
VIRUS HAD DECIMATED YOUR IMMUNE
SYSTEM AND THE CARE YOU RECEIVED
WAS NOT IMPACTFUL.
IN BOTH CASES POORLY MANAGED
CHRONIC CONDITIONS CONTRIBUTED
TO THE DISPARITY WE SAW.
IN COVID-19.
ONE OF THE THINGS IN COVID-19
VERY IMPACTFUL WAS
MULTI-GENERATIONAL HOUSEHOLDS IN
CERTAIN ZIP CODES IN CERTAIN
PARTS OF CERTAIN CITIES
CONTRIBUTED SIGNIFICANTLY TO
RAPID SPREAD OF VIRUS IN
IMMUNITY.
MASS INCARCERATION BOOTH BOTH
CASES FOR HIV AND CORONA VIRUS
ALSO CONTRIBUTED TO SPAN OF
VIRUS AND SPREAD OF DISEASE.
ONE OF THE SOCIAL CON SECTION
HERE THAT IS REALLY IMPORTANT IS
MISTRUST OF HEALTHCARE MEDICAL
RESEARCH, THAT IS FOUND IN
COMMUNITIES OF COLOR ACROSS THE
COUNTRY.
IN TERMS OF ECONOMIC INSTABILITY
WE HAVE LOW WAGE JOBS THERE IS A
WEALTH GAP THAT IS JUST
EXTRAORDINARY, WE LOOK AT THE
DATA.
SO THESE ARE SOME OF THE
PARAMETERS, SOME OF THE FACTORS
TO THINK ABOUT WHEN WE CONSIDER
THESE DEGREES OF SEPARATION FOR
TECHNOLOGY, MANY MINORITY
HOUSEHOLDS AND SCHOOLINGS LIKE
TOOLS TO BE TAKE ADVANTAGE OF
SERVICES PROVIDED USING
WEB-BASED TECHNOLOGY OFTENTIMES
PEOPLE IN POOR COMMUNITIES WERE
NOT ABLE THE SIGN UP FOR THOSE
VACCINES TELEHEALTH MANIFESTED
ALSO.
THE OTHER THING IS THE
TECHNOLOGY USE OF TECHNOLOGY AND
HEALTHCARE SETTINGS IS RAPIDLY
EXPANDING.
THE PROBLEM IS THOSE ALGORITHMS
DEVELOPED FOR PRECISION MEDICINE
AN INDIVIDUALIZED TREATMENT THEY
ARE BIASED LIKE BIASES THAT WE
FOUND IN HEALTHCARE DELIVERY
BEFORE ALGORITHMS CAME ALONG ARE
BAKED INTO THE ALGORITHMS AND
THAT HAS TO CHANGE.
WHAT THAT RESULTS IS THAT
MINORITY COMMUNITIES GET LESS
THAN OPTIMAL CARE BECAUSE OF
THESE BIASES.
THE REAL PART I WANT TO MAKE IS
THAT THERE IS A WEDGE THAT IS
LAUNCHED BETWEEN INDIGENOUS
PEOPLE AND PEEP OF COLOR AND
HAVING BEST INDIVIDUAL HEALTH
AND WELLNESS, THAT IS SOMETHING
THAT WE HAVE BEEN SLOW TO
ACKNOWLEDGE AND TALK ABOUT.
THE SYSTEMIC RACISM IF YOU DIG
DEEP IN ANY ONE OF THE SIX
DEGREES OF SEPARATION,
INEVITABLY LEADS YOU TO THIS ONE
CONCLUSION.
THAT'S SYSTEMIC RACISM HAS LED
TO ALL OF THESE CONVERSATIONS WE
ARE HAVING FOR SCHOOLS,
COMMUNITIES WE LIVE IN, HAVING
ACCESS TO QUALITY EDUCATION,
NEIGHBORHOODS WE LIVE IN, HAVE
BEEN DICTATED BY SYSTEMIC
RACISM, ECONOMIC STABILITY IS
CERTAINLY A FACTOR AND AS I
POINT OUT TECHNOLOGY IS ONE OF
THESE.
IN ORDER TO ALLOW DISADVANTAGED
COMMUNITIES TO ACHIEVE BEST
HEALTH AND WELLNESS, WE HAVE TO
DEAL WITH THIS WEDGE THAT
SEPARATES THEM FROM IT AND IT IS
SYSTEMIC RACISM.
THANKFULLY RACISM IS NOW
RECOGNIZED AS A MAJOR FACTOR
CONTRIBUTING TO POOR HEALTH.
THERE ARE NUMEROUS SCIENTIFIC
STUDIES THAT ARE NOW ATTEST TO
THIS AND I WILL TALK ABOUT THAT
IN A MINUTE.
THE CDC DECLARED RACISM A
SERIOUS HEALTH THREAT THAT HAS
FAR REACHING AND UNACCEPTABLE
CONSEQUENCES. PRESIDENT BIDEN
ESTABLISHED A COVID-19 EQUITY
TASK FORCE WHICH YOU HEARD
ABOUT.
AND WE HAVE ACTUALLY MADE
RECOMMENDATIONS TO HIM REGARDING
THINGS TO DO TO ELIMINATE GAPS.
AND AS A MEMBER FRANCIS COLLINS
ADVISORY COUNCIL I WAS REALLY
PLEASED AND THANKFUL TO HIM THAT
ON BEHALF OF THE ORGANIZATION HE
ACKNOWLEDGED RACE IMTO BE A
FACTOR AND SET IN MOTION A
PROGRAM OF ACTIVITIES TO DEAL
WITH IT.
IT IS CALLED UNITE.
SO I WANT TO GIVE DR. COLLINS
CREDIT FOR DOING THIS.
IT WAS THE FIRST TIME I EVER
EXPERIENCED SOMEONE LEADING A
NATIONAL ORGANIZATION WHO HAD
THE COURAGE TO STAND UP AND SAY
WE HAVE A PROBLEM, LET'S FIX IT.
MY COLLEAGUE AT HARVARD SCHOOL
OF PUBLIC HEALTH IS LEADING
AUTHORITY ON THIS, DR. DAVID
WILLIAMS, HAS PUBLISHED DOZENS
AND DOZENS OF PAPERS THAT
PROVIDE OBJECTIVE EVIDENCE THAT
RACISM ALONE WHEN YOU ACCOUNT
FOR ALL OTHER FACTORS RACISM BY
ITSELF CAN IMPACT HEALTH AND
THEREFORE EASY TO MEASURE
OBJECTIVES THAT WE CAN LOOK AT
TO TELL US THAT THAT IS TRUE.
MORE LIFE EXPECTANCY, HIGHER
BLOOD PRESSURE, LOWER RATES OF
VACCINATION, AND STRAIN ON
MENTAL HEALTH, THINGS WE CAN
MEASURE THAT CAN BE DIRECTLY
ADISTRIBUTED TO RACISM --
ATTRIBUTED TO RACISM HAVING
OTHER PARAMETERS AND FACTORS
CONSIDERED.
WHEN THERE IS RACIAL INEQUALITY
THAT LEADS TO ECONOMICS
INSTABILITY AND DISPARITIES.
ECONOMIC DISPARITIES LEAD TO
EQUAL ACCESS TO HEALTHCARE, BUT
EVEN WHEN THERE IS ACCESS TO
HEALTHCARE, RACISM BECOME A
FACTOR BECAUSE IT IS WELL
UNDERSTOOD AND WELL DOCUMENTED
THAT MANY DOCTORS DISBELIEVE
NEGLECT AND DISCRIMINATE AGAINST
BLACK AN BROWN PATIENTS.
THIS IMPLICIT BIAS TOWARD
MINORITIES WE ARE WORRIED ABOUT
IT IN TERMS OF LONG COVID
BECAUSE THAT INVOLVES SIGNATURE
TOMS NOT DIAGNOSED EASILY BY
OBJECTIVE TESTS AND ARE TENS OF
THOUSANDS OF BLACK AND BROWN
PEOPLE WHO HAVE LONG COVID WORRY
ABOUT WHETHER OR NOT THEY WILL
GET THE CARE THEY DESERVE THAT
THEY NEED BECAUSE OF THIS WELL
KNOWN IMPLICIT BIAS WHEN WE
ENGAGE THE HEALTHCARE SYSTEM.
ANOTHER THING TO POINT OUT IS
THAT FOR WHOLE CENTURY FROM 1900
TO 2000, PERCENT OF U.S.
PHYSICIANS WHO ARE BLACK BARELY
BUDGED AND WAS NEVER MORE THAN
4%. IN FACT FOR MOST CENTURY IT
WAS LESS THAN 3%.
HOVERED AROUND THAT.
AND THAT'S A PROBLEM.
EVEN TODAY AS I SIT AND SPEAK
WITH YOU EVEN THOUGH WE
REPRESENT 13% OF THE POPULATION,
AFRICAN AMERICANS STILL
CONSTITUTE ABOUT 5% OF
PHYSICIANS.
THE SAME THING IS RUE FOR
HISPANICS AS WELL.
ANOTHER THING TO POINT OUT,
200,000 LICENSED DENTISTS IN THE
UNITED STATES, 6,000 WHOM ARE
BLACK, ONLY 3%.
QUITE REMARKABLY THERE'S 68
SCHOOLS OF DENTISTRY IN UNITED
STATES OF AMERICA AND ONE SCHOOL
IN NASHVILLE, TENNESSEE, IS
RESPONSIBLE FOR 40% OF ALL BLACK
DENTISTS WHO PRACTICE IN THE
UNITED STATES.
EVEN THOUGH THERE'S 67 OTHER
SCHOOLS WITH CAPACITY TO TRAIN
DENTISTS.
LIKEWISE, THERE'S 254 ACCREDITED
PHYSICIAN ASSISTANT PROGRAMS,
150,000 OR SO PHYSICIAN
ASSISTANTS IN THE UNITED STATES.
LESS THAN 3% ARE BLACK, AND ONLY
ONE IN A THOUSAND OF THEM ARE
BLACK MALES.
I POINT THIS OUT BECAUSE WE NOW
UNDERSTAND THAT WHEN THE
HEALTHCARE PROVIDERS REFLECT
POPULATION THEY CARE FOR, THE
OUTCOMES ARE MUCH BETTER.
THAT IS NOT TO SAY THAT IF YOU
ARE A WHITE PHYSICIAN YOU CAN'T
PROVIDE GREAT CARE TO BROWN OR
BLACK PERSON BECAUSE THAT
HAPPENS EVERY DAY.
THE POINT IS OVERALL WORK FORCE
REFLECT IT IS POPULATION, WE
KNOW THE OUTCOMES ARE BETTER.
SO JUST WANT TO SHARE A FEW
RECOMMENDATIONS WE MADE TO
PRESIDENT BIDEN.
IN THE TEN MONTHS WE SPENT
WORKING ON HEALTH EQUITY TASK
FORCE.
ONE OF THE MAJOR RECOMMENDATIONS
WE MADE WAS TO ELEVATE AND
EXPLOIT THE KNOWLEDGE AND
EXPERTISE OF COMMUNITIES.
IN OTHER WORDS, TO HAVE WHAT WE
CALL CULTURAL HUMILITY TO
RECOGNIZE THE SOME COMMUNITIES
HAVE THE ANSWERS.
THEY ARE JUST LACKING THE
RESOURCES AND WHEREWITHAL TO
IMPLEMENT THOSE SOLUTIONS.
WE ALSO SPENT A LOT OF TIME
TALKING ABOUT THE FACT THAT NOT
ONLY SOMETIMES IS DATA NOT
AVAILABLE TO ALLOW GOOD
DECISIONS TO BE MADE, BUT THE
DATA IS IN MOST CASES NOT
DISAGGREGATED TO ALLOW YOU TO
UNDERSTAND WHAT IS HAPPENING TO
CERTAIN POPULATIONS AND LIVED
EXPERIENCES.
SO WE ARE RECOMMENDING THAT
DISAGGREGATE THE DATA BE
PRODUCED, AND REPORTED SO THAT
DECISIONS CAN BE MADE THAT ARE
REASONABLE AND HAVE THE BEST
OUTCOMES.
WE ALSO THINK IN ALL THE
AGENCIES, IN THE UNITED STATES
GOVERNMENT, ALL THE PRACTICES
POLICIES AND ALL THOSE SHOULD BE
GOVERNED QUITE SOME TIME TO COME
TO INCLUDE HEALTH EQUITY AS
PRIORITY FACTOR IN THOSE
PROCESSES AND PRACTICES.
AND ONE OF THE MAJOR
RECOMMENDATIONS WE MADE AND THIS
IS ONE OF THE ONES THAT WE SPENT
A LOT OF TIME TALKING ABOUT, WE
ALL AGREED ALL OF US ON THE
HEALTH EQUITY TASK FOES, HUMAN
RIGHT HAS TO BE DECLARED A --
HEALTHCARE HAS TO BE DECLARED A
HUMAN RIGHT.
TO ACKNOWLEDGE THE FACT THAT WE
REALLY DO BELIEVE ALL LIVES ARE
VALUABLE AND SAME BECAUSE THE
PANDEMIC HAS SHOWN US THAT A LOT
OF WAYS WE SAY THAT BUT IT
DOESN'T APPEAR TO BE TRUE IN OUR
COUNTRY.
SO HOW DO WE DISLODGE WEDGE OF
SEPARATION?
WE HAD THE MAKE SURE
INSTITUTIONS THAT TRAIN
HEALTHCARE PROVIDERS ARE HELD
ACCOUNTABLE FOR TRAINING DIVERSE
GROUP OF TRAINEES.
WE HAVE TO MAKE SURE THE BIAS
AND MEDICAL DECISION MAKING AND
ALGORITHMS DEVELOPED THOSE BE
ADDRESSED AND ELIMINATED AS
QUICK AS POSSIBLE.
WE BELIEVE GOVERNMENT HAS DUTY
TO MAKE SURE ENVIRONMENTAL
JUSTICE IS ENFORCED SO ALL OF US
HAVE ACCESS TO CLEAN WATER,
SANITATION AND HEALTHY FOODS AND
THAT WE ALL LIVE IN SAFE
COMMUNITIES WITH A POSSIBILITY
OF HAVING PHYSICALLY ACTIVE
LIFESTYLES.
PHYSICAL ACTIVITY EVER TIFTED BY
ITSELF WOULD MAKE A HUGE
DIFFERENCE IN THE HEALTH STATUS
OF MOST AMERICANS.
LAST, WE BELIEVE THAT ALL
FEDERAL AGENCIES SHOULD DO WHAT
NIH HAS DONE, TO ACKNOWLEDGE
RACISM IS A FACTOR AND HIRING
AND POLICY MAKING ALLOCATION OF
RESOURCES, AND DO AS NIH HAS
DONE, AND IMPLEMENT A PLAN TO
ELIMINATE IT.
SO JUST A FEW MORE WE ALSO THINK
HEALTHCARE ORGANIZATIONS IN OUR
DRY SHOULD BE INCENTIVIZED TO
PARTNER WITH LOCAL COMMUNITY
ORGANIZATIONS, THAT ARE
ADDRESSING THE SOCIAL
DETERMINANTS OF HEALTH,
HEALTHCARE PROVIDERS
ORGANIZATIONS ARE NOT SET UP TO
ADDRESS THE SOCIAL DETERMINANTS
OF HEALTH, THAT'S NOT WHAT THEY
ARE DESIGNED TO DO.
WHAT THEY HAVE BEEN DOING OVER
THESE DECADES BUT PARTNERING
WITH COMMUNITY ORGANIZATIONS WE
BELIEVE THEY CAN ACTUALLY BE
EFFECTIVE IN ADDRESSING THOSE
SOCIAL DETERMINANTS.
WE ALSO STRONGLY BELIEVE THE
INDIAN HEALTH SERVICE SHOULD
FINALLY BE FULLY FUNDED TO MAKE
SURE INDIGENOUS PERSONS CAN HAVE
ACCESS TO QUALITY HEALTHCARE AND
INCLUDING TELEMEDICINE AND
TELEHEALTH.
WE ALSO THINK BEHAVIORAL HEALTH
IS A HUGE PROBLEM ESPECIALLY FOR
MINORITY POPULATIONS AND THE
GOVERNMENT SHOULD SET UP
STANDARDS ACROSS ALL
ORGANIZATIONS TO MAKE SURE
UNDERSERVED POPULATIONS CAN GET
THE EQUITY CENTERED BEHAVIORAL
HEALTHCARE THEY NEED.
LASTLY, WE BELIEVE TECHNOLOGY
WHICH IS ONE OF THE SIX DEGREES
OF SEPARATION HAS TO BE
ADDRESSED TO MAKE SURE THAT
RURAL INDIVIDUALS MEMBERS THAT
ARE PART OF BIPOC COMMUNE AT
THIS AND UNDERSERVED COMMUNITIES
HAVE ACCESS TO HEALTHCARE
SERVICES DELIVERED THROUGH
TECHNOLOGY TELEMEDICINE AND
TELEHEALTH.
SO THERE ARE LOTS OF OTHER
RECOMMENDATIONS WE HAD BUT THESE
ARE MAJOR ONES TO SHARE WITH
YOU.
MY MAIN POINT IS IF YOU LOOK AT
ANY OF THOSE SIX DEGREES OF
SEPARATION AND YOU PROBE DEEP
ENOUGH, YOU COME TO THE SAME
CONCLUSIONS.
YOU CAN GET AWAY FROM THE FACT
SYSTEMIC RACISM OVER DECADES, I
WOULD SAY OVER 400 YEARS, HAS
PUT US IN A POSITION WHERE SOME
MEMBERS OF POPULATION ARE
DISADVANTAGED WHEN IT COMES TO
HEALTH AND HEALTHCARE.
AND DEALING WITH RACISM HAS TO
BE PART OF OUR STRATEGY.
I THINK THAT IS IT.
THANK YOU.
>> THANKS VERY MUCH FOR THE
WONDERFUL PRESENTATIONS.
I WILL OPEN UP NOW FOR QUESTIONS
ANYONE MAY HAVE.
>> AND SUGGESTIONS.
>> I THINK IN THINKING ABOUT THE
QUESTION FIRST OF ALL I THANK
YOU FOR BRINGING IN THE SIX
SEPARATION OF THE TECHNOLOGY
BECAUSE AS WE RELY MORE ON
TECHNOLOGY THIS IS NOT -- THE
GAP IS GOING TO GET WORSE.
SO IN TERMS OF HOW DO WE
ACCELERATE THAT SPECIFIC GAP OF
SEPARATION BECAUSE THERE ARE
MULTIPLE BUT THAT TECHNOLOGY ONE
IS SORT OF INCEPTION.
>> I THINK ONE OF THE PROBLEMS
IS THE NUMBER OF STUDENTS WHO
GET EXPOSED TO TECHNOLOGICALLY
INTENSE CAREER OPTIONS ARE VERY
FEW.
THAT IS A REASON WE STARTED
SCHOOL OF APPLIED COMPUTATIONAL
SCIENCES AT MEHARRY TO OFFER
DEGREES AND DATA SCIENCE
BIOMEDICAL DATA SCIENCE ROLLING
OUR FIRST CLASS THIS FALL AND WE
BELIEVE -- I BELIEVE PERSONALLY
THAT STUDENTS CANNOT BE EXCITED
ABOUT SOMETHING YOU ARE NOT
EXPOSED TO.
WE GOT EXPOSED MORE STUDENTS TO
THE POWER OF AND BEAUTY OF I
WOULD SAY DATA SCIENCE AND WHAT
THAT CAN DO AND MAKE SURE THEY
ARE INVOLVED IN DEVELOPING THE
ALGORITHMS AND DOING THE
RESEARCH.
TO ME IT IS ONE OF THE MOST
EXCITING THINGS GOING NOW.
IS DATA SCIENCE AND LARGE DATA
SETS AND DEVELOPING
INTERVENTIONS BASED ON THOSE
DATA SETS.
SO I THINK THE ONE THING WE HAVE
TO DO IS TO DO MORE TO ENCOURAGE
MORE YOUNG PEOPLE, TO HAVE AN
INTEREST IN TAKE ON TECHNOLOGY
SPECIFIC CAREERS.
GOING FORWARD.
IN AND OUT OF HEALTHCARE FOR
THAT MATTER.
>> MELISSA ROSS RAISING HER
HAND.
MELISSA.
>> I THINK COMMISSIONER RIGHT
BEFORE ME, DR. --
>> THE GENTLEMAN I AM.
>> THANK YOU SO MUCH.
WANT TO LOWER MY HAND SO IT
DOESN'T STAY ON FOREVER.
THANK YOU DR. HILDRETH FOR YOUR
PRESENTATION.
I APPRECIATED SEEING THE
RECOMMENDATIONS TO THE BIDEN
ADMINISTRATION AND YOUR TIME
LINE OF PRIOR ADMINISTRATION
RESPONSIVE TO THE COVID PANDEMIC
IS GREAT TO SEE AS WELL SO THANK
YOU FOR THAT.
I AM FIRST NATION (INAUDIBLE) SO
SPEAKING FROM LINES OF MIXED
RACE INDIGENOUS PERSON, REALLY A
LOT ABOUT HOW CAN WE SHAKE UP
THE SYSTEMS FOR IMPACT.
FOR MORE EQUITABLE IMPACT. THE
THINGS WE CONTINUE TO DO, BOTH
WITHIN THE NIH AND WITHIN
SCIENCE MORE GENERALLY ARE
PRODUCING MAYBE NO CHANGES OR
INCREMENTAL CHANGES IN EQUITABLE
REPRESENTATION, CERTAINLY THEY
ARE NOT INCLUDING HEALTH
INEQUITIES, THEY ARE ONLY
GETTING WORSE.
SO I'M JUST -- I'M WONDERING A
LOT ABOUT WHAT CAN WE DO WITHIN
SAY THE CONFINES OF NIDA OR THE
NIH TO SHAKE IT UP.
WHAT ARE SOME BOLD INITIATIVES
THAT WE CAN TAKE ON.
CURIOUS IF YOU HAVE THOUGHTS ON
THIS, FROM MY PERSPECTIVE, KATHY
ETZ PART OF NIDA HELPED
COMMISSION A REPORT THAT SOME OF
US ENGAGED IN INDIGENOUS HEALTH
RESEARCH BROUGHT FOR REVIEWERS,
TO CONSIDER THINGS LIKE STOP
CONFLATING SIGNIFICANCE WITH
SIZE OF SAMPLE OF POPULATION.
STOP COUNTING ONLY PUBLICATIONS
AS METRICS OF SUCCESS AND
IMPACT.
FOR SCIENCE.
THESE ARE SMALL THINGS, CURIOUS
IF OTHER IDEAS WAYS TO BUST OUT
OF THE MODEL BECAUSE STATUS QUO
IS NOT WORKING AS YOU KNOW.
THANK YOU.
>> I DON'T HAVE ANY IDEAS THAT
YOU HAVEN'T HEARD ALREADY.
AS RADICAL FROM THAT PERSPECTIVE
THAT THE DIRECTIVE NIH TOOK THE
BOLD STEP AND IT WAS REALLY A
BOLD STEP TO SAY RACISM IS REAL,
WE HAVE TO DEAL WITH IT.
AND I THINK THAT JUST THAT ACT
ALONE SENT A MESSAGE TO
EXTRAMURAL COMMUNITY THAT NIH
LEADING BY EXAMPLE.
TO ME I HAVE ALWAYS THOUGHT
THAT'S THE BEST WAY TO LEAD IS
TO LEAD BY EXAMPLE.
I HAD TO THANK FRANCIS
PERSONALLY.
FOR DOING THIS BECAUSE I HAVE
BEEN DOING MEDICAL RESEARCH
SINCE I WAS A SOPHOMORE AT
HARVARD.
I WITNESSED SOME THINGS THAT ARE
TROUBLING TO ME, FOR EXAMPLE,
WHEN I WAS AT JOHNS HOPKINS I
SENT IN A GRANT FOR REVIEW AND
I'M SURE YOU HEARD ME SAY THIS
BEFORE.
THE ENVIRONMENT ALWAYS GOT A
ONE, DIDN'T MATTER HOW CRAPPY
THE REST OF GRAT WANT, THE
ENVIRONMENT GOT A ONE.
NOW AT MEHARRY MEDICAL COLLEGE
WE HAVE AMAZING INVESTIGATORS WE
GET -- FOR ENVIRONMENT THOUGHS
THEY NEVER SET FOOT ON CAMPUS.
WE HAVE A GREAT ENVIRONMENT.
MY POINT IS THAT WE HAVE TO FIND
WAYS TO DISMANTLE SOME OF THE
LONG STANDING PERSPECTIVES THAT
ARE WRONG.
THEY ARE JUST WRONG.
I THINK THAT PART OF WHAT NEEDS
TO HAPPEN IS SOME REALLY HONEST
CONVERSATIONS.
I DON'T LIKE TALKING RACISM AND
I DIDN'T MEAN FOR THAT TO BE THE
SUBJECT OF MY TALK TO BE HONEST
WITH YOU BUT WEENIE GOT THE
INVITATION FROM SUSAN AND SHE
ASKED ME TO SPEAK ABOUT WHAT
NEEDS TO BE DONE IN TERM TERMS
OF HEALTH EQUITY, YOU CAN'T GET
AROUND IT, IT IS ALL AROUND US,
IT IS PART OF WHAT WE DO.
SO WHAT I WOULD SAY IS FIND A
WAY TO ENGAGE TRUSTED
MESSENGERS, TRUSTED OPINION
LETTEDDERS AND INVOLVE THEM IN
THE THINGS YOU ARE DOING AND
THAT WILL HELP YOU ENGAGE
COMMUNITIES THAT YOU TRY TO
REACH AND TO ME THAT'S ONE OF
THE MOST EFFECTIVE WAYS OF
HAVING THE THINGS THAT YOU DO BE
IMPACTFUL IN THE COMMUNITIES BY
CONNECTING TO HAVING SOME
ASSOCIATION WITH THOSE
INDIVIDUALS WHO TRUST IT.
THAT IS WHY MY HIV WORK EARLY ON
IS PARTNERING WITH THE FAITH
LEADER IN THE BLACK CHURCH AND
THAT IS ONE THING TO SUGGEST TO
YOU.
I KNOW I DIDN'T ANSWER YOUR
QUESTION BUT THOSE ARE THOUGHTS
THAT I HAVE TO REFLECT ON.
>> COMMISSION O DARE.
>> THANK YOU SO MUCH, FIRST AND
FOREMOST, DR. HILDRETH, IT IS AN
HONOR TO MEET YOU, I HAVE HEARD
A LOT ABOUT YOUR WORK I'M
DELIGHTED TO HEAR FROM YOU I'M
WONDERING WILL YOU SHARE WITH US
YOUR SLIDES.
I HAVE NEVER SEEN A PRESENTATION
THAT IN DEPTH MOST -- I THINK MY
COLLEAGUES HERE FIRST CAME ON
FOR MY FIRST MEETING I TALKED
ABOUT SOCIAL DETERMINANTS OF
HEALTH.
IT IS AN ISSUE.
IT IS AN ISSUE THAT I'M
FIGHTING.
FOR YEAR IN COOK COUNTY.
BUT WE ARE THE SECOND LARGEST
COUNTY IN THE COUNTRY BUT WE ARE
FIGHTING NATIONAL, NATIONAL
ASSOCIATION OF -- I DECLARED
RACISM A PUBLIC HEALTH CRISIS
HERE IN COOK COUNTY.
WHICH BROUGHT US ON THE FIRST
CHIEF EQUITY OFFICER.
DECLARED GUN VIOLENCE A PUBLIC
HEALTH CRISIS HERE IN COOK
COUNTY, WE CREATED A MILLION
DOLLAR FUND BUT IN ADDITION A
$36 MILLION FUND.
PROVIDED IT'S HAPPENING IN
UNDERSERVED COMMUNITIES. LASTLY
WE DECLARED MENTAL HEALTH AND
THE LACK OF BEHAVIORAL HEALTH
SERVICES PUBLIC HEALTH CRISIS.
AND MY COLLEAGUES DID IT
UNANIMOUS UNDER MY LEADERSHIP
AND WE FUNDED THAT THROUGH ARPA
DOLLARS AT $60 MILLION.
MY QUESTION TO YOU IS I HAVE
HEARD YOU TALK ABOUT THE SOCIAL
DETERMINANTS OF HEALTH.
AND I -- MY GOAL IS TO PULL
TOGETHER EVERY ELECTED OFFICIAL
IN THIS COUNTRY THAT I CAN.
HOW DO WE DEAL WITH THIS -- WITH
THE POLITICAL DETERMINANTS OF
HEALTH.
AND DANIEL DOS TALKED ABOUT
THAT.
AT THE MOREHOUSE THATCHER
INSTITUTE SCHOOL OF MEDICINE, WE
KNOW POLITICAL DETERMINANTS OF
HEALTH EXIST, HOW DO WE FIT THAT
INTO THE SPECTRUM OF WHAT YOU
TALKED ABOUT TODAY.
>> COMMISSIONER DEAR, I MAKE IT
A POINT TO LEAD POLITICS
POLITICIANS, MY TRAINING AS A
SCIENTIST AND I TRY TO STAY IN
MY ORBIT BUT I DO BELIEVE THAT
POLARIZATION WE ARE WITNESSING
MANY THE UNITS RIGHT NOW IS
DANGEROUS AND I THINK THAT I GOT
INTO SCIENCE BECAUSE I BELIEVE
LAWS OF NATURE AND PHYSICS WOULD
WORK LIKE ANYBODY ELSE AND IF I
DID GOOD SCIENCE I COULD DO A
GOOD SCIENCE BECAUSE OF THAT.
I STILL BELIEVE THAT TO THIS
DAY, THAT IS WHY I CHOSE SCIENCE
AND RESEARCH BECAUSE I BELIEVE
THAT TO BE TRUE.
I THINK AS I SHARED WITH THE
PREVIOUS INDIVIDUAL, DR., I'M
SORRY, DR. WAHLS, I'M SORRY,
THAT WHAT WE NEEDED THIS COUNTRY
ARE SOME HONEST CONVERSATIONS.
I DON'T WANT TO MAKE PEOPLE
UNCOMFORTABLE TALKING RACISM
BECAUSE FIRST THING PEOPLE DO IS
SAY I'M NOT A RACIST.
I'M NOT CALLING ANYBODY RACIST.
WHAT I'M SAYING IS WE HAVE
SYSTEMS IN PLACE THAT HAVE BEEN
BORN OUT OF NON-OBJECTIVE
PERSPECTIVES BY PEOPLE IN THE
PAST AND IT IS TIME FOR THEM TO
BE DISMANTLED.
SO WHILE THERE ARE LOT OF PEOPLE
WHO ARE MY FRIENDS, COLLEAGUES
WHO DON'T LOOK LIKE ME, THEY ARE
CLOSE CONFIDENTS OF MINE, POINT
IS IF WE TAKE TIME TO HAVE
HONEST COFFERSES WE CAN GET PAST
THIS.
WE GOT TO HAVE THE
CONVERSATIONS.
I JUST SAW THAT DR. LANDER
RESIGNED AS THE CHIEF POLICY
OFFICER SCIENTIFIC POLICY
OFFICER FOR THE PRESIDENT.
WHY?
BECAUSE OF BEHAVIORS
UNACCEPTABLE.
THEY SHOULD BE UNACCEPTABLE
WHETHER HIGH SCHOOL MIDDLE
SCHOOL, PRESIDENT'S TEAM,
WHATEVER BUT WE HAVE TO BE
HONEST, WE CAN'T KEEP SAYING ONE
THING AND DOING ANOTHER.
IT DRIVES ME CRAZY.
SO WHAT I'M SAYING TO ALL OF YOU
IS LET'S HAVE SOME HONEST
CONVERSATIONS, SOME WILL BE
UNCOMFORTABLE BUT WILL MAKE A
BETTER SCIENCE, BETTER
COMMUNITIES, BETTER NATION IF WE
JUST HAVE THOSE HONEST
CONVERSATIONS THAT'S MY MAIN
MESSAGE TODAY AND I HOPE WE CAN
ALL AGREE THAT THAT MIGHT BE A
GOOD THING.
>> VERY GOOD THING.
ONE MORE QUESTION BECAUSE DR.
LAKSHMI IS RACING HERE.
THIS IS GOING TO BE QUICK.
WITHIN YOUR 60 YEARS OF
OPPRESSION YOU POINTED OUT
MISTRUST IN MEDICINE AND MELCAL
RESEARCH AS ONE OF THE ISSUE,
THAT CAME INTO FOCUS DURING THE
VACCINATION.
SO THE QUESTION IS WHAT CAN WE
DO AS A ACADEMIC INSTITUTION AND
FROM NATIONAL INSTITUTE, WHAT
CAN WE DO TO ADDRESS THIS.
>> WHAT I DID IN MY NUMEROUS
TOWN HALLS AND PRESENTATIONS WAS
TO POINT OUT THAT IN THIS CASE
THINGS WERE DIFFERENT.
WE HAD YOUNG BLACK SCIENTISTS AT
NIH, DR. CORBETT WHO WAS KEY IN
DEVELOPING THE VACCINE, WE HAVE
PEOPLE WHO ARE MEMBERS OF THE
DATA SCIENCE MONITORING BOARDS,
DSMB, WHATEVER THEY ARE CALLED
AND THEN YOU HAD ME AND MY
COLLEAGUE SITTING ON THE FDA
REVIEW PANEL.
WE HAVE TO POINT OUT TO PEOPLE
AND BE HONEST, BE ABLE TO BACK
THIS UP, THAT SCIENCE TODAY
LOOKS VERY DIFFERENT THAN WHAT
IT LOOKED LIKE IN THE TIMES THAT
THE MISTRUST WAS ENGENDERED.
THAT REQUIRES WORK.
IT IS NOT GOING TO BE EASY,
GOING TO REQUIRE WORK.
THAT IS WHY I THINK WE HAVE TO
IDENTIFY TRUSTED MESSENGERS, AND
HAVE THEM HAVE CONVERSATIONS
WITH COMMUNITIES WE ARE TRYING
TO ENGAGE.
AND WE CAN BE VERY SUCCESSFUL.
WHAT DOES THAT MEAN?
THERE NEEDS TO BE MORE
MESSENGERS PART OF THESE
ORGANIZATIONS.
THAT IS WHAT NORA IS TRYING TO
ACHIEVE IN NIDA, WHAT NIH IS
TRYING TO ACHIEVE AND DURING ALL
THAT WE CAN MAKE A DIFFERENCE.
BY PLEA TO EVERYONE AND I HAVE
CHANCE TO SPEAK TO, TIME FOR
HONEST UNCOMFORTABLE
CONVERSATIONS.
LET ME FOLLOW BY SAYING THAT,
I'M OVER TIME NOR RAY BUT
WOULDN'T MORE THING TO POINT
OUT.
SOME OF THE POLITICIANS ARE DE
DECRYING CRITICAL RACE THEORY
BECAUSE IT WILL MAKE WHITE
CHILDREN UNCOMFORTABLE.
WHAT ABOUT THEIR ACTUAL
SUFFERING OF BLACK AND BROWN
KIDS FOR 400 YEARS, WHAT ABOUT
THAT?
I'M GOING TO GET INTO MY
EMOTIONS HERE SO I'M GOING TO
LEAVE THAT ALONE CONVERSATIONS
DON'T DEAL WITH THAT SO LET'S
HAVE CONVERSATIONS.
LET'S DO THAT.
>> DR. HILDRETH, DON'T EVER
APOLOGIZE FOR YOUR EMOTION, I
THIS HI THE EMOTIONS CONVEYS THE
EMERGENCY OF WHAT WE ARE TRYING
TO DEAL WITH.
IT IS INSPIRATIONAL TO HEAR YOU
AND TO SEE CLARITY OF PROCESSES
WE CAN TACKLE IN ORDER TO CHANGE
IT.
I LIKE YOU BELIEVE IT CAN BE
CHANGED.
BUT I LIKE YOU ALSO BELIEVE THIS
REQUIRES VERY PROACTIVE
ENGAGEMENT AND NOT LETTING GO.
>> YES.
>> THANKS VERY MUCH.
>> THANK YOU, NORA.
THANKS, EVERYONE.
HAVE A GREAT DAY.
>> THANK YOU.
>> NOW AFTER THAT WONDERFUL
PRESENTATION WE ARE GOING TO GO
INTO THE NEXT ITEM INTO GOING TO
BE GIVEN BY OUR OWN DR. ALBERT
AVILA, WHO IS PRESENTING ON THE
BUILDING AND SUSTAINABILITY OF
DIVERSITY PROGRAMS ACROSS THE
SCIENTIFIC CAROLINA CONTINUUM.
ALBERT, PLEASE JUMP RIGHT IN.
>> GREAT.
CAN YOU HEAR ME?
>> YES.
>> THANK YOU SO MUCH.
IT IS MY PLEASURE TO PROVIDE
UPDATE TO EVERYBODY HERE ON
COUNCIL AND NIDA BUILDING AND
SUSTAINING DIVERSITY WORK FORCE
PROGRESS ACROSS THE SCIENTIFIC
CARE CONTINUUM, WHAT NIDA IS
DOING IN OFFICE OF HEALTH
DISPARITIES IN THIS SPACE AND WE
LOOK FORWARD TO FEEDBACK TO HELP
GUIDE US ON -- IN OUR WORK IN
THIS SPACE, IT IS AN HONOR TO
FOLLOW DR. HILDRETH, NOT SURE IF
HE IS STILL ON THE CALL.
SEVEN YEARS AGO ALMOST TO THIS
DAY, SEVEN YEARS FIVE DAYS AGO,
NIDA COUNCIL SUBCOMMITTEE WORK
GROUP ON DIVERSITY WHICH DR.
HILDRETH CHAIRED AND DR. WAHL IS
ON COUNCIL NOW SERVED ON,
PROVIDED A REPORT TO DR. VOLKOW,
THEIR CHARGE WAS TO PROVIDE
CONCRETE RECOMMENDATIONS TO THE
NIDA DRUG STRATEGIES TO INCREASE
NUMBER OF UNDER-REPRESENTED
MINORITIES CONDUCTING DRUG ABUSE
RESEARCH AND TWO INCREASE NUMBER
OF GRANT APPLICATIONS SUBMIT AND
FUBBED IT FROM UNDERSTOOD
REPRESENTED MINORITY
INVESTIGATORS.
THE RECOMMENDATION, THESE NEXT
TWO SLIDES ARE TAKEN FROM THAT
PRESENTATION SEVEN YEARS AGO.
AND A LOT OF WORK HAS BEEN BUILT
OFF THESE RECOMMENDATIONS YOU
WILL SEE INCREASE FUNDING TO
DIVERSITY SUPPLEMENT PROGRAM AND
STRENGTHEN THOSE PROGRAM
PRACTICES.
FIND MINIMUM OF FIVE K-99 AWARDS
TO UNDER-REPRESENTED VIATORSND
ENSURE T 32 PROGRAMS ARE USING
SLOTS FOR DIVERSITY, SCHOLARS
AND SUPPLEMENT THOSE THAT ARE
DOING A GREAT JOB.
INITIATE AND COORDINATE A
COLLABORATIVE TRAINING NETWORK.
WITH MULTIPLE LOCATIONS, IN
SUBSTANCE USE AND ADDICTION
RESEARCH.
INCREASE FUNDING TO TRAVEL AND
NETWORK SCIENTIFIC CONFERENCES,
AND ENSURE THAT CONFERENCE
GRANTS R 13s INCLUDE
MINORITIES ON PANEL SPEAKERS IN
REGARDS TO SECOND CHARGE TO
INCREASE APPLICATION FROM
UNDER-REPRESENTED GROUPS
DEMYSTIFY NIH AND NIDA GRANT
PROCESS, CREATE MENTORING
PROGRAMS INCREASE SCIENTIFIC
PERSONNEL WHEN THE ODHD,
IMPLICIT BIAS TRAINING FOR
REVIEW MEMBERS.
FOA ON COMMUNITY BASED
PARTICIPATORY RESEARCH AND AREAS
RELEVANT TO UNDERSERVED
COMMUNITIES AND PROVIDE RACEET RACE
MR. ETHERIDGE: NICITY DATA TO
NIH TO MAKE ACCESSIBLE TO THE
PUBLIC.
WE TOOK THAT AND STARTED TO
WORK.
WE ALSO LOOKED IN THE LITERATURE
AND WE ARE STILL CURRENTLY
LOOKING IN THE LITERATURE.
WILL THERE'S LOT OF OPINION
PIECES COMMENTS PAPERS ON THE
NEED TO INCREASE DIVERSITY WIFE
HEARD IT HERE TODAY AND WILL
STILL HEAR BUT PAPERS ARE COMING
OUT HOW CULTURAL DIVERSITY
INCREASING GENDER DIVERSITY,
REALLY DRIVES INNOVATION.
AND DISCOVERY.
SO WE USING THIS TO ALSO HELP
INFORM OUR ACTION AND OUR
PROGRAMS.
NOW LET'S LOOK AT THE SCIENTIFIC
WORK FORCE DATA BECAUSE HA IS
THE OTHER PIECE WE ARE TAKING
INTO CONSIDERATION AND FIRST
LET'S START AT THE Ph.D.
LEVEL.
THESE ARE Ph.D. RECIPIENTS,
FUNDED OFF THE NIH, THIS IS NIH
WIDE DATA.
TRAINING AND FELLOWSHIP AWARDS.
THAT'S COMPARING 2000 TO 2017.
THOSE ON TRAINING MECHANISMS.
IN 2000 AFRICAN AMERICANS
CONSISTED OF 5.3% OF TRAININGS
FUNDED ON THOSE MECHANISMS.
IN 2017 EVEN THOUGH THEIR N WENT
UP DOUBLED IT IS NOW 4% OF THE
PORTFOLIO AND EVERY RACE AND
ETHNICITY LISTED HERE WENT DOWN
ACCEPT THE WHITE TRAINEES IN THE
Ph.D. PROGRAMS.
MOVING TO THE OTHER END OF THE
SPECTRUM, LOOK AT PI RESEARCH
PROJECT GRANTS ACROSS THE NIH.
AGAIN IN 2010, HISPANICS
CONSTITUTESSED 4% OF THOSE PI
ACROSS THE NIH WITH RESEARCH
PROJECT GRANTS.
AND IN 2020 IT'S 4%.
BLACKS, MADE UP 1.7% AND 1.8 --
.8% GAIN OVER THE DECADE.
AND AGAIN, THE Ns WENT UP A
LITTLE BIT BUT OVERALL PERCENT
OF THE PORTFOLIO REMAINEDDED THE
SAME.
DESPITE OUR EFFORTS IN DIZZINESS
WE PUT INTO THIS WORK DAY OF DAY
IT IS STILL SHOWS EVEN IF NOT
INCREASES.
BRING CLOSER HOME TO NIDA.
AND THIS DATA SHOWS NEW NIDA
GRANTEES BY RACE ETHNICITY
BROKEN DOWN BY MECHANISM, RO1,
BY NATURE ARE NEW INVESTIGATORS
BUT INCLUDED ON THIS SLIDE TO
GIVE A PERSPECTIVE AND TALK
ABOUT THE FELLOWSHIPS K AWARDS
BUT SO THE RO1 MECHANISM, NEW
INVESTIGATORS, BLACK OR AFRICAN
AMERICAN NEW INVESTIGATORS
CONSTITUTE 3.5% OF OUR RO1
AWARDEES IN 2020.
AGAIN, NEW INVESTIGATORS, SO
THEY HAVE NOT COMPETITIVELY
RECEIVED RO1 OR RPG 3.5%.
WHITE 77.8%, HISPANIC 3.9% YOU
CAN SEE WHAT THE OTHER RACE
ETHNICITIES ARE.
BUT MORE ALARMING TO ME, ARE
FELLOWSHIP AND K AWARDS.
THIS IS THE COHORT THAT WILL BE
APPLIED TO Rs THE NEXT TWO TO
FIVE YEARS DEPENDING WHERE NAY
ARE IN THE CAREER STAGE.
YOU CAN SEE WHAT THOSE
PERCENTAGES ARE, 3.4% OF KNOLL
SHIPS, THESE ARE PRE-DOC POST
DOC EARLY AWARDS.
AND THE K AWARDS, K99, 01, K 23.
AGAIN VERY LOW PERCENTAGES IN
THESE OTHER MECHANISMS.
NOW I WANT TO WALK YOU THROUGH
SOME DATA ANALYSIS THAT WE ARE
DOING AT THE RPG LEVEL ACROSS
ALL GRANTEES.
WHAT I'M SHOWING YOU NOW, THIS
IS NO LONGER NEW INVESTIGATORS,
THESE ARE GRANTEES THAT SUBMIT
AD GRANT IN 2020.
THE FIRST RIVER PLOT ARE THOSE
FROM APPLICATIONS FROM BLACK
APPLICANTS, AND THIS OTHER ONE
BOTTOM ONE IS FROM WHITE
APPLICANTS.
I WILL WALK THROUGH THE TOP
RIVER PLOT TO SHOW YOU HOW
ANALYSIS UNFOLDED.
IN 2020 WE RECEIVED 84
APPLICATIONS, FROM BLACK
APPLICANTS, 84 APPLICATION, 2.6%
WHAT WE RECEIVED THAT YEAR.
OF THOSE, ABOUT HALF, 43 WERE
DISCUSSED, 15% RECEIVED PRIORITY
SCORE LOWER THAN 30, BETTER THAN
30 AND 13 OF THOSE WERE AWARDED.
HOWEVER THOSE APPLICATIONS THAT
RECEIVED A SCORE 30 OR HIGHER,
28 OF THEM, FIVE WERE AWARDED
FOR A TOTAL OF 18 IN FUNDING
RATES OF 21.4%.
WE WENT THROUGH THE SAME
ANALYSIS FOR WHITE APPLICANTS
AND OTHER RACES AND ETHNICITIES
YOU CAN SEE THE FUNDING RATE FOR
BLACK APPLICANTS AND WHITE IS
ABOUT THE SAME, WITH BLACK
APPLICANTS SLIGHTLY HIGHER.
SO THIS PROVIDES MORE CONCRETE
DATA NOW THAT SHOWS WE NEED TO
WORK ON INCREASING NUMBER OF
APPLICATIONS, FUNDING RATE IS
STILL HOLDING STRONG OR
COMPARABLE.
SO ONE THING WE WANT TO ADDRESS
IS BRINGING MORE APPLICATIONS
INTO OUR PULL.
JUST TO SHOW YOU HISPANIC VERSUS
NON-HISPANIC DATA FOLLOWING THE
SAME FORMULAS TO WALK LIEU THE
RIVER PLOT.
FUNDING RATE HISPANIC VERSUS
NON-HISPANIC IS ABOUT THE SAME.
WE TOOK THOSE APPLICATIONS, NORA
ASKED US TO LOOK AT WHAT AREAS
OF RESEARCH THOSE 84
APPLICATIONS CAME INTO WHEN
SUBMITTED TO NIDA.
ANECDOTALLY WE HAVE SAID THIS
AND I HEARD IT YESTERDAY
MORNING, THAT MINORITIES SUBMIT
APPLICATIONS TO HEALTH
DISPARITIES RESEARCH.
WE DIDN'T HAVE THE DATA TO BACK
THAT UP.
SO WHEN WE LOOK AT 2020, THE 84
RPG APPLICATIONS WE RECEIVED, WE
SAW 54% OF THOSE FROM AFRICAN
AMERICAN APPLICANTS WERE
SUBMITTED TO DESPR AND THE OTHER
BENEFIT TO DMTD SO BASIC SCIENCE
RELATED VERGE WE THOUGHT THIS
WAS GOING TO BE -- WOULD BE
LARGER.
SO I THINK WHAT YOU CAN SEE WITH
THE OTHER POPULATIONS, ORANGE
BARS GET REREVERSE SOD WE
GROUPED THE OTHER POPULATIONS
TOGETHER AND IT IS 30% VERSUS
55% DSPR VERSUS DMB.
SO WE ARE USING THIS AND LOOKING
DEEPER TO UNDERSTAND BUT ALSO
POINTS OUT EVERYONE IS AN
INDIVIDUAL AND WE WANT TO JUST
BE CAREFUL NOT TO LUMP
MINORITIES INTO HEALTH
DISPARITIES RESEARCH, AS THE
DATA SHOWS IT IS ALMOST 5050.
WE ALSO INTERESTED IN
INSTITUTIONS AND BUILDING
PARTNERSHIPS WITHIN INSTITUTIONS
SPECIFICALLY MSI, AND HBCUs.
SO THIS DATA SHOWS 11 YEARS
APPLICATIONS FROM NIDA TO
HISTORICALLY BLACK COLLEGES AND
UNIVERSITY CONSISTND OVER 11
YEARS 20 SUBMITTED ONE GRANT TO
NIDA.
YOU CAN SEE MEHARRY AND HOWARD
ARE TWO MAJORITY -- TWO
INSTITUTIONS SUBMITTING THE VAST
MAJORITY OF THE APPLICATIONS AND
OVER 11 YEARS, 106 APPLICATION
SUBMITTED AND 11 FUNDED.
SO WE WANT TO WORK TO BUILD
INCREASE APPLICATION POOL AND
PROMOTE HBCU SUBMIT MORE
APPLICATION TO NIDA AND WORK
WITH THEM IDENTIFYING THE
APPROPRIATE MECHANISMS FOR THEIR
SUCCESS.
SO TAKEN TOGETHER ALL THIS WORK
IS REALLY DRIVING OUR STRATEGIC
APPROACH TO ENHANCING DIVERSITY
IN ADDICTION WORKS FOR.
WE ARE REALLY TRYING TO BE
INTENTIONAL WITH THIS WORK.
SO WE HAVE TOO MANY DRIVING
FACTOR, ENHANCING THE NUMBER AND
INCLUSION OF FUNDED
INDIVIDUALINGS FROM DIVERSE
BACKGROUNDS.
PROVIDING ACCESS, SUPPORT AND
OPPORTUNITIES FOR SCIENTISTS
FROM DIVERSE BACKGROUNDS TO DO
MEANINGFUL CONTRIBUTE SOUSE SANS
ABUSE AND RESEARCH AND
SCIENTIFIC ENTERPRISE SO I WILL
FOCUS ON WHAT WE ARE DOING AT
THE INDIVIDUAL LEVEL AND TOUCH A
LITTLE BIT ON THE INSTITUTION,
AND KNOW WE ARE STILL TRYING TO
BUILD THE SCIENTIST STAKEHOLDER
AND WHAT THAT LOOKS LIKE BUT
WALK YOU THROUGH WHAT WE ARE
DOING SO FAR.
THE MISSION REMAINS THE SAME
FROM 2015, TO STRENGTHEN THE
NIDA EXTRAMURAL SCIENTIFIC
PORTFOLIO THROUGH MORE DIVERSE
ROBUST EXTRAMURAL RESEARCH WORK
FORCE.
SO NOW I WILL WALK YOU THROUGH
MY MODEL CAREER DEVELOPMENT
LADDER AND TALK ABOUT PROGRAMS
WITHIN THIS LADDER AT THE
DIFFERENT CAREER STAGES AND AT
NIH WE REALLY HAVE OPPORTUNITIES
STARTING MAINLY AT THE HIGH
SCHOOL AND UNDERGRADUATE LEVEL.
WITHIN OUR OFFICE OF DIVERSITY
WE HAVE THE NIDA SUMMER RESEARCH
CANCERSHIP PROGRAM I WILL SHARE
WITH YOU IN A MINUTE.
MENTORSHIP.
WE HAVE THE DIVERSITY R 25, A
RESEARCH TRAINING PROGRAM, AND
THAT SUPPORTS CAREER STAGES FROM
UNDERGRAD THROUGH EARLY STAGE
INVESTIGATOR.
WE HAVE A SUMMER R 25 PROGRAM
FOR HIGH SCHOOL STUDENTS AND
TEACHERS AND UNDERGRADS FOR
SUMMER EXPERIENCES.
WE ALSO PARTICIPATE IN THE BLUE
PRINT UNDERGRADUATE PROGRAM AND
WE PARTICIPATE IN THE CEPA
AWARD.
SCIENCE EDUCATION PARTNERSHIPS
WHICH RK-12 AND WE CO-FUNDED ONE
WITH NIGMS. THE NIDA RESEARCH
PROGRAM IS A GEM HERE AT NIDA.
THIS IS A PAID EIGHT WEEK SUMMER
INTERNSHIP IN SUBSTANCE USE AND
ADDICTION RESEARCH TO ENHANCE
PARTICIPATION OF
UNDERREPRESENTED UNDERGRAD
STUDENTS CONDUCTING SUBSTANCE
USE AND ADDICTION RESEARCH.
ALL UNDERGRADS ELIGIBLE TO APPLY
AND AWARDS ARE MADE TO ALL RACES
AND ETHNICITIES.
IT WORKED WITH EXPERIENCED PIs
WITH HANDS ON RESEARCH AND HOST
OF OTHER RESEARCH AND
PROFESSIONAL DEVELOPMENT
ACTIVITIES.
AND IN 2021, THERE WERE TWO NEW
PROGRAM ENHANCEMENTS ADDED,
SUMMER SEMINAR SERIES WHERE WE
TALK DIFFERENT AREAS OF RESEARCH
IN NIDA AND WE HAVE A SESSION ON
GRADUATE SCHOOL AND USING A
RECORDER TO IDENTIFY TRAINING
PROGRAMS AND WE HAVE A PANEL OF
PAST SUMMER RECIPIENTS, WHAT
THEY HAVE GONE ON TO DO AND
PIs.
I DO WANT TO SAY THAT IN BOTTOM
OF SYSTEM OF MY SLIDES I HAVE
CONTRIBUTIONS BY AND IT TAKES A
WHOLE TEAM TO DO THESE, SO FOR
EXAMPLE THIS PROGRAM IS
COORDINATED BY JULIE AND I BUT
WE HAVE A HOST OF PEOPLE ACROSS
NIDA INCLUDING 50 NIDA REVIEWERS
THAT RECEIVE APPLICATION AND
HELP EVALUATE THEM.
IN 2022, THIS CURRENT YEAR WE
HAVE 182 PIs SET UP REGISTERED
TO HOST THE STUDENT ON
REGISTRATION GUIDE, 103 VIRTUAL
OR HYBRID.
WHEN I MADE THESE SLIDES WE HAD
A LITTLE BIT LESS THAN 200 AND
NOW AT 220 APPLICATION JUST FROM
OVER NIGHT.
AND THE DEADLINE IS COMING UP AT
THIS POINT.
WE USED A HUB AND SPOKE MODEL
FOR THIS PROGRAM, NIDA IS THE
HUB AND WE CONCENTRATE ON WE
HAVE PRETTY MUCH THE PROGRAM
LOGISTICS OUTREACH APPLICATION,
THE PUNNING SUPPORT AND SOME
OTHER ASPECTS.
AND WE RELY ON RESEARCH TO
PROVIDE RESEARCH TRAINING
PROFESSIONAL DEVELOPMENT,
MENTORING AND THINGS LIKE THAT,
REALLY THROUGH THIS COOPERATIVE
PROGRAM, COOPERATIVE AGREEMENT
SO TO SPEAK WE HONED IN ON
REALLY STRONG PROGRAM AND
HOPEFULLY WE WROTE A PAPER ON
THIS AND HOPEFULLY OUT IN THREE
WEEKS, OTHER AGENCY USE AS A
MODEL.
IN 2021 WE RECEIVED 493
APPLICATIONS AND MADE 53 AWARDS
FOR 17% SUCCESS RATE.
YOU CAN SEE THE BREAK DOWN IN
RACE ETHNICITY CATEGORIES FROM
LAST YEAR.
OUR INTERN MENTOR FEEDBACK FOR
THIS PROGRAM IS REALLY STRONG.
JUST AS WE ASK QUESTIONS HOW DID
PARTICIPATING IN SUMMER RESEARCH
PROGRAM AFFECT YOUR INTEREST IN
SCIENCE CAREER IN OVER 90% SAID
INCREASE SOMEWHAT OR ALLOT AFTER
PLEADING THE INTERNSHIP, WE
ASKED HOW IT AFFECTED THE
INSTITUTION Ph.D. OVER 75%
SAID INCREASE SOMEWHAT OR A LOT.
WE ASKED THE MENTORS FROM THE
LAST THREE YEARS, AFTER
INTERNSHIP YOUR STUDENT INTERN
HOW DO YOU CONTINUE ANY
PARTNERSHIP OR ANYTHING BEYOND
THAT?
AND THE GREEN SHOWS THAT 15% ARE
-- HAVE WRITTEN OR WRITING A
PAPER AFTER INTERNSHIP SO NOW
SUMMER INTERNS ARE PUBLISHED.
OTHERS ARE HIRING, AND THEN THE
OTHER THE TEAL BLUE BAR AT THE
END SHOWS THAT OVER 30% ARE
STILL SOME TYPE OF
COMMUNICATION, EITHER HIRING
THEM BACK AS TECHS OR RECRUITING
TO THEIR SCHOOL TO DO GRADUATE
STUDIES.
SO NOW MOVING UP THE NEXT CAREER
WRUNG ON THE CAREER LADDER IS
THE PRE-DOC.
AND PROGRAM SUPPORTED BY NIDA
THAT WE EITHER MANAGE OR THAT WE
PARTICIPATE IN ARE DIVERSITY
SUPPLEMENT PROGRAM I HIGHLIGHT
IN A MINUTE, THE F 99 K 00
DIVERSITY D SPAN AWARD, PRE-DOC
TO POST DOC TRANSITION AWARD
LIKE THE K99 R 00, BUT FOR THE
PRE-DOC POST DOC STAGE.
DIVERSITY F 31, DIVERSITY R 25
AND THE DIVERSITY TRAVEL AWARD
WHICH IS A RECOMMENDATION BY THE
SUBCOMMITTEE TO COUNCIL SEVEN
YEARS AGO.
AND WE HAVE A SUPPLEMENT
WORKSHOP THAT I WILL SHARE IN A
MINUTE.
HOWEVER, BEFORE I DO, I WANT TO
GO TO THE POST DOC CAREER STAGE
AND TALK ABOUT SOME OF THE
PROGRAMS THAT WE HAVE THERE
BECAUSE THERE IS A LOT OF --
THERE'S SOME OVERLAP.
THE POST DOC STAGE, BEFORE I DO
YOU WILL SEE THAT THAT WRUNG IS
SLIGHTLY -- IS SLIGHTLY SLANTED.
YOU WILL ALSO SEE THAT THE
DISTANCE, THE STEP UP IF YOU
WILL FROM PRE-DOC TO POST DOC IS
BIGGER AND THAT IS INTENTIONAL.
WHAT I'M SEEING IS THAT THIS IS
A BIG -- ONE OF THE BIG LEEPS
AND THAT POST DOC CAREER STAGE
FROM WHEN I READ AND TALK TO
PEOPLE INDIVIDUALLY, PERSONALLY,
THIS IS THE CAREER STAGE
BECOMING MORE CRITICAL TO ME.
AND I HEAR WHERE WE NEED TO PUT
SOME THOUGHT.
SO I'M INTERESTED TO HEAR
FEEDBACK FROM COUNCIL WHAT WE
CAN DO AT THIS CAREER STAGE.
SO WE HAVE DIVERSITY SUPPLEMENT,
PARTICIPATE IN THE MOSAIC R 99 K
00 LIKE THE REGULAR FOR DIVERSE
INDIVIDUALS OR INDIVIDUAL STUDY
HEALTH DISPARITIES RESEARCH.
WE HAVE -- PARTICIPATE IN A
BRAIN F 32 AS WELL AS REGULAR F
32.
THE F 32, REGULAR STILL REMAINS
PRIMARY MECHANISM THAT WE USE
FOR EARLY ENTRY POST DOCS.
WE HAVE DIVERSITY R 25, WE HAVE
THE NIDA DIVERSITY SCHOLARSHIPLY
TALK IN A SECOND.
AGAIN TRAVEL AWARDS FOR POST
DOCS TO GO NETWORK AND HOPE WE
CAN DO THESE AGAIN STARTING THIS
YEAR TO CONFERENCES SCIENTIFIC
CONFERENCES.
WE ALSO USE THE NIDA LOWER PINK
PROGRAM AS AN INCENTIVE TO KEEP
PEOPLE IN THE RESEARCH.
ENTERPRISE.
SO I WANT TO SHARE WITH YOU THE
DIVERSITY SUPPLEMENT PROGRAM AND
I KNOW THERE WAS A QUESTION
EARLIER ON IT SO HOPEFULLY WE
CAN CIRCLE BACK TO THAT
QUESTION.
BUT TO BRING YOU UP TO SPEED,
MOST FOLKS KNOW THE GOAL OF THE
PROGRAM IS CONGRESSIONALLY
MANDATED PROGRAM TO ENHANCE
DIVERSITY OF THE ADDITIONAL
RESEARCH WORK FORCE RECRUITING
AN RETAINING POST BACKS PRE-AND
POST DOCS AND EARLY STAGE
INVESTIGATORS SO THIS IS WHAT
NIDA USES IT FOR.
WE OFFER TWO TO THREE YEARS OF
FUNDING.
DEPENDING ON THE CAREER STAGE.
AND WE HAVE EMPHASIZE
INDEPENDENT GRANT FUNDING.
ALSO OFFER FOLLOW-UP SUPPORT
THROUGH WORKSHOP.
YOU CAN SEE THE MAJORITY OF THE
SCHOLARS WITHIN OUR DIVERSITY
SUPPLEMENT PROGRAM FROM THE LAST
SIX YEARS ARE HISPANIC AND BLACK
AFRICAN AMERICAN BUT WE MAKE
AWARDS TO EVERYBODY TO ALL RACES
AN ETHNICITY AND WE TRY HARD TO
RECRUIT ACROSS ALL POPULATIONS.
IN REGARDS TO OUR DATA ANALYSIS
FOR THIS PROGRAM, AND WE -- ONE
OF THE THINGS WE LOOK AT IS
SUBSEQUENT NIH GRANT ACTIVITY
AFTER THEY RECEIVE THE
SUPPLEMENT.
SO I'M GOING TO WALK YOU THROUGH
COUPLE OF COHORT.
2013, 28 SUPPLEMENTS THAT YEAR.
OF THOSE 17 APPLIED FOR A GRANT,
WELL OVER 50%.
OF THOSE 17, 62 APPLICATIONS
SUBMITTED FROM THOSE 17 FOLKS.
OF THE 62, 12 FUNDED AND THEY
WENT TO EIGHT DIFFERENT
INDIVIDUALS.
SO OUT OF 17, HALF WERE FUNDED.
IN 2015, THERE WERE 29, 16
SUBMITTED A GRANT, SO FAR SIX
FUNDED.
SO THE CONCLUSION IS
APPLICATIONS SUBMISSION RATE IS
ABOUT 50% OF OUR SCHOLARS.
KEEP IN MIND SOME OF THESE
SCHOLARS WERE UNDERGRADS,
DIVERSITY SUPPLEMENT AND IT HAS
A VERY DIFFERENT CONTEXT THAN
SOMEONE WHO HAS POST DOC.
SO WE ARE NOT GOING TO REACH
100%.
BUT WE HAVE OVER 50% SUBMISSION
RATE AND THEN WITHIN THAT, WE
HAVE DEPENDING THE YEAR WE HAVE
A LITTLE BIT OVER 50%, AROUND
50% OR 40% SUCCESS RATED.
WE LIKE TO GET THAT OUT.
SO WHAT ARE NUMBERS IN TERMS OF
SUPPORT AND FUNDING NOW?
IN 2019 WE RECEIVED 27
APPLICATIONS WITH 19 AWARDS.
IN 2020 WE RECEIVED 35
APPLICATIONS AND MADE 32 AWARDS.
IN 2020 WE RAMPED UP OUR PROGRAM
OUTREACH.
WE RECEIVED 69 APPLICATIONS, NOT
INCLUDING THE NINE THAT WENT TO
THE NIH HEEL AND BRAIN PROGRAM
SO ADDITIONAL NINE NIDA RELATED,
GROUP WE PROVIDED DIRECT SUPPORT
TO PIs AND APPROXIMATE PRIA --
APPLICANTS IN TERMS OF
CONSULTATION.
IN TERMS OF THOSE REVIEWED,
THAT'S 69 FROM NOVEMBER TO JUNE
AND THESE GROUP OF PEOPLE DOWN
HERE, THE NIDA DIVERSITY
SUPPLEMENT COMMITTEE REALLY PUT
A LOT OF TIME AND EFFORT INTO
REVIEWING THESE APPLICATIONS.
BECAUSE OF THAT WE PROVIDE
EXCELLENT FEEDBACK SO THEY CAN
COME BACK ANOTHER TIME AND BE
SUCCESSFUL AT THE DIVERSITY
SUPPLEMENT.
ED FROM FROM THOSE 69, 34 FUNDED
IN ADDITION TO 31 CONTINUING
INCLUDING 65 SUPPORTED IN 2021
AT 5.3 MILLION.
I MENTION WE EMPHASIZE SUPPORT
OF THIS PROGRAM AMEND ONE
RECOMMENDATION WAS STRENGTHEN
THE DIVERSITY SUPPLEMENT PROGRAM
SO WE WORKED ON THE PROFESSIONAL
DEVELOPMENT WORKSHOP AND IN 2021
WE DECIDED TO HOLD VIRTUALLY,
COUNSEL IN 2020.
SO WE COLLABORATED WITH NIAAA
AND NIMH PROVIDED 100 SCHOLARS
FROM POSTBACK TO EARLY STAGE
INVESTIGATOR CAREER STAGE DR.
VOLKOW CUBE AND GORDON
PRESENTED.
FRIEND WE USED GATHER TOWN, FOR
OUR SCIENTIFIC POSTER SESSION
AND FOR OUR REALLY POPULAR MEET
APPEAL SMALL BREAK OUT SESSION.
WE HAD TALKS ON FUNDING
OPPORTUNITIES, APPLICATION
REVIEW STRATEGIES, REALLY WHAT
THE COUNCIL RECOMMENDED IN TERMS
OF DEMYSTIFYING THE GRANT
PROCESS.
YOU CAN SEE WE HAVE A PICTURE OF
WHAT ONE SLIDE OF EVERYONE
GATHERED.
WE HAD 140 PEOPLE THERE.
T THE PICTURE ON THE BOTTOM IS
WHAT IT USED TO BE LIKE WHEN WE
HAVE IT IN PERSON AND I'M
EXCITED TO SAYNA IN 2022 THIS IS
AN NIH WIDE WORKSHOP OTHER
INSTITUTES WHERE WE HAVE 12
INSTITUTES JOINING ARE REALLY
EXCITED TO JOIN IN ON THIS
PROFESSIONAL DEVELOPMENT
WORKSHOP FOR DIVERSITY
SUPPLEMENT RECIPIENTS. SO WE
TRYING TO FIGURE HOW TO MANAGE
THE LARGE NUMBER OF PEOPLE
PARTICIPATING.
I WANT DO INVESTIGATOR SPOTLIGHT
OF DR. SABRINA, A 2015
SUPPLEMENT SCHOLAR.
SHE USED THAT SUPPLEMENT TO
APPLY FOR A NIDA K 23, AND LOAN
REPAYMENT PROGRAM BOTH AWARDED.
LAST YEAR SHE WAS AWARDED THE
LOUIS SULLIVAN ENDOW
PROFESSORSHIP.
I HAVE PRIVILEGED TO BE INVITED
TO HER CEREMONY.
IN IT SHE SPECIFICALLY MENTIONED
HOW PIVOTAL THE SUPPLEMENT AND
SUPPORT SHE RECEIVED WAS IN HER
CAREER, TO BE SUCCESSFUL AND TO
SUSTAIN A RESEARCH CAREER.
SO NOW MOVING THE CAREER LADDER
WE ARE GOING TO THE EARLY STAGE
INVESTIGATORS LEVEL.
YOU CAN SEE DEPENDING WHERE YOU
ARE ON THAT WRUNG, YOUR STEP UP
IS GOING TO BE EITHER A LITTLE
SHORTER OR A LITTLE LONGER.
AND THERE ARE MANY FACTORS THAT
MAY CONTRIBUTE TO SOMEONING
WITHOR BEING ON THAT LOWER PART
OF THE WRUNG BUT MAKE SURE
SUPPORT IS IN PLACE TO MAKE THE
LEAP UP AND BE SUCCESSFUL AND
SUSTAIN RESEARCH ENTERPRISE SO
WE HAVE BEEN SCHOLARS NETWORK
PROGRAM, SUPPLEMENTS AGAIN R 25
INCLUDING THE CLINICAL, WE
PARTICIPATE IN THE R 15 AND THE
-- WE GIVE ASSISTANCE TO
GRANTEES IN ALL THESE AREAS.
WE HAVE A NETWORKING EVENT AND
AGAIN TRAVEL AWARDS IN THE
SUPPLEMENT.
I WANT TO HIGHLIGHT THE OTHER
NIDAS, NIDA SCHOLARS NETWORK
WHICH CAME -- BORN OUT OF THAT
SUBCOMMITTEE.
THIS IS A COMPETITIVE AIMED AT
FUNDING UNDER-REPRESENTED
PSIs.
POST DOCS RES CONDITION AND
EARLY STAGE INVESTIGATORS ARE
ELIGIBLE.
U IT IS A TWO PART PROGRAM.
DR. CHAVKIN IS A MENTOR AND
OTHERS HAVE BEEN INVOLVED WITH
THIS PROGRAM.
ONCE INTERN -- SCHOLAR IS
SELECTED, THEY GET MATCH WITH A
SCIENTIFIC COACH AND THIS
SOMEONE AN EXPERT IN THEIR AREA
OF RESEARCH, USUALLY NIDA
FUNDED, OR PREVIOUS NIDA FUNDED
PI.
THEY ALSO GET MATCH PROGRAM
OFFICER AND WE INVITE THEM TO
PART ONE GOING OVER A LOT OF
DEMYSTIFYING THE NIH GRANT
REVIEW -- AND GRANT AND REVIEW
PROCESS.
AND WE OFFER STRATEGIES.
THIS YEAR I BROUGHT IN MY
COLLEAGUE FROM CSR AND THEY TALK
ABOUT THE EARLY CAREER REVIEWER
PROGRAM AND HOW THE GET INVOLVED
WITH THAT.
SO THEY MEET WITH COACHING
ALLIANCE AND THERE IS AN INTERIM
PERIOD THEY ARRIVE WITH GRANT
USED FOR PART TWO, WHICH IS THE
MOCK REVIEW, THEY CONSULT BACK
WITH COACHES AND POs AND ME
AND OTHERS FOR ADVICE ALONG THE
WAY, USUALLY THREE AND A HALF
MONTHS.
THEN THEY SUBMIT THE MOCK GRANT,
ALL COMPONENTS MOVE TO MOCK
REVIEW AND THEY GET PARTICIPATE,
BASICALLY FLIES ON THE WALL,
COME BEHIND THE CURTAIN AND SEE
WHAT A GRANT REVIEW LOOKS AND
FELTS LIKE.
THEY GET TO HEAR THEIR REVIEW AS
WELL AS REVIEW OF THEIR ENTIRE
COHORT.
YOU CAN IMAGINE SOMETIMES IT
GETS A LITTLE BIT EMOTIONAL BUT
IT IS A GREAT EXPERIENCE FOR
EVERYBODY TO PARTICIPATE IN AND
REALLY TRANSFORMATIVE.
SO WHAT IS THE SUCCESS OF THIS
INTERVENTION PROGRAM?
IN 2016 WE HAVE 14 FOLKS
PARTICIPATE, SCHOLARS, 13 OF
THEM SUBMITTED A GRANT, THEY
HAVE BEEN VERY BUSY, SUBMITTED A
HUNDRED GRANTS.
17 OF THOSE HAVE BEEN FUNDED AND
THEY WENT TO 11 PEOPLE.
YOU CAN SEE JUST THE GREAT
SUCCESS SO FAR THAT THIS PROGRAM
IS HAD AT LEAST WITHIN APPLYING
FOR GRANTS.
THEY'RE STILL IN THE SYSTEM,
WORKING REAPPLYING, AND WE HAVE
ALMOST 100% APPLICATION
SUBMISSION RATE AND HIGH LEVEL
SUCCESS ACROSS THE PROGRAM.
IN ADDITION WE -- THIS YEAR IN
JANUARY WE HAD OUR FIRST REUNION
NETWORKING EVENT, SCHOLARS ARE
REACHING TO ME SAYING THEY
WANTED THE OTHER SCHOLARS, WANT
TO COLLABORATE WITH FOREIGN
PARTNERSHIPS SO WE PUT TOGETHER
THIS REUNION EVENT WHERE WE
FOSTER CLAY B RATION AND
PARTNERSHIPS TO FORM A NETWORK.
WE HAD BREAK OUT SESSIONS WHERE
THEY CAN TALK WITH OTHER FOLKS
WHO ARE INTERESTED IN PARTNERING
WITHIN A SPECIFIC SCIENTIFIC
AREA AND HOPE IT LEADS TO MORE
PARTNERSHIPS AND MORE
COLLABORATION IN THE FUTURE.
NOW THERE, IS A NETWORK SET UP
AND FOR ALL -- THEY ARE ALL
EMAILING EACH OTHER.
AS A MATTER OF FACT WILL IS AN
EMAIL YESTERDAY ON SUBMITTING
PUBLICATIONS.
SOMEONE EDITOR AND THEY ARE
ASKING FOR PUBLICATION FROM THIS
GROUP.
I WANT TO POINT OUT TWO COMMENTS
REAL QUICK.
FROM DR. JOHNSON, SAME AT THE
NDSN AND NIDA SUPPLEMENT PROGRAM
LIFELINE LITERALLY LIFELINE IS
ACADEMIA AND DR. ORTIZ HELP
GETTING MY R21 FUNDED AND THE
SUPPLEMENT NIDA DIVERSITY WERE
PIVOTAL FOR ME STAYING IN
ACADEMIA.
WE HEAR THIS TIME AND AGAIN.
HE RECEIVED A KO 1 WITH THE
ACTUAL APPLICATION THAT HE USED
FOR THE 2019 PROGRAM.
THEN A YEAR LATER YEAR AND A
HALF LATER SUBMITTED A NIDA R 25
SO NOW START TRAINING UNDERGRADS
IN SUBSTANCE USE AND ADDICTION
VERGE AND HE'S SPECIALLY
INTERESTED IN THOSE FROM
HISTORICALLY UNDER-REPRESENTED
ACADEMIA.
THE LAST CAREER LADDER, QUICKLY
GOING THROUGH, IS THE PROFESSOR.
I WILL HIGHLIGHT TWO THINGS.
NIDA IS PARTNERED WITH NIMHD AND
ISSUED NOTICE TO RESEARCH CENTER
AND MINORITY INSTITUTIONS RCMI
WITH A SUPPLEMENT.
AND THIS IS OUR SECOND
ITERATION, SO WE DID ONE IN
2021, THIS IS OUR 2022 NOTICE.
THESE PROVIDE $15,000 A YEAR FOR
UP TO TWO YEARS AND THE PURPOSE
IS TO SUPPORT NEW INVESTIGATORS
TO CONDUCT PILOT STUDY AND
COLLECT DATA TO BE USED FOR
INDEPENDENT GRANT.
THIS IS ONE WAY WE ARE TRYING TO
REACH INSTITUTIONS FROM MSIs
AND HBCUs.
FROM THE FIRST ITERATION WE
FUNDED 4 EARLY STAGE
INVESTIGATORS.
AT MSI INSTITUTIONS.
TO CONDUCT SUBSTANCE USE IN
NEUROSCIENCE RELATED RESEARCH.
THE APPLICATION FOR THAT LAST
WEEK -- DEADLINE LAST WEEK SO TO
SEE WHICH ONES WE GET IN.
THIS IS SOMETHING TO BRING TO
EVERYONE'S ATTENTION, THIS WAS
RELEASED LAST WEEK.
AND THERE WAS A QUESTION ON
SUPPLEMENTS AND SO THIS IS
SOMETHING THAT EVERYONE MIGHT BE
ABLE TO TAKE ADVANTAGE OF.
THE ADMINISTRATIVE SUPPLEMENTS
TO RECOGNIZE EXCELLENCE IN DEIA
MENTORSHIP.
THE SUPPLEMENT AWARD IS UP TO
$250,000 IN DIRECT COSTS, NOT TO
EXCEED (INAUDIBLE).
AND IT IS FACULTY MEMBERS WHO
ARE MENTORING OR -- AND/OR
MENTORSHIP AS PART OF EXISTING
AWARD OR DEMONSTRATED A
COMMITMENT AND DEMONSTRATED A
COMMITMENT TO OUTSTANDING MENTOR
SHIP OR TRAINING.
WHAT I THINK IS UNIQUE THAT I
WANT TO HIGHLIGHT IS ALMOST
EVERY MECHANISM IS ELIGIBLE FOR
THIS.
Rs Ps ARKSs Ks Ts, AND
ARE ALL ELIGIBLE.
THE ONLY THING NOT ARE THE Fs
AND A FEW Rs I THINK THE R 25
IS NOT ELIGIBLE.
SO I WILL STOP HERE AND JUST SAY
WHAT ARE THE NEXT STEPS?
WHAT ARE THE NEXT STEPS HERE IN
NIDA AND ODHD IN TERMS OF
SUPPORTING THE LADDER AND WHAT
CAN WE DO?
I'M LOOKING AT FEEDBACK FROM YOU
GUYS ON WHAT YOU THINK WE CAN DO
ESPECIALLY ATTENTION ON
POST-DOCTORAL CAREER STAGE.
HOW CAN WE GROW AND SUSTAIN
PARTNERSHIPS WITH HBCUs AND
OTHER MSIs.
WE ARE LOOK AT INVESTIGATOR
WADES TO PROMOTE DIVERSITY IN
THE APPLICATION POOL.
BOTH FOR NEW AND AT RISK
INVESTIGATOR GRANTS, THIS WILL
BE PRESENTED AT CONCEPT
CLEARANCE AND THEN ALSO
PARTNERING ON THE NEW EXCELLENCE
DEI INVESTIGATOR GRANTS OFFSET
WHAT CALLED THE DIVERSITY TAX,
UNITE INITIATIVE AND THIS WAS
RECENT WILL I CLEARED BY NI
MANYGMS COUNCIL AND NIDA IS ONE
OF THE FOUR INSTITUTES HELP TO
WRITE THIS FOA THEN EXPAND OUR
NETWORK.
NDSN SUPPORT AND OPPORTUNITIES
NETWORK.
SO WITH THAT, I WILL STOP AND
HOPEFULLY GET SOME FEEDBACK FROM
YOU GUYS.
THANK YOU.
>> THANKS VERY MUCH.
WE HAVE A QUESTION FROM DR.
RAJITA SINHA.
>> THAT WAS AMAZING.
IT WAS REALLY COMPREHENSIVE AND
HIGHLIGHTS NIDA'S COMMITMENT AND
ALL OF YOUR COMMITMENT TO REALLY
EXPANDING THIS AND -- IN A VERY
GENUINE AND CONCERTED WAY SO
CONGRATULATIONS ON THAT, THERE
IS ROOM OF COURSE TO GROW THIS
AS YOU ARE ILLUSTRATING.
I HAD A COUPLE OF THOUGHTS.
I THINK SUMMER RESEARCH
INTERNSHIP PROGRAM I REMEMBER
FROM SEVERAL MANY YEARS AGO THAT
IS REALLY GROWN, IT WAS LOVELY
TO SEE THE NUMBERS AND THAT YOU
HAVE EXPANDED NATIONALLY.
ONE THOUGHT I HAD, NIDA IS SO
GREAT WITH SUPPORTING T 32ESS.
AND THERE IS THIS DROP THAT
HAPPENS WITH THESE
UNDERGRADUATES AND THEN THEY
DON'T WANT TO DO Ph.D.s.
AND GRAD SCHOOL.
A LOT OF US WHO HAVE T 32s
HAVE POST BACK PROGRAMS JUST
LIKE THE IRP DOES AND I WONDERED
IF THERE COULD BE MORE
STRUCTURED CONNECTION WITH THE T
32s AROUND THE POST BACK AND
NIDA MAY NOT HAVE TO SUPPORT
THAT, IT COULD COME FROM GRANTS
PEOPLE HAVE OR MAYBE A MIX OF IT
ANYWAY, THAT'S A SEPARATE ISSUE
BUT SORT OF ADDITIONAL TIER OF
CONNECTING PEOPLE WHO ARE
GETTING OUT OF UNDERGRAD AND
THEN KEEPING THEM IN SCIENCE
THROUGH YOUR PROGRAMS THAT ARE
IN FACT DEVELOPED IN PEOPLE AT
THAT NEXT STAGE.
THERE IS THAT DROP BETWEEN
GRADUATING, DOING SUMMER
PROGRAMS, RESEARCH AT THE
UNDERGRAD LEVEL AND COMMITTING
TO THE Ph.D..
SO THAT WAS ONE THOUGHT I HAD.
THE SECOND THING HAD TO DO WITH
POST-DOCS.
I THINK THERE THE SAME ISSUE
AROUND IF THERE ARE WAYS FOR
HISTORICAL BLACK COLLEGES AND
SOME OF THE OTHER WHERE THERE IS
ALL OF US HAVE PIPELINE
INITIATIVE.
AT OUR INSTITUTION.
SO THERE'S WAYS TO CREATIVELY
THINK ABOUT CONNECTING DOING A
HUB AND SPOKE WHICH YOU HAD THAT
BEAUTIFUL DIAGRAM WHERE YOU
CONNECT INSTITUTIONS THAT TEND
TO HAVE LOWER NUMBERS AND
DESPERATELY TRYING TO ATRACK NEW
CANDIDATES TO CONNECT WITH
PLACES WHERE THERE IS ENERGY,
THERE ARE PEOPLE AND REALLY FOR
US TO COLLABORATE BY OFFERING
SHORT TERM PLACEMENTS
INTERNSHIPS OR LONGER TERM
COLLABORATING WITH FACULTY AT
HBCUs.
I'M THINKING MORE BROADLY, WE AT
OUR CTSA WE TRIED THIS WE ARE
DOING THIS WITH UNIVERSITY OF
PUERTO RICO, THE YALE CTSA IS
DOING IT.
WE STARTED TO HAVE SOME
DISCUSSIONS WITH HOWARD AS WELL.
SO I THINK WITH YOUR COMMITMENT
AND YOUR AMAZING NETWORK AND
STRUCTURES IN PLACE, THIS COULD
BE REALLY A WIN WIN IF YOU CAN
BUILD ON THAT.
>> MORE TO COME ON THAT AT
CONCEPT CLEARANCE.
AND THEN TO YOUR FIRST POINT, WE
WILL LOOK AT INVITING T 32s TO
THE SUMMER SEMINAR SERIES MAYBE
AS A WHICH TO BRIDGE PEOPLE.
MAYBE YOU CAN GIVE A SHORT TWO
MINUTE PRESENTATION ON YOUR
PROGRAM WHATEVER T 32 DIRECTION
YOU WANT TO COME AND THAT'S THE
WAY INTRODUCING BUT WE WILL WORK
ON THAT BECAUSE THAT IS OUR NEXT
STEP IS HOW WE CAN FORM
PARTNERSHIPS.
>> THANK YOU.
>> TO YOUR SECOND POINT THERE IS
ACTION ON THIS.
IT IS JUST HOW WE DO IT.
>> THANK YOU SO MUCH.
GAIL.
>>
>> GREAT.
THANK YOU VERY MUCH FOR THAT.
I APPRECIATE IT.
I JUST HAVE A COUPLE OF
COMMENTS.
ONE, IT IS MORE DIFFICULT FOR
PHYSICIAN EARLY PHYSICIAN
SCIENTISTS TO WORK AS YOU CAN
SEE THAT THE TWO INDIVIDUALS
THAT YOU HIGHLIGHTED ARE
Ph.D.s.
, SO IF YOU HAVE A PHYSICIAN
SCIENTIST WHO HAS TO WORK
CLINICALLY TO KEEP UP THEIR
SALARIES, THIS REDUCED SALARY
THAT IS ALLOWED FOR THE
DIVERSITY SUPPLEMENT JUST
DOESN'T WORK.
YOU HAVE TO HAVE ASK THE
DEPARTMENT TO SUPPLEMENT A HUGE
AMOUNT OF FUNDING WHICH IS JUST
DOESN'T HAPPEN A LOT, WE ARE
ACTUALLY DOING IT HERE FOR SOME
OF US.
BUT I STILL DO HAVE SOME
RESOURCES.
BUT IT IS DIFFICULT.
SO I THINK THAT THE MONEYS THAT
ARE ALLOTTED ARE VERY SMALL AND
PHYSICIAN SCIENTISTS AND THE
AMOUNTS OF MONEY FOR THE
DIVERSITY FOR THE PROJECT OF
$1,500 A YEAR JUST DOESN'T EVEN
MEET BASIC KINDS OF THINGS THEY
NEED TO DO.
MY OTHER -- I'M HOPING YOU WILL
THINK ABOUT THAT BECAUSE THAT IS
A REAL DETRIMENT TO THE
PHYSICIAN SCIENTIST.
>> IS THAT WHAT YOU WERE
REFERRING TO EARLIER?
>> YES.
YES.
>> SO THE $1,500 IS THE NUMBER
YOU WERE REFERRING TO.
>> YES.
SO $1,500 -- SUBMITTING WHAT I
NOTICE.
SO ONE OF MY MENTEES.
SO FOR OUR LARGE CN.
IT IS LIKE $60,000 OR SOMETHING
AND THAT IT IS $1,500 AND I CAN
WORK WONDERS BECAUSE I -- GRANTS
SO I CAN MOVE AROUND AND MAKE
THINGS HAPPEN FOR HIM BUT IT IS
REALLY A VERY DIFFERENT -- IT
HAS TO BE A DIFFERENT, HIS OWN
IN THIS CASE A HIM, HIS OWN WORK
SO IT IS INVOLVING MORE ANALYTIC
WORK, ETZ.
BUT THE OTHER THING -- SO THAT
IS WHY IT IS UPSETTING TO ME IT
IS SO SMALL, YOU WILL GET MORE
APPLICANTS FOR PHYSICIAN
SCIENTISTS IF IT COULD BE
ACTUALLY SOMETHING THAT THE
DEPARTMENTS COULD AFFORD TO ALSO
PARTNER AND SHARE.
THE OTHER THING I JUST HAVE THIS
THOUGHT, THE OTHER DAY WAS THAT
I AM PI OF A K 12 WHICH IS YOUNG
INVESTIGATORS.
AWARD HERE.
WE HAVE BEEN HAD SOME SUCCESS IN
RECRUITING CERTAIN SUCCESS
RECRUITING WOMEN, I WON'T TAKE
CREDIT BUT SOME SUCCESS IN
UNDER-REPRESENTED MEDICINE.
CANDIDATES BUT NOT AS MUCH AS I
WOULD LIKE.
SO I WONDER, JUST WONDERING TO
PUT THIS OUT THERE, IS TO THINK
ABOUT ALLOWING PROGRAMS THAT K
12s DO HAVE SCHOLARS IN
DIFFERENT INSTITUTIONS, BECAUSE
WE ARE ALWAYS A LITTLE BIT LIKE
WHAT -- WE ARE ASSUMING PEOPLE
WILL COME TO OUR INSTITUTION
WHICH IS QUITE UNFAIR REGARDING
FAMILIES AND JUST PLACES THAT WE
LIVE MAY NOT BE CONDUCIVE FOR
CERTAIN POPULATIONS.
SO WE HAVE ALL THE STRENGTH HERE
AND WE EXPECT SOMEONE TO COME TO
US FOR TWO, THREE YEARS,
WHATEVER, FOUR YEARS.
WE ARE -- WE COULD ACTUALLY
REACH OUT TO THESE PEOPLE OF
COURSE WITH THE ZOOM WITH ALL
THE THINGS WE ARE NOW DOING AND
THEN STILL SEEING EACH OTHER AT
SOME POINTS DURING THE YEAR
MAKING SOME ALLOWANCES.
WE COULD REALLY HAVE A LONG
TERM, NOT A SHORT TERM LIKE A
SUMMER OR WHATEVER BUT A LONG
TERM MULTI-YEAR RELATIONSHIP
WITH YOUNG FACULTY AT DIFFERENT
SITES INCORPORATE INTO THINGS
LIKE THE K 12.
IN THE PAST THIS IS NOT BEEN
LOOKED ON AS VERY WELL, EVERY
TIME I HAVE BEEN A SECONDARY
MENTOR ON A COUPLE OF K 12s AT
DIFFERENT INSTITUTIONS, BUT I
WAS A SECONDARY MENTOR AND IT
WAS REALLY DO A LOT OF
EXPLAINING OF HOW THAT WORKS I
THINK WE HAVE TO NOT EXPECT THAT
THESE INDIVIDUALS ARE GOING TO
COME LIVE WITH US IN DIFFERENT
STATES AND DIFFERENT
INSTITUTIONS FOR YEARS AND WE
HAVE LONG TERM RELATIONSHIPS BUT
WE COULD EASILY DO THAT FROM
AFAR.
WOULDN'T SAY EASILY BUT WE CAN
DO FROM AFAR NOW THAT WE HAVE
LEARN AD LOT FROM ZOOM AND MANY
NOW SCHOLARS DOING MOST OF OUR
EDUCATION AND ALL OF OUR
MEETINGS AND OUR RESEARCH AND
PROGRESS ARE ALL DONE BY ZOOM,
SO WHY COULDN'T IT BE DONE IN A
DIFFERENT PLACE?
IT IS PROVIDED THAT INSTITUTION
WOULD ALSO HAVE SOME OTHER
THINGS ASSOCIATED WITH IT THAT
THEY COULD LEARN FROM.
ANYWAY, JUST A THOUGHT OUT
THERE, TO BROADEN THIS ASPECT,
WE SHOULDN'T EXPECT PEOPLE TO
COME TO US ALL THE TIME.
WE COULD CERTAINLY GO TO OTHERS
IN DIFFERENT INSTITUTIONS.
>> THAT IS A GOOD POINT, WE CAN
-- WE KNOW THAT MODEL YOU ARE
DESCRIBING IS USING THE CLINICAL
R 25 SO THE CLINICAL R 25 BRINGS
IN FOLKS FROM DIFFERENT PLACES
THEY WORK SET OF PARTNERSHIPS
THEN DO BOOT CAMPS FOR A ONE OR
TWO WEEK PERIOD, FLY INTO UC SAN
FRANCISCO OR OTHER AREAS SO WE
HAVE A MODEL CONNECTED AND THEY
DO MONTHLY MEETINGS AN THINGS
LIKE THAT OR CHECK INs, WHAT
HAVE YOU.
THERE IS A MODEL THAT EXISTS, IT
IS NOT ONLY K 12, THERE'S OTHER
--
>> THINK ABOUT IT BECAUSE I'M
INVOLVED IN R 25 TOO.
IT IS NOT THE SAME LEVEL OF MY
HELPING THOSE INDIVIDUALS BECOME
INDEPENDENT INVESTIGATORS.
IF THERE ARE ONES VENTSLY.
IT IS NOT THE SAME --
EVENTUALLY.
SO WE HAVE TO TO THINK HOW WE
GET THAT LEVEL OF -- THAT SAME
LEVEL OF SUPPORT IN A MORE
SUSTAINED FASHION THAN AN R 25
DOES.
>> WE ARE AT 4, 03, I WANT TO
THANK YOU FOR YOUR WONDERFUL
PRESENTATION AND INCREDIBLE
WORKING COMMITMENT TO DIVERSITY.
AND NOW WE ARE GOING TO GO INTO
THE LAST STAGE OF OUR COUNCIL
TODAY WHICH IS A CONCEPT
CLEARANCE.
THE FIRST WILL BE CLEARANCE FOR
NIDA RACIAL EQUITY INITIATIVE
AND IS GOING TO BE PRESENTED BY
DR. ARYEH CRUMP.
PLEASE JUMP IN.
>> HI, EVERYONE.
THANKS SO MUCH FOR JOINING US
TODAY.
I'M HERE ON BEHALF OF THE RACIAL
EQUITY INITIATIVE GROUP.
THAT HAS A SLATE OF CONCEPTS TO
PRESENT AND WE'LL PULL THAT UP
NOW.
PRESENTING FOUR RESEARCH
CONCEPTS AND ONE PSYCHOWORK
FORCE CONCEPT ON BEHALF OF THE
GROUPMENT OUR EXPECTATION IS TO
STRENGTHEN SCIENCE FOR DIVERSE
TEAMS OF INVESTIGATORS AND TO
SUPPORT RESEARCH AND TRAINING AT
DIVERSE AWARDEE INSTITUTIONS.
SO NOTE THAT THE CONCEPT THAT
I'M PRESENTING TODAY HAVE BEEN
THE WORK OF MANY DEDICATED NIDA
STAFF MEMBERS.
SO I DON'T WANT TO UNDERSTATE
THAT, THIS IS A GROUP EFFORT.
FIRST CONCEPT IS ADDRESSING
RACIAL EQUITY IN SUBSTANCE USE
AND ADDICTION OUTCOMES TO
COMMUNITY ENGAGED RESEARCH.
AND THIS CONCEPT IS BEING LED BY
DR. KATHY ETZ FROM VESPER.
IT PROPOSES TO SUPPORT HIGH
IMPACT ENGAGED RESEARCH TO
IDENTIFY DEVELOP IMPLEMENT OR
TEST STRATEGIES TO I A DRESS
RACIAL ETHNIC DISPARITIES IN
SUBSTANCE USE AND ADDICTION.
PROJECTS WILL ADVANCE SCIENCE BY
MOVING BEYOND RESEARCH THAT
CONCEPTUALIZES RACE ETHNICITY AS
AN INDIVIDUAL LEVEL PREDICTOR
THAT INSTEAD LOOKING TO STUDIES
THAT DEVELOP KNOWLEDGE TO CREATE
EQUITY.
SO LOOKING MORE AT STRUCTURAL
INFLUENCES RATHER THAN
INDIVIDUAL INFLUENCES.
I WILL TAKE A PAUSE HERE AND SEE
IF THERE ARE ANY COMMENTS OR
QUESTIONS ABOUT THE FIRST
CONCEPT?
>> YOU MAY WANT TO DESCRIBE THEM
ALL.
MIGHT BE EASIER.
>> THAT'S FINE.
THE SECOND CONCEPT IS THE AWARD
PROGRAM FOR RACIAL EQUITY, I'M
LEAD FOR THIS PARTICULAR
CONCEPT.
THIS CONCEPT PROPOSES TO SUPPORT
EARLY STAGE INVESTIGATORS TO
CONDUCT HIGHLY INNOVATIVE
STUDIES THAT ARE FOCUSED ON
ACHIEVING EQUITY FOR U.S. RACIAL
ETHNIC MINORITY POPULATIONS
DISPROPORTIONATELY AFFECTED BY
HARMS RELATED TO SUBSTANCE USE
AND SUBSTANCE USE DISORDER.
THE PROPOSED STUDIES WOULD
ANSWER CHALLENGING QUESTIONS
WITH THE POTENTIAL TO INFORM
STRATEGIES FOR SYSTEM LEVEL
CHANGES TO POLICY AND PRACTICE.
THE NEXT CONCEPT IS -- WAS
DEVELOPED THE LEAD FOR THIS
CONCEPT THE DR. BONNIE
PARIYADATH FROM DMB.
THIS IS ENTITLED NEUROCOGNITIVE
MECHANISMS UNDERLYING THE IMPACT
OF STRUCTURAL RACISM ON THE
SUBSTANCE USE TRAJECTORY.
THIS CONCEPT FOCUSES ON
EXPLORATORY MECHANISTIC RESEARCH
SEEKING TO PARSE THE COMPLEX
EFFECT OF STRUCTURAL RACISM AND
INVESTIGATE THEIR IMPACT ON
NEUROCOGNITION WITH EMPHASIS ON
INFORMING INTERVENTIONS.
PROJECTS INCORPORATE
MULTI-SECTIONAL APPROACHES AND
IMPLEMENT BROAD EXPERTISE
INCLUDING ON COMMUNITY ENGAGED
RESEARCH.
NOW, WE ARE ALSO PROPOSING TO
HAVE A CENTER THAT WOULD SUPPORT
RESEARCH ON RACIAL EQUITY AND
HEALTH DISPARITIES AND THIS
CENTER WOULD PROVIDE TECHNICAL
SCIENTIFIC AND WILL GISTIC
SUPPORT TO FACILITATE
COLLABORATIONS BETWEEN
INVESTIGATORS INVOLVED IN THE
OTHER PROGRAMS AND THE IDEA IS
TO MAXIMIZE IMPACT OF THESE
PROJECTS THE CENTER WOULD
PROVIDE EXPERTISE AND
INFRASTRUCTURE TO GROW NIDA
RESEARCH TO HEALTH EQUITY
MEETING HIGH STANDARDS FOR
COMMUNITY COLLABORATION AND
DISSEMINATION OF RESEARCH
FINDINGS.
THESE ARE CAN CONCEPTS THAT ARE
FALLING UNDER RESEARCH GAPS AND
OPPORTUNITIES GROUP.
AND I'M ALSO GOING TO PRESENT A
CONCEPT THAT WAS DEVELOPED BEING
LED BY DR. SUSAN WRIGHT FROM
DMB, THIS CONCEPT IS TRAINING
AND DIVERSIFYING THE DATA
SCIENCE WORK FORCE FOR ADDICTION
RESEARCH.
SO THIS CONCEPT IS TO HAVE
RESEARCH ON ARTIFICIAL
INTELLIGENCE AND MACHINE
LEARNING.
THESE CONCEPTS OFFER EXCITING
OPPORTUNITIES TO ACCELERATE
INNOVATION IN BIOMEDICAL
RESEARCH AND HEALTHCARE.
WHILE ADDRESSING HEALTH
DISPARITY AND INEQUITIES.
THE PARTICULAR CONCEPT PROPOSES
TO SUPPORT MERITORIOUS RESEARCH,
STRENGTHSEN RESEARCH ENVIRONMENT
AND COLLABORATION FOR SUCCESSFUL
DATA SCIENCE, PROJECTS, AND
EXPOSE UNDERGRADUATE AND/OR
GRADUATE STUDENTS FROM
BURGEONING DATA SCIENCE PROGRAMS
TO RESEARCH IN THIS AREA.
AND SO THAT COVERS THE GROUP OF
CONCEPTS THAT WE ARE PROPOSING
AND WE ARE VERY HAPPY TO TAKE
ANY QUESTIONS THAT YOU MAY HAVE
ABOUT THEM.
OKAY THANK YOU.
APPRECIATE IT.
>> ANY QUESTIONS?
IF -- I DON'T SEE ANY HANDS
RAISED.
I'M TRYING TO SEE NOW, NO HANDS
RAISED BUT THANKS VERY MUCH FOR
THAT PRESENTATION.
>> THANK YOU VERY MUCH.
>> SO THEN WE CAN GO INTO THE
NEXT CONCEPT WHICH IS GOING TO
BE PRESENTED BY DR. SUNILA NAIR
FROM DIVISION OF SCIENCE AND
BEHAVIOR.
PLEASE JUMP IN.
>> HI, EVERYONE.
I WILL BE PRESENTING FIVE
CONCEPTS TODAY ON BEHALF OF THE
DIVISION OF NEUROSCIENCE AND
BEHAVIOR AND THE FIRST CONCEPT
IS TRANSFORMATIVE RESEARCH ON
BAYING IS MECHANISMS OF
POLYSUBSTANCE USE AN ADDICTION.
THE GOALS OF THIS CONCEPT IS TO
SEEK IDEAS THAT DOES NOVEL AND
EXPLORATORY HYPOTHESES THAT WILL
ADVANCE MECHANISTIC
UNDERSTANDING OF POLYSUBSTANCE
USE AT BASIC NEUROBIOLOGICAL
PHARMACOLOGICAL AND BEHAVIORAL
LEVELS.
THE SECOND CONCEPT IS RESEARCH
ON COUNTER ACTING THE
DELETERIOUS AFFECT OF ACUTE
OPIOID EXPOSURE AND THIS IS LED
BY DR. KIRAN VEMURI.
TO SUPPORT CUTTING EDGE RESEARCH
TO IDENTIFY NOVEL THERAPEUTIC
TARGETS AND APPROACHES LEADING
TO MEDICAL COUNTER MEASURES THAT
CAN LIFE THREATENING ENS CALLED
OPIOID EXPOSURE OR POISONING.
EASY TO ADMINISTER IN A MASS
CASUALTY SITUATION, AND
EFFECTIVE AS POST EXPOSURE
THERAPIES.
THE CONCEPT WILL ALSO SUPPORT
MEEKNIST UK RESEARCH AIMED AT
UNDERSTANDING AND TREATING THE
DELAYED PERSISTENT EFFECTS OF
ACUTE OPIOID EXPOSURE.
THE THIRD CONCEPT IS BRAIN
BEHAVIORAL QUANTIFICATION AND
SYNCHRONIZATION LED BY DR. HOLLY
MOORE.
THE GOAL OF THIS CONCEPT IS TO
BRING NEUROSCIENCE THE MOST
ADVANCE HIGH RESOLUTION
MULTI-MODAL METHOD TO CAPTURE
BEHAVIOR AT LEVEL BEHELD IN
CONCERT WITH DATA FROM THE
ENVIRONMENT IN WHICH THE
ORGANISM IS EMBEDDED AND FURTHER
TO DEVELOP NOVEL COMPUTATIONAL
MODELING APPROACHES TO INTEGRATE
MULTIPLEX DATA AND THIS WILL
REVEAL INSIGHTS ABOUT BEHAVIOR.
THE NEXT CONCEPT IS BY DR.
OLIVIER BERTON, LARGE SCALE IN
THE GREATER FUNCTION MAPPING AND
FROM FILING OF CELL ENSEMBLES
RADIATING ACTION IN ROW DEBIT
BRAIN.
THE GOAL OF THIS PROGRAM IS TO
ENABLE GENERATION OF MOLECULARLY
ANNOTATED CATALOG AND ATLAS OF
CELL ASSEMBLIES AN TYPES THAT
MEDIATE RESPONSE TO OPIOIDS.
THIS CONCEPT WILL SUPPORT
CONTINUATION OF EXPERIMENTAL
STUDIES AND BUT A COLLECTION
EFFORT INITIATED IN 2020 AND
DEVELOP RELATED DATA CENTER
COMPETENCE TO MAKE THREE CELLS
PUBLICLY AVAILABLE AND THESE
WILL BECOME WITH THE BRAIN
INITIATIVE DATABASES, TO ENABLE
JOINT SECONDARY ANALYSIS BY
THESE SCIENTIFIC COMMUNITIES.
THE LAST CONCEPT ALSO LED BY DR.
OLIVIER BERTON LEVERAGES CUTTING
EDGE TRACING APPROACHES TO CHART
EFFECT OF ADDICTIVE SUBSTANCES
ON BRAIN DEVELOPMENTAL
TRAJECTORIES.
AND THIS CONCEPT WILL SUPPORT
THE APPLICATION OF AN YOU KNOW
INVESTIGATIVE CELL LINEAGE AND
CONNECTIVITY TRACING APPROACHES
TO QUANTITATE AFFECT OF
ADDICTIVE SUBSTANCE ON
DEVELOPMENTAL FRA VECTORRIES OF
CELL TYPES IN RODENT BRAIN IN
VIVO.
AND THESE PROJECTS MAY SAMPLE
THE ENTIRE PERIOD OF EMBRYONIC
AND POSTNATAL DEVELOPMENT AND
REINVESTIGATE THE EFFECT OF ANY
ADDICTIVE SUBSTANCE WITH HIGH
TRANSLATIONAL AND PUBLIC HEALTH
RELEVANCE.
SO THOSE ARE FIVE CONCEPTS THAT
WE HAVE FROM B AND B AND WE WILL
BE HAPPY TO ANSWER ANY
QUESTIONS.
>> ANY QUESTIONS, COMMENTS?
I DON'T SEE ANY HANDS RISING.
YOUR OPPORTUNITY.
IF NOT, WE CAN GO INTO THE NEXT
-- YES.
SORRY, I DIDN'T SEE YOU.
>> THESE ARE WONDERFUL OF COURSE
MY OWN PERSONAL PERSPECTIVE THE
LAST TWO ARE INTRIGUING.
WONDERING IF OBVIOUSLY THESE ARE
BIG INITIATIVES BUT IF THERE ARE
WAYS TRYING TO BEGIN TO THINK
HOW LARGE SCALE MAPPING
INITIATIVES SEQUENCING SPECIFIC
CELL POPULATIONS OR RACING
TRAJECTORIES USING THESE COOL
BAR CODING TYPE OF APPROACHES IF
THERE IS WAY OF LINKING TO HUMAN
GENETICS.
SEE IF WE CAN IDENTIFY ALLELES
WE IDENTIFY HUMAN ADDICTION
VULNERABILITY AND WHICH CELLS
EXPRESS AND WHICH PATHWAYS MIGHT
BE INFLUENCED, JUST SEEMS GREAT
OPPORTUNITY TO BRING HUMAN
GENETICS MORE INTO PLAY.
>> YES.
THIS IS THE CONTACT -- OLIVIER,
THE CONTACT FOR THIS CONCEPT.
THE IDEA IS TO IF POSSIBLE SOME
OF THESE PROGRAMS TO INCLUDE
SOME STUDIES THAT COULD USE SOME
POST MORTEM TISSUES, FROM HUMAN
PATIENTS.
THAT COULD BE LOOKING AT
SPECIFIC DEVELOPMENTAL TIME
POINTS. TO TRY TO MAKE SOME
PARALLELS RAINS RATIONAL
PARALLELS ACROSS WHAT IS
OBSERVED IN ANIMAL MODELS AND
SOME DEVELOPMENTAL DATA. SO NOT
SPECIFICALLY WE DIDN'T HAVE
SPECIFIC PLAN YET TO INCORPORATE
HUMAN GENETIC DATA BUT THIS
COULD DEFINITELY BE AN
OPPORTUNITY TO --
>> EXCELLENT.
SOUND LIKE GREAT STUFF.
EVENTUALLY GET HUMAN GENETICS,
THERE ARE TWO OBVIOUSLY WOULD BE
ATTRACTIVE.
THANKS.
>> OKAY.
>> ANY OTHER QUESTIONS?
IF NOT WE CAN GO INTO THE NEXT
PRESENTATION, WHICH IS GOING TO
BE GIVEN BY OFFICE OF
TRANSLATIONAL INITIATIVES AND
PROGRAM INNOVATIONS BY PRESENTED
BY DR. STACIE GUTOWSKI.
STACIE, PLEASE JUMP IN.
>> HELLO, EVERYBODY.
MY NAY IS STACIE GUTOWSKI, THANK
YOU FOR THE INTRODUCTION I WILL
BE PRESENTING THREE CONCEPTS ON
TRANSLATIONAL INITIATIVES AN
PROGRAM INNOVATION.
THE FIRST CONCEPT BY MYSELF WILL
BE FOR NOVEL DRUG MEDICAL DEVICE
DEVELOPMENT TOOLS WHICH ARE
KNOWN AS DDT AND MDDT TO
EXPEDITE CREATION AND REGULATORY
APPROVAL OF NEW THERAPIES FOR
SUBSTANCE USE DISORDERS.
THIS CONCEPT SUPPORTS
DEVELOPMENT OF NEW DEVELOPING
TOOLS AND ADVICE DEVELOPMENT
TOOLS WHICH ARE QUALIFIED TO BE
FDA FUTURE USE DEVELOPMENT OF
MEDICAL PRODUCTS.
DNT IS -- QUALIFIED BY FDA CAN
BE UTILIZED BY ANY RESEARCHER IN
THE INITIATIVE SPACE AND WILL BE
BY FDA REGULATORS TO SUPPORT
FUTURE DRUG AND MEDICAL DEVICE
APPROVALS.
THE SECOND CONCEPT BY CHRIS
CONRAD IS FOR THERAPEUTIC
DEVELOPMENT OF PSYCHOPATHOGENNIC
COMPOUNDS IN SUBSTANCE USE
DISORDERS TO SUPPORT THE
PSYCHOGENIC COMPOUNDS AS
TREATMENT FOR DISORDERS.
IT WILL RANGE EARLY STAGE DRUG
DISCOVERY TO THE PRE-CLINICAL
DEVELOPMENT OF NATURAL OR
SYNTHETIC COMPOUNDS BASED FOR
SUBSTANCE USE DISORDER.
THE THIRD CONCEPT ALSO LED BY
MYSELF AS WELL AS ELAINE WILL BE
ENABLING SUBSTANCE USE DISORDER
THERAPEUTIC RESEARCH, THERE ARE
DIFFERENCES BETWEEN REQUIREMENT
AND DATA COLLECTION NECESSARY TO
OBTAIN REGULATORY APPROVAL
VERSUS HEALTH ECONOMIC DATA
NECESSARY TO SUPPORT
REIMBURSEMENT MANY THE UNITED
STATES, LEADING TO DELAYS IN THE
DECISION MAKING FOR PAYERS FOR
DIGITAL HEALTH PRODUCTS
SUBSTANCE USE DISORDER.
THIS CONCEPTS WILL SUPPORT
RESEARCH AND CLINICAL TRIALS
CLINICAL TRIALS DEMON
INVESTIGATE SAFETY EFFECTIVENESS
OF DIGITAL THERAPEUTICS FOR SUD
RESULTING IN DATA PACKAGES THAT
LEAD TO REQUIREMENTS FOR
INCLUSION IN AND REIMBURSEMENT
FROM DIGITAL AREAS AS WELL AS
PRIVATE PAYERS.
WE ARE AVAILABLE TO TAKE ANY
QUESTIONS YOU MAY HAVE ABOUT
THESE CONCEPTS.
>> STACIE, THANKS.
ANY QUESTIONS OR COMMENTS?
I SEE THAT LAKSHMI RAISED HER
HAND.
LAKSHMI.
>> I WAS LOOKING FOR
CLARIFICATION ON THE
PSYCHOPLASTIC GENIC COMPOUNDS.
>> AT THIS POINT I'M GOING TO
TAG IN CHRISTOPHER.
>> CAN YOU CLARIFY THE
PSYCHOPLAST GENIC COMPOUNDS WITH
ME
>> I USE THIS NAME BECAUSE I
WANTED TO BE INCLUSIVE TO PSYCH
DELLICS AND ALSO
NON-HALLUCINOGENIC LIKE
COMPOUNDS DEVELOPED.
SO IN THAT AREA.
THESE COULD BE 5 H 2A AGONISTS
OR ANY OTHER DISSOCIATED
COMPOUNDS AS WELL.
>> OKAY.
THANKS.
>> ANY OTHER QUESTIONS?
IF NOT, STACIE, THANK VERY MUCH
FOR THE PRESENTATION.
WE CAN GO INTO THE LAST
PRESENTATION WHICH IS GOING TO
BE GIVEN BY DR. ALBERT AVILA,
DIRECTOR OF OFFICE OF E RESEARCH
TRAINING DIVERSITY AND
DISPARITIES AND HE WILL BE
GIVING CONCEPTS.
ALBERT.
>> THANK YOU.
SO THE FIRST CONCEPT IS CALLED
LEADING ADDICTION DIVERSITY AND
DISCOVERY AND EDUCATIONAL
RESEARCH AND LA,R FOR SHORT,
PRESENTING THIS ON BEHALF OF
EXTRAMURAL WORK FORCE SCIENTIFIC
WORK FORCE, COMMITTEE.
THE PURPOSE IS TO CREATE
PARTNERSHIPS IN COLLABORATIONS
BETWEEN LIMITED RESOURCE
UNIVERSITIES INCLUDING
INSTITUTIONS WITH DEMONSTRATED
COMMITTEE COMMITMENT TOE SH
ISING UNDERREPRESENTED GROUPS.
NIH T 32 FUNDED INSTITUTIONS TO
JOINTLY TRAIN SUBSTANCE USE
DISORDER RESEARCHERS.
THE GOAL OF THIS PROGRAM IS TO
ENSURE THERE IS A DIVERSE POOL
OF UNDERGRADUATE AND GRADUATE
STUDENTS WHO COMPLETE THEIR
DEGREE AND TRANSITION TO
SUBSTANCE USE ADISTINCTION
RESEARCH FOCUSED PROGRAMS AND
CAREERS.
TO ACHIEVE THE GOAL THE SUPPORT
WILL BE PROVIDED TO THE LIMITED
RESOURCE INSTITUTIONS TO PROVIDE
HIGH QUALITY TRAINING AND
MENTORING THAT WILL THEN PREPARE
EMPOWER THEIR SCHOLARS.
THE SECOND GOAL SO CREATE
PARTNERSHIPS AND COLLABORATION
BETWEEN LIMITED RESOURCE
UNIVERSITIES WITH T 32 FUNDED
INSTITUTION TO FOSTER EXCHANGE
OF IDEAS, AS WELL AS SPARK AND
SUSTAIN THE INTEREST AND
SUBSTANCE USE ADDICTION RESEARCH
AMONG SCHOLARS FROM DIVERSE
BACKGROUNDS.
WE SEE THIS AS A WIN WIN FOR
BOTH INSTITUTIONS.
THE SECOND INITIATIVE IS
RESEARCH -- CALLED RESEARCH
OPPORTUNITIES FOR NEW AT RISK
INVESTIGATORS TO PROMOTE
SCIENTIFIC WORK FORCE DIVERSITY.
YOU SAW THE DATA ON NEW
INVESTIGATORS EARLIER.
I'LL PRESENT THIS ON BEHALF OF
OFFICE DIVERSITY HEALTH
DISPARITIES AT NIDA.
THE GOAL IS TO POO SUPPORT AND
SUSTAIN NEW AND AT RISK
INVESTIGATORS FROM DIVERSE
BACKGROUNDS WHO ARE CONDUCTING
SUBSTANCE USE ADDICTION
RESEARCH.
DESPITE EFFORTS TO IMPROVE
EQUITY AND OPPORTUNITIES IN THE
SCIENTIFIC ENTERPRISE
INFORMATION EDUCATIONAL RESEARCH
OPPORTUNITIES ARE STILL NOT
EQUITABLE.
ONE OF THE MOST VULNERABLE
POINTS IN RESEARCH ERICA REAR IS
RECEIVING AND RENEWING AN RBG
AWARD TO SUSTAIN RESEARCH
PROGRAM.
TO THAT END THIS FIVE YEAR
RESEARCH AWARD WILL SUPPORT
RESEARCH PROTECT SOMEWHERES FROM
NEW AT RISK INVESTIGATORS
DIVERSE BACKGROUNDS INCLUDING
THOSE UNDER-REPRESENTED IN
HEALTH RELATED SCIENCES TO ARE
PROVIDE RESOURCES TO CONTINUE
WORK THROUGH AND ALONG THAT
STAGE.
THIS AWARD WILL HELP SERVE AS
ONE STEP TOWARDS PROMOTING
SUSTAINING DIVERSE INCLUSIVE
SCIENTIFIC WORK FORCE AND
EXTRAMURAL RESEARCH NEEDS.
THANK YOU.
>> ALBERT, THANKS VERY MUCH.
WE WANT TO OPEN UP FOR QUESTIONS
OR COMMENTS.
ANYONE?
I DON'T SEE ANY HANDS RISEN.
SO I GUESS YOU ANSWERED THEM
VERY THOROUGH.
ALBERT, THANKS VERY MUCH.
>> THANK YOU P.
>> AND THAT IS THE CONCEPT STAGE
OF OUR OPEN COUNCIL MEETING
TODAY AND WE NOW GO INTO THE
PUBLIC COMMENT PERIOD WHICH
ACTUALLY IS WHEN I READ ANY
PUBLIC COMMENT SUBMITTED PRIOR
TO COUNCIL TO DR. SUSAN WEISS.
TO MY UNDERSTANDING THERE HAVE
BEEN NO COMMENTS SUBMITTED TO
HER SO THERE IS NOTHING I CAN
REALLY READ BUT FOR FUTURE
MEETINGS IF YOU ARE ATTENDING
THE MEETING FIELD ANY COMMENTS
TO US THAT YOU WOULD LIKE US TO
BRING TO THE ATTENTION OF
COUNCIL AT THE END OF THE OPEN
COUNCIL SESSION.
SORRY?
>> WE WILL ALSO ACCEPT COMMENTS
ON THIS SESSION WITHIN TEN DAYS
OF THE COUNCIL.
IF THERE IS SOMEBODY WATCHES WHO
WANTS TO SUBMIT COMMENTS, PLEASE
DO.
>> SUSAN THANKS.
WITH THAT UNLESS THERE IS
SOMETHING ELSE, SUSAN, I GUESS
THAT I -- WE CAN ADJOURN AND
BEFORE WE ADJOURN THOUGH I WANT
TO THANK YOU AGAIN FOR YOUR
PARTICIPATION IN COUNCIL AND
REMIND YOU THAT THE INVOLVEMENT
IS NOT JUST WHEN WE ARE MEETING
FORMALLY FOR COUNCIL BUT FEEL
FREE AT ANY TIME TO COMMUNICATE
WITH YOU IDEAS, THAT IS
RESPONSIBILITY OF COUNCIL THAT
WAY WE CAN DIVERSIFY
PERSPECTIVES.
SO UNLESS ANYTHING ELSE YOU WANT
TO FINALIZE WITH SUSAN, WE CAN
ADJOURN?
>> NO, AGAIN, THANK YOU ALL, WE
APPRECIATE YOUR TIME AND YOUR
CONSIDERATION.
UNTIL NEXT TIME.